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  Six different isoforms of Type IV collagen (colIVα1-6) have been identified. 
The individual isoforms of colIV are termed alpha chains and are translated from six 
different COLIV genes (COLIVA1-A6). Collagen Type IV gene products compose the 
structural framework of basement membranes. The glomerular basement membrane 
(GBM) is a specialized basement membrane involved in the ultrafiltration processes of 
the kidney.  The colIVα1-α5 chains are expressed in the human GBM while the colIV 
α1-α6 chains are expressed in the canine GBM. Many inherited diseases of the kidney 
have been reported and mutations in genes regulating kidney function have been 
identified. Alport syndrome (AS) is the most common form of human hereditary 
nephritis (HN). AS is defined as an inherited progressive kidney disorder associated with 
sensoneural deafness and is characterized by extensive thickening and multilamminar 
splitting of the GBM when examined by electron microscopy. AS has both X-linked 
(XLAS) and autosomal (ARAS) modes of inheritance. Mutations in the COLIVA5 gene 
are responsible for XLAS. A form of HN with characteristic splitting of the GBM with 
X-linked inheritance has been described in Samoyed dogs. A specific mutation in the 
 iv
COLIVA5 gene has been identified in Samoyed dogs affected with HN. Mutations in the 
COLIVA3 and COLIVA4 genes are responsible for ARAS. A form of HN has been 
identified in English cocker spaniel dogs (ECS) that has been described as autosomal in 
inheritance and includes GBM abnormalities including extensive lammination 
characteristic of ARAS. Both ARAS and ECS-HN show loss of the colIVA3 and 
colIVA4 chains in the GBM when examined with monoclonal anitibodies. ECS-HN has 
been hypothesized to have the same molecular basis of disease as ARAS. As such, we 
have isolated and characterized canine COLIVA3 and COLIVA4 sequences from 
normal dogs and ECS dogs affected with HN and compared the coding regions of these 
candidate genes.  
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Collagens are found in all vertebrate species as well as in Drosophila, sea 
urchins, nematodes and sponges (Blumberg et al., 1988). It is suggested that all 
collagens evolved from a common ancestral unit of a 54 base pair (bp) repeat (Chu et al., 
1984). Although diverse in their distribution and function, all collagens share features 
that group them as a family. In 1986 a conference was convened to discuss the 
biochemistry of collgens (Uitto et al., 1986). At the time of the conference 10 members 
of the collagen family had been described. Five years previous, only five members of the 
collagen family had been reported. Whereas many of the initial collagens were described 
on a biochemical basis of classification, many of the new collagens being reported were 
based on genetic sequence homologies. One of the main objectives of the conference 
was to derive a consensus definition of a collagen. As a result, a collagen is described as 
a triple helical domain that is expressed extracellularly where it performs a structural 
function.  The word collagen is derived from the ancient Greek word kolla for glue and 
the helical nature of collagens has been known for some time.  
 
This dissertation follows the format of Journal of Cell Biology. 
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X-ray crystallography was used to illucidate the double helical nature of DNA 
and this method was also used to determine the triple helical nature of collagen fibers. In 
1954, Ramachandran and Kartha first used this technique to identify the interchain 
hydrogen bonding and the importance of glycine in the amino acid composition of 
collagen (Ramachandran, 1954). In 1955, they later reported a more detailed spacial 
analysis, emphasized the importance of proline residues and described the coiled coil 
nature of collagen (Ramachandran, 1955). In the same year Rich and Crick, using the 
same methodology, added information on the primary amino acid sequence and 
proposed a refined structure (Rich, 1955). The helical structure of collagens is essential 
for the association of the three alpha chains and is termed the collagenous domain of the 
molecule. The helical structure is made possible by the incorporation of the amino acid 
glycine at every third residue creating the characteristic collagenous sequence. Collagens 
are triple helical molecules with the sequence Gly-X-Y where Gly represents the amino 
acid glycine while X and Y can represent any other amino acid. Most commonly X and 
Y are represented by the amino acids proline or hydroxyproline (which account for 
approximately 20% of the collagenous structure) or hydroxylysine which is used to 
create interchain stabilizing bonds with other hydroxylysine amino acids to stabilize the 
quaternary structure of the molecule.  
The collagens undergo extensive post-translational modification. Lysine is 
modified by lysyl hydroxylase and the altered amino acid is then used to form interchain 
crosslinks used for quaternary stabilization. This enzyme was first isolated in 1958 and 
identified as a necessary physiological component of crosslinking collagens and elastin, 
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a molecule found in the basement membranes of the heart (Pinnell and Martin, 1968). 
The necessary nature of these crosslinks is evident by the addition of lathyrogen which 
prevents crosslinkage. Lathyrogens, such as β-aminoproionitrile (BAPN), are found in 
plants and when digested by livestock can lead to extreme illness or death. The inherited 
connective tissue disease Ehlos-Dandrome Syndrome type VI is also associated with a 
defect in lysyl hydroxilase (Pinnell et al., 1972). Hydroxylysine is also used as a site for 
glycosylation (Spiro, 1967a). Type IV collagen of the GBM was also shown to be 
glycosylated (Spiro, 1967b). The importance of the glycosylation is unknown but could 
possibly help the molecules become more hydrophillic, an essential characteristic of 
basement membranes. The collagens are synthesized intracellularly in an immature form 
and then transported extracellulary. The immature collagen is termed procollagen and 
was first identified in cultured human fibroblasts using chromatographic techniques 
(Layman et al., 1971) and the bones of rats using pulse-chase experiments (Bellamy and 
Bornstein, 1971). These reports showed that the conversion from a pre-procollagen to a 
procollagen occurred extracellularly by an excreted enzyme (then termed a zymogen) 
that had proteolytic activity. In 1979 the specific proteolytic enzyme responsible for the 
release of the N- and C-terminal pro-peptides was identified (Kao et al., 1979). 
Glycine is necessary at every third residue in the collagenous sequence because 
its single hydrogen atom as its side chain is the smallest of all amino acids and causes 
the least possible amount of steric hindrance. Substitution of any other amino acid 
creates a steric hindrance that disrupts the helical structure. Thus, a base change creating 
a single amino acid substitution could create disturbances in the structural integrity of 
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the collagen molecule. This was first seen in mutations in collagen type I genes in 
osteogenisis imperfecta (Vuorio and de Crombrugghe, 1990).  Collagen molecules 
consist of three monomers wound together in the left-handed triple helix. The individual 
monomeric molecules are termed alpha chains. The collagens are an extended family of 
proteins and are categorized as types based on various biochemical techniques (Uitto et 
al., 1986). Each type of collagen is given a Roman numeral as its type designation (type 
I collagen, type II collagen, etc.) and at least 19 types of vertebrate collagen have been 
identified (Kivirikko and Myllyla, 1987; Prockop and Kivirikko, 1995; van der Rest and 
Garrone, 1991; Vuorio and de Crombrugghe, 1990). 
Although the first collagen was isolated from the tail tendon of rats by acid 
extraction in the widely reported experiments by Nagoette beginning in 1927, the next 
identified collagen was not identified until 1969 from chicken cartilage (Miller and 
Matukas, 1969). This second identified collagen created the need for a system of 
nomenclature. The present nomenclature of collagens categorizes this collagen as 
collagen type II and the first collagen isolated by Nagoette as collagen type I.  In 1971, 
Kefalides isolated a unique collagen from the anterior lens capsule from bovines and 
identified this as type IV collagen (Kefalides, 1971). The technique of cyanogen 
bromide cleavage of purified collagen extract used by Kefalides was the same method 
used to identify other collagens including the identification of collagen type III isolated 
from chicken skin a year earlier (Miller et al., 1971). In 1963, with the use of ion 
exchange chromatography, Piez first identified the alpha chain subunits of collagen type 
I (Piez, 1963). He termed the most abundant of the alpha chains α1 and the second most 
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abundant alpha chain α2 and described the nature of collagen type I as being composed 
of two α1 chains and one α2 chain, thus describing a trimer of (α1)2(α2)1 (Piez, 1963).  
A collagen molecule could be composed of a single species of identical alpha chains or a 
combination of different alpha chain species. A single alpha chain species is associated 
with a single collagen type. The identity of the alpha chain is defined by the type of 
collagen with which it is associated and by its order of identity with respect to the other 
monomers of the same type. For example, the alpha 1 chain of type I collagen (colIVα1) 
was defined before the alpha 2 chain of type I collagen (colIVα2) and the alpha 1 chains 
of type I collagen (colIα1) are not the same as the alpha 1 chains of type II collagen 
(ColIIα1). The role of the collagens is structural and together they are the most abundant 
protein in the body. 
 
 
Type IV Collagen 
 
 Six different isoforms of mammalian type IV collagen (colIVα1-6) have been 
identified. The individual isoforms of colIV are termed alpha chains and are translated 
from six different colIV genes (COLIVA1-A6) (Hudson et al., 1993). All colIV isoforms 
have a similar function, molecular structure and genetic composition, but different 
molecular organization and patterns of expression. The characteristics of collagen type 
IV will be the focus of this section.  
 6
Structurally, collagen type IV is an essential component of basement membrane 
architecture. Type IV collagen allows the formation of a network of collagen molecules 
rather than a collagen fiber, because the mature colIV molecule has characteristics that 
make it different from the fiber forming collagens. Type IV collagen contains more than 
20 interruptions in the Gly-X-Y collagenous sequence resulting in a more flexible 
collagen molecule (Brazel et al., 1988; Dolz et al., 1988; Hofmann et al., 1984). These 
inturruptions in the collagenous sequences range from 21 interruptions for the α1 chain 
of type IV collagen (colIVα1) (Brazel et al., 1987) to 26 interruptions for the colIVα4 
chain (Mariyama et al., 1994). The colIVα2 and colIVα3 chains each have 23 
interruptions in their collagenous sequence (Brazel et al., 1988; Leinonen et al., 1994) 
while the colIVα5 and colIVα6 chains have 22 and 25 interruptions (Pihlajaniemi et al., 
1990; Zhou et al., 1994b).  The multiple interruptions of collagen type IV are different 
with respect to the fiber forming collagens like collagen type I which contains an 
uninterrupted collagen domain (Hofmann et al., 1984).  
Terminal non-collagenous sequences of fiber forming collagens are cleaved, but 
for type IV collagen these sequences are preserved and used for self assembled 
networks. Three alpha chains of colIV molecules self associate in parallel fashion with 
their c-terminals at one end of the triple helix and their amino terminals at the other end 
of the molecule (Timpl et al., 1981). Both the c-terminal globular domain and the amino 
terminal collagenous domain of type IV collagen are involved in higher order assembly. 
Each alpha chain has a c-terminal non-collagenous globular domain and collectively the 
c-terminals of a colIV molecule are termed the NC-1 domain (Timpl et al., 1981). NC-1 
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domains from two triple-helical colIV molecules associate to form c-terminal linked 
dimers. Amino terminal sequences from four colIV molecules associate and, 
collectively, forms a structure termed the 7S domain (Kuhn et al., 1981).   
The 7-S domain of type IV collagen was identified from multiple sources 
including EHS tumor cells, bovine lens capsule and human kidney (Dixit et al., 1981; 
Risteli et al., 1981). This novel collagen domain had a sedimentation coefficient of 7.2S 
and resisted bacterial collagenase but had an amino acid sequence similar to basement 
membrane collagen. The molecule was found to be highly glycosylated, but the origin of 
the molecule was unknown. The 7S domain is secured with disulfide bonds and 
hydrophobic interactions (Siebold et al., 1987). The 7S domain has many important 
features. These include a 21 residue N-terminal non-triple helical region (NH-1), a 117 
residue triple helical region (TH-1) that is responsible for the aggregation of the four 
molecules and a 10 residue non-triple helical region (NH2) that creates an area 
responsible for flexibility in this region (Siebold et al., 1987).  Through these 
associations, colIV molecules create a network and form the structural foundation of 
basement membranes. 
The network model for the organization of type IV collagen molecules in 
basement membranes was first proposed after the identification of the non-collagenous 
c-terminal domain termed the NC-1 domain (Timpl et al., 1981). This model suggested a 
regular network of type IV collagen molecules generated by sites interacting at the 
opposite ends of each molecule. By rotary shadowing electron microscopy, it was 
observed that the 7S domain connected four molecules while the NC-1 domain 
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connected two molecules and formed a lattice network. The proposed structure indicated 
a network similar to chicken wire that was continuous and could explain the mechanical 
strength and flexibility of basement membranes. Later, it was shown by electron 
microscopy that type IV collagen could self assemble in vitro when purified collagen 
type IV isolated from EHS cells was heated and allowed to reconstitute (Yurchenco and 
Furthmayr, 1984). This report suggested a more complex network than the initial 
chicken wire model and indicated lateral assembly of the molecules as opposed to a 
strict head to head and tail to tail configuration. Lateral associations were shown to exist 
through similar methods of experimentation and identified the mechanism of lateral 
associations to be from interactions of the NC-1 domain with specific intermolecular 
sites (Tsilibary and Charonis, 1986). The lateral association was inhibited by anti NC-1 
antibodies. This is an important finding with regards to this research because it showed 
that, while the NC-1 domain is important for molecular stability, there are several sites 
within the molecule for investigation with regards to disruption of the matrix that might 
result in pathogenesis. In other words, the NC-1 domain must have sites internally in 
associated molecules with which to bind. Further complexity of the matrix assembly was 
shown in situ by the observation of a super helical formation of different monomeric 
trimers of collagen type IV molecules around an established basement membrane matrix. 
This modified model of the structural framework of basement membrane matrices 
indicated a structure much more like a fabric than chicken wire (Yurchenco and Ruben, 
1987). 
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 The most common network of colIV molecules in basement membranes is 
composed of two colIV alpha 1 chains and one colIV alpha 2 chain (colIV(a1)2(a2)1) 
(Hudson et al., 1993). It was shown that these trimers are formed beginning at the NC-1 
domain of the C-terminus, proceeds to the N-terminus 7S region, that the process can be 
reversed at 50°C, and the trimer can be reconstituted at 25°C (Dolz et al., 1988). 
Removal of the NC-1 domain with pepsin leads to a loss of the refolding ability. The 
colIV (α1)2(α2)1 trimer has been found to be present in most basement membranes and 
has wide tissue distribution (Trueb et al., 1982). The minor species of collagen type IV 
(α3,α4, α5, and α6), have been shown to have a limited tissue distribution (Kleppel et 
al., 1989a). These six colIV alpha chains could in theory form 56 different kinds of triple 
helical monomers (Hudson et al., 1993). Definitive evidence regarding all of the 
molecular associations of the colIV alpha chains is still an active area of research, 
although some molecular associations have been reported. As previously mentioned, the 
colIV (α1)2(α2)1 trimer has been identified in most basement membranes. Using co-
precipitation techniques with monoclonal antibodies to colIV NC-1 domains, a 
heterodimeric complex of two colIVα3 and one colIVα4 chain in the GBM has been 
reported (Johansson et al., 1992). Earlier studies in the same tissue with the same 
techniques indicated a homotrimeric structure of three colIV α3 chains (Saus et al., 
1988). ColIVα3 homodimers, (colIVα3)3, have also been reported in embryonic tissues 
(Haralson et al., 1985). More recently, investigators have reported a disulfide crosslinked 
complex of colIVα3-α4-α5 chains of type IV collagen from bovine kidney (Gunwar et 
al., 1998). This finding could explain why patients with Alport Syndrome frequently 
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show no immunohistochemical staining of either the colIVα3, α4 or α5 chains which 
are normally present in human GBM (Kashtan et al., 1996; Kleppel et al., 1989a; 
Nakanishi et al., 1994; Yoshioka et al., 1994). In these patients, genetic analysis shows 
that the molecular basis of disease has been identified as a mutation in the COLIVA5 
gene and that the COLIVA3 and COLIVA4 genes are unaffected and transcribed at 
normal levels. Therefore, these results suggest that mutations in the gene encoding the 
colIVα5 chain causes defective assembly of not only the colIVα5 chains, but also the 
colIVα3 and colIVα4 chains in the GBM. For our studies the converse could also be 
true, mainly, that mutations in either the COLIVA3 or COLIVA4 genes that disrupt 
protein structure could also disrupt the assembly of colIVα3-α4-α5 trimers and thus lead 
to the same GBM defect. The exact nature of the colIV interactions is still unknown. The 
molecular assembly of colIV products could involve multiple combinations the colIVα3, 
colIVα4, colIVα5 and colIVα6 chains. The association of these chains could also be at 
the transcription/translation level because, as will be discussed below, mRNA expression 
of the colIVα3, α4 and α5 chains appears to be coordinated (Thorner et al., 1996). 
Research on seminiferous tubule basement membrane in bovine testes has shown three 
major hexameric complexes of colIV molecules (Kahsai et al., 1997). One is the classic 
colIV(α1)1(α2)2 network, and the others represent two novel networks. One of the novel 
networks involves all of the colIV alpha chain species (colIVα1-α6), while the other 
novel network is restricted to the colIVα3-α6 chains. Beyond these novel networks, 
using monoclonal antibodies and HPLC technology the content of colIVα3 in these 
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basement membrane structures was calculated to be 40% while the content of the 
colIVα4 chains was 18% (Kahsai et al., 1997). The result of this research shows highly 
complex, interactive, coordinated and heterogeneous nature in the composition of colIV 
molecules in basement membrane matrices.  
 Collagen type IV genes are highly conserved. Our research using Genbank of 
comparative sequence analysis of corresponding colIV alpha chains in different 
mammalian species, consistently show over 80% homology at the nucleotide level. 
COLIV genes share similar genetic structure and all consist of many exons over large 
areas of genomic DNA. Each mammalian COLIV gene has over 50 exons and covers at 
least 100 kb of genomic DNA (Soininen et al., 1989; Zhou et al., 1994a; Zhou et al., 
1994b). COLIV genes generate similar sized transcripts of over 5,000 bases and produce 
similar sized products. The colIVα1 chain represents the smallest product with 1,642 
amino acids (Soininen et al., 1987) and the colIVα2 chain is the largest with 1,676 
amino acid residues (Hostikka and Tryggvason, 1988).  The  human col IV α3, α4 α5 
and α6 chains have 1,642, 1,652, 1,659 and 1,670 amino acids respectively (Leinonen et 
al., 1994; Mariyama et al., 1994; Zhou et al., 1992), (Zhou et al., 1994b)).   
Although the colIV “classical” chains (colIVα1 and colIVα2) have been shown 
to be present in most basement membranes, the minor species of colIV (colIVα3, 
colIVα4, colIVα5 and colIVα6) have a limited tissue distribution. The limited 
distribution of these products suggests a specific functions in the tissues where they are 
expressed. The isolation of the minor species of collagen all arose from investigations 
into the molecular composition of the GBM. As such, much of the investigation into 
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collagen type IV tissue distribution has been focused primarily on basement membranes 
of the kidney. Immunohistochemical staining with monoclonal antibodies can be used to 
study the expression of specific proteins. Chain-specific antibodies directed against 
individual collagen type IV α chains can be used to detect expression of these products 
in specific basement membranes.   
In the kidney, the colIVα3 and colIVα4 chains are expressed predominately in 
the GBM and are also detected to a minor extent in Bowman’s capsule and the distal 
tubules (Butkowski et al., 1989; Kleppel et al., 1989b) and, extrarenally, these chains are 
also detected in the testis (Kahsai et al., 1997). The colIVα5 chain is also detected in the 
above locations, as well as the collecting ducts of the kidney and, extrarenally, in the 
skin (Kleppel et al., 1992). The restricted distribution of these molecules suggests a 
specified role in these structures. 
  The homology of the collagen gene family with respect to molecular techniques 
can be seen in the history of the isolation of the COLIVA5 gene (Pihlajaniemi et al., 
1990). In an investigation to isolate collagen type V genes (not COLIV genes), a human 
placental cDNA library was screened with an avian fribrillar collagen gene. This probe 
was expected to hybridize strongly to collagen type V genes and several colonies with 
positive signals were isolated. Two of the clones were COLIA1 genes and one was a 
COLIVA1 sequence. Another clone isolated in this study had interruptions of the 
collagenous sequence and was identified as a previously unidentified type IV collagen 
sequence, COLIVA5. 
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The COLIVA6 gene is X-linked and lies head to head, adjacent to the 
COLlIVA5 gene, where they share a common promoter (Oohashi et al., 1994; Sugimoto 
et al., 1994; Zhou et al., 1994a). The isolation of the COLIVA6 gene followed the 
identification of a distinct pattern found in the COLIV genes. In the analysis of the 
COLIVA1-A5 sequences, it was found that the genes could be divided into two distinct 
groupings. Based on DNA sequence homology, the COLIVA1, COLIVA3 and 
COLIVA5 genes were found to belong to an α1-like class and the COLIVA2 and 
COLIVA4 genes were classified as α2-like genes. This nomenclature also identified the 
colIVα1 and colIVα2 as “classical” chains to distinguish them from the other tissue 
specific chains. Because it appeared that there was a missing member of the alpha 2-like 
genes, and it was shown that the COLIVA1 and COLA2 genes are arranged in a head to 
head configuration and shared common promoter elements, it was hypothesized that the 
COLIVA5 gene was likewise paired with an unidentified collagen type IV gene.  Using 
the homology inherent in these genes, a COLIVA4 clone was used to screen a human 
lens library, and several overlapping clones were isolated (Oohashi et al., 1994). 
Characterization of these sequences showed them to contain a novel COLIV isoform that 
was identified and classified as the COLIVA6 gene (Oohashi et al., 1994). Mapping of 
COLIVA6 localized the gene to the same region as COLIVA5 on chromosome Xq22 
and showed that the genes are also transcribed by a common promoter (Sugimoto et al., 
1994).  Although COLIVA6 is expressed in some tissues in the kidney such as 
Bowman's capsule and the collecting ducts, it is not expressed in the GBM of humans or 
in young dogs, but is expressed in older dogs (Peissel et al., 1995; Lees et al., 2000). 
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As mentioned previously, the colIVα1 and colIVα2 chains were first identified 
in 1971 by Kefalides from cyanogen bromide cleavage of bovine anterior lens capsule 
(Kefalides, 1971). The genes for the colIVα1 and colIVα2 monomers of type IV 
collagen have been isolated, sequenced and located autosomally on human chromosome 
13 (Griffin et al., 1987; Saus et al., 1989; Soininen et al., 1988). These genes in the 
human are arranged in a head to head configuration and are transcribed by a common bi-
directional promoter (Poschl et al., 1988; Soininen et al., 1988). This promoter region 
had no detectable transcriptional activity in transient gene expression assays after fusion 
to the chloramphenicol acetylase (CAT) gene in either direction indicating the necessity 
of additional elements for efficient and tissue specific expression of both genes (Poschl 
et al., 1988).  No molecular defects in these genes have been identified in HN. It is 
unlikely that mutations in COLIVA1 and COLIVA2 genes would be found in specific 
diseases since these genes are expressed in embryonic development and their products 
are found in most basement membranes (Trueb et al., 1982). In other words, structural 
defects in these molecules would not be tolerated in development and would lead to 
wide ranging pathologies. In fact, temperature sensitive mutations in the COLIVA1 and 
COLIVA2 genes in C. elegans cause embryonic lethality (Guo 1989). It is suggested that 
genetic defects resulting in a loss of function in a tissue specific collagen species, such 
as COLIVA3 or COLIVA4, is more likely in autosomal forms of HN.  
The colIVα3 chain was first isolated using antibodies from patients with 
Goodpasture syndrome (GS). GS is an autoimmune disorder in humans where patients 
have circulating antibodies to GBM components and develop rapidly progressive 
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glomerulonephritis. After collagenase digestion, preparations from bovine GBM that 
reacted with Goodpasture sera identified the NC-1 domain of collagen type IV as the 
targets of Goodpasture antibodies (Wieslander et al., 1984). Further investigation with 
lens basement membranes using reverse-phase HPLC, SDS-PAGE and amino acid 
sequencing showed the Goodpasture antigen to be a novel collagen type IV isoform 
designated colIVα3 (Butkowski et al., 1987; Saus et al., 1988). Another result of this 
same investigation was the identification of another novel collagen type IV isoform 
designated colIVα4. Although the above investigation only briefly characterized these 
novel proteins with respect to differential electrophoretic migration patterns and 
immunoreactivity, the discovery of new colIV isoforms opened the door to many other 
findings including the understanding of basement membrane structure and function. 
These findings also helped to explain the molecular basis of many inherited basement 
membrane pathologies that will be discussed below. 
The human COLIVA3 and COLIVA4 genes have been mapped to human 
chromosome 2 and, similar to the genes described above, are situated in a head to head 
configuration (Kamagata et al., 1992; Mariyama et al., 1992; Morrison et al., 1991).  
They have also been mapped autosomally in the dog (personal communication). In the 
human genome, both the COLIVA3 and COLIVA4 genes have been suggested to cover 
over 100 kb and to contain over 50 exons (Boye et al., 1998; Heidet et al., 2001). Each 
gene produces a product of approximately 1,700 amino acids from an ~5,000 base 
coding region (Leinonen et al., 1994; Mariyama et al., 1994). Partial bovine COLIV 
cDNA sequences have also been isolated using human sequences as primers for PCR 
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amplification (Morrison et al., 1991). The COLIVA3 and COLIVA4 genes produce 
major components of the GBM and aberrations in these genes have been found in 
humans with autosomal HN which will be discussed in later sections (Boye et al., 1998; 





Extracellular matrices (ECMs) are classified into two categories. One form of 
ECM fills spaces between cells and has many receptors for the binding of cytokines and 
growth factors. The other form of ECM creates basement membranes, which are thin 
sheets around tissues and were initially termed reticulin (Rambourg and Leblond, 1967). 
Together the separate components of basement membranes create a scaffold for cells and 
maintain the structural integrity of many tissues. Although having similar components, 
basement membranes are not necessarily the same in all tissues. Early immunological 
assays of the canine kidney showed differences between the basement membranes of the 
tubules and of the GBM (Krakower, Goodman 1955). Their research showed that 
although these basement membranes were made predominantly from collagen, the 
antigenic epitopes differed between these structures although, at the time of this report, 
the collagens causing the immunological reactions they observed had not been 
identified. The ECM plays an important role in modulating the behavior of cells with 
which it interacts. The major molecules that constitute the ECM include collagen type 
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IV, entactin/nidogen (E/N), laminin and heparine sulfate glycoprotein (HSGP). A model 
system for the study of ECM components is the Engelbreth-Holm-Swarm (EHS) cell 
line, which is derived from a benign mouse tumor and produces abundant ECM 
molecules (Swarm, 1964). The EHS matrix consists of 60% laminin, 30% colIV, 3% 
heparine sulfate proteoglycans and 6% E/N (Kleinman et al., 1986). 
The glomerular basement membrane (GBM) is a specialized ECM created 
predominately by podocytes of the kidney. Aberrations in the GBM have been shown to 
be associated with podocyte abnormalities including effacement and resulting kidney 
pathologies including proteinuria. The major components of the GBM and their 
molecular interactions will be discussed in this section, except for colIV whose role in 
the GBM has been described above and will also be discussed in subsequent sections.  
Although constituting a small proportion of overall basement membrane mass, 
E/N will be discussed first because of its ability to bind to all of the other major 
components of the GBM. Two groups characterized this molecule independently from 
different sources. The first group described a basement membrane component isolated 
from a mouse carcinoma cell line and named the molecule entactin (Carlin et al., 1981). 
Another group isolated a similar product from the EHS matrix and named the molecule 
nidogen (Timpl et al., 1983). Both molecules were glycoproteins of approximately 150 
kD. Amino acid and cDNA sequence analysis of entactin and nidogen in mouse and 
human demonstrated that both were identical molecules and thus can be referred to 
collectively as E/N (Durkin et al., 1988; Mann et al., 1989; Nagayoshi et al., 1989). The 
gene for E/N has been located autosomally on human chromosome 1 (Olsen et al., 
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1989), and it has been shown that E/N expression can be detected at the 8-16 cell stage 
in mouse development (Dziadek and Timpl, 1985; Wu et al., 1983). Expression of E/N 
has also been found in the GBM (Saxena et al., 1990). Electron microscopic rotary 
shadowing of E/N shows a linear molecule composed of three globular domains (G1, G2 
and G3) separated by two rod-like domains, and has a total length of approximately 
30nm (Fox et al., 1991). E/N binds to laminin via the G3 domain (Mann et al., 1988) and 
to collagen IV via its G2 domain (Aumailley et al., 1989; Fox et al., 1991). E/N has also 
been shown to bind to the protein core of HSGPs in basement membranes (Battaglia et 
al., 1992). Thus, although E/N was first identified by co-immunoprecipitation with 
laminin, it appears that apart from being able to bind to itself, E/N can bind to all of the 
other major basement membrane components. Its ubiquitous and early expression 
indicate a strong role in basement membrane assembly.  
Other isoforms of E/N have been reported in mouse and human (Kimura et al., 
1998; Kohfeldt et al., 1998). The mouse isoform has been termed entactin-2 while the 
human isoform is termed nidogen-2. These new isoforms can be conjointly termed E/N-
2. These molecules show similar structure to the original E/N-1 molecules, but share less 
than 50% sequence homology to the E/N-1 isoforms (Kohfeldt et al., 1998). E/N-2 is 
proposed to have similar function to E/N-1 because E/N-2 binds to laminin, but at a 
different site and with less affinity than E/N-1, and has colIV and HSGPs binding ability 
equal to the E/N-1 isoforms (Erickson and Couchman, 2000). The discovery of E/N-2 
suggests the other E/N isoforms may exist and may be a growing family of ECM 
molecules with different tissue specific functions. 
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Many non-collagenous glycoproteins are building blocks of ECMs, but the 
laminins are the most ubiquitous and abundant in basement membranes. Laminin was 
first isolated from an EHS matrix (Timpl et al., 1979). Laminins are large 
heterotrimereric molecules of 400-600 kD and it has been shown that the laminins can 
self assemble in vitro into independent networks via intermolecular bonding (Yurchenco 
et al., 1992; Yurchenco et al., 1985). The network forming ability of laminin is thought 
to be important for basement membrane stability. The laminins have evolved into a 
family of proteins with many different isoforms. These laminin isoforms include five 
different α-chains (α1-α5), three different β-chains (β1-β3) and three different γ-chains 
(γ1-γ3) (Burgeson et al., 1994). The composition of a mature laminin molecule includes 
one of each of the three chains. It is possible to predict which laminin trimers are present 
in basement membranes by co-localization with immunohistochemical staining of 
individual laminin chains. Theoretically, 45 trimeric formations of laminin chains can 
exist (5α chains x 3β chains x 3γ chains). To date, however, only 12 different laminin 
isoforms have been reported (Burgeson et al., 1994). The most abundant laminin in the 
GBM is laminin-11 composed of a trimer of α5β2γ1 chains (Miner et al., 1997). 
Laminin-9 (α4β2γ1) has been reported in developing GBM (Miner et al., 1997), but the 
α4 chain gradually disappears as the glomerulus matures (Miner et al., 1998). The 
functions of the laminins have been inferred by identification of mutations in these genes 
in specific diseases, or by knockout experiments of specific laminin chains in mice. It is 
presumed that the knockout of a specific laminin chain will result in the loss of function 
of the mature laminin trimeric molecule. Knockout experiments involving the β2 chain 
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in mice results in early death due to massive proteinurea and show fusion of the 
podocyte foot processes, although, the GBM appears normal (Noakes et al., 1995). 
While the α5 chain of laminin is also present in laminin-10 (α5β1γ1) which is present in 
most basement membranes of the kidney (Miner et al., 1997), laminin α5 genetic 
knockouts also affects laminin-11 (α5β2γ1) in the GBM. As expected, the α5 knockouts 
have much more devastating effects on kidney development and the mice die in utero  
(Miner et al., 1998). The α5 chain of laminin has been shown to be essential for 
glomerulogenisis, and the laminin α5 knockout mice also have neural tube defects that 
indicate the importance of this chain in other tissues (Miner and Li, 2000).   
Like the E/N isoforms described above, the laminins can form associations with 
other ECM molecules. A strong component of laminin function in basement membrane 
architecture involves molecular associations with integrins. Integrins are a diverse family 
of integral membrane glycoproteins that function to mediate interactions of cells with the 
ECM. Integrins also function to mediate cell:cell interactions and cell signaling 
(DeSimone et al., 1987). Integrins are dimeric proteins that contain α and β chains. 
There have been 19 integrin α and 8 integrin β chains reported and 25 different 
combinations of these chains have been described (Humphries, 2000). The molecular 
association of laminins and integrins directly links the ECM to the surface of the cells. 
Many regions of laminin have been reported to associate with integrins and many 
integrin–laminin associations have been reported (Belkin and Stepp, 2000). 
 As mentioned previously, the laminins bind E/N in a 1:1 equimolar association; 
that is, one molecule of laminin binds one molecule of E/N. Unlike E/N, however, 
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laminin can self assemble to form an independent network in basement membranes 
(Yurchenco et al., 1992).  The specific epitope of laminin that binds E/N has been 
located on the γ chains with the γ1 chain having the strongest association, and antibodies 
to this region inhibit laminin:E/N binding (Mayer et al., 1993). Thus, the laminin-E/N 
interaction connects the colIV and laminin networks as well as other ECM components 
such as the HSPGs. The direct binding of laminin to HSGPs can increase these 
interactions. The triple helical core of laminin has been shown to bind to agrin, a specific 
HSGP in the in the GBM (Denzer et al., 1997).  
The carbohydrate content of basement membranes was first demonstrated by 
periodic acid-shiff staining techniques and attributed to glycoproteins in 1957 (Leblond 
and Inoue, 1989). Heparine sulfate glycoproteins (HSPGs) are found in all basement 
membranes and consist of a protein core to which several carbohydrate chains are 
attached (Paulsson et al., 1987). HSPGs contain heparine sulfate as its 
glycosaminoglycan (GAG) side chain that is composed of unbranching repeating 
disaccharide units with the aminosugar glucosamine. The glucosamine component of 
HSPG is extremely sulfated and creates a hydrophilic positively charged environment in 
basement membranes (Kanwar and Farquhar, 1979b). The anionic nature of the GBM 
created by the presence of HSPG is extremely important to GBM permselectivity and 
will be discussed in later sections.   
Based on immunoflourecent studies with antibodies directed against the core 
proteins of HSGPs, the most abundant HSGP in the GBM is agrin (Groffen et al., 1997; 
Groffen et al., 1998). Low levels of agrin are also detected in other basement membranes 
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in the kidney in the rat, but are attributed to different agrin isoforms (Raats et al., 1998). 
The 95nm protein core of agrin has many domains but its most N-terminal region has 
been shown to be necessary for the binding of laminin-1 (Denzer et al., 1997; Denzer et 
al., 1995). Agrin has also been shown to bind laminin-2 (Cotman et al., 1999) and 
integrin α5β1 (Martin and Sanes, 1997) and, although these specific isoforms have not 
been identified in the GBM, as has been discussed, intermolecular associations are 
essential for GBM architecture. Although this investigation focuses on the components 
of the GBM, agrin is also known as a key component of the neuromuscular junction 
(Denzer et al., 1998).  Agrin was first identified as a synaptic organizing protein 
associated with aggregation of acetylcholine receptors and acetylcholinesterase at 
regenerating neuromuscular junctions in vivo in Torpedo (an oceanic ray)  (Nitkin et al., 
1987). Initially identified as an aggregating factor, the molecule was termed agrin. Agrin 
has been characterized as a large glycoprotein of over 400 kD when fully glycosylated 
(Tsen et al., 1995) and has been mapped autosomally in both human and mouse 
(Kallunki et al., 1991; Rupp et al., 1991).  The importance of agrin has been 
demonstrated with knockout experiments in mice which result in aberrant kidney 
development and death at birth (Gautam et al., 1996).  
Other proteoglycans in basement membranes of the kidney include perlecan, 
bamacan and colXVIII. Perlecan is widely expressed in the kidney, but has restricted 
distribution and is not predominant in the GBM (Groffen et al., 1998). Bamacan is a 
chondroitin sulfate glycoprotein which also has widespread distribution in the kidney, 
but has not been detected in the GBM (Wu and Couchman, 1997). ColXVIII has been 
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shown to be a glycoprotein (Halfter et al., 1998) and expression of colXVIIIα1 has been 
reported in the GBM (Muragaki et al., 1995). ColXVIII has been classified into a 
subfamily of non-fibrillar collagens with multiple interrupted triple helical domains, but 
any role in any pathology has yet to be determined (Oh et al., 1994).  
One of the fascinating aspects of basement membrane biology is the ability of the 
individual components to self assemble in vitro. Individual basement membrane 
components from EHS cells (including laminin, E/N, collagen type IV and HSPG) were 
isolated from purified extracts and, when combined, at physiologic temperatures, 
spontaneously assembled into structures that resembled the lamina densa of basement 
membranes (Grant et al., 1989).  
The increased knowledge of basement membranes, including the above studies, 
indicates a complexity of basement membrane architecture through specific molecular 
associations that reflect the diverse nature and function of all ECMs. For example, it is 
now problematic to discern the exact point of transition from the ECM, the cell 
membrane and the cytoskeleton. The specific focus of this study is directed toward the 
GBM, a specialized ECM. The GBM is subjected to tremendous forces and constant 
pressure from birth until death. The delicate nature of this structure can be revealed if 
any component has a loss of function from either environmental influences or genetic 
aberrations. The composition of basement membrane structure that has been described 
above is based on specific intramolecular and intermolecular associations and has been 
focused primarily on molecules expressed in the GBM. Interruptions in these molecular 
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associations result in decreased performance of the GBM and, as will be discussed 
below, an overall loss of kidney function. 
 
Kidney Structure and Function 
 
The kidneys  regulate arterial pressure, extracellular fluid osmolarity, blood and 
extracellular fluid volumes, acid-base balances in the body and the excretion of 
nitrogenous waste products. Although the kidneys perform many physiological 
functions, the focus of this investigation will concentrate on the kidney as the site for the 
ultrafiltration of plasma.  
Many aspects of human kidney function can be found in numerous textbooks on 
physiology including “The Textbook of Medical Physiology” (Guyton, 1991) and 
“Physiology” [Sperelakis, 1996]. Other resources written with specific reference to 
kidney function include “(The) Kidney” [Brenner 1991] and “Pathology of the Kidney” 
[Heppinstall, 1992]. These references will be used to describe the basic nature of kidney 
physiology. 
Normally, there are both left and right kidneys and each kidney is profused with 
one renal artery and drained with one renal vein. In between, the flow from the renal 
artery is divided into individual arterioles, many of which introduce blood to individual 
nephrons. Although there are two kinds of nephrons, the cortical nephrons and the 
juxtaglomerular nephrons, each nephron is capable of formation of urine. Therefore, 
although nephrons in mammalian kidneys number in the hundreds of thousands, urine 
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formation can be described using a single nephron.  Each glomerulus, it’s associated 
tubule and vascular structure defines a nephron. Blood flows to the glomerulus, the main 
filter of the kidney, through the afferent arteriole and exits through the efferent arterial. 
Every component of blood is passed through the capillary structure of the glomerulus. 
The afferent arteriole is divided into approximately fifty capillaries in each glomerulus. 
The capillaries of the glomerulus are uniquely fenestrated, that is, the capillaries of the 
glomerulus have thousands of small holes averaging from 500 A° to 100 A° in diameter. 
This allows the blood of the capillary structure of the glomerulus to come into direct 
contact with the underlying basement membrane (GBM). The GBM is sandwiched 
between the endothelial capillaries of the glomerulus and the epithelial cells that 
surround the glomerular capillaries. The epithelial cells are called podocytes. Podocytes 
are specialized epithelial cells that interdigitate with one another to form the foot 
processes. The interdigitation of podocytes forms slit diaphragms (also known as 
filtration slits) in the glomerular epithelium. The podocytes of the glomerulus are 
surrounded by another epithelial structure known as Bowman’s capsule. Bowman’s 
capsule forms the first structure of the urinary space and is the collecting site for the 
primary filtrate that is created by the ultrafiltration of plasma. 
Thus, ulrafiltration of plasma is directed in the glomerulus from the fenestrated 
capillary across the GBM and through the slit diaphragms created by the epithelial 
podocytes and into Bowman’s capsule. From Bowman’s capsule the primary filtrate 
flows into the tubular structure of the nephron where further processing of the primary 
filtrate occurs. The active participation of the tubular epithelial cells contribute to the 
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processing of the primary filtrate and is an essential process for the ultimate formation of 
urine.  
One of the basic functions of urine formation can be described as the excretion of 
unwanted substances. Unwanted substances in the blood include excesses of sodium, 
potassium and chloride ions as well as end products of metabolism including urea and 
creatinine. In as it is a basic function of the nephron to clear the plasma of unwanted 
substances, the nephron must be selective and not allow cells or large proteins to pass 
into the urinary space. While the average human has about 40 liters of total body fluid, 
180 liters of plasma is filtered per day, creating 14 liters of primary filtrate and 
ultimately 1.4 liters of urine per day. Therefore, the glomerulus filters a large amount of 
plasma to create a primary filtrate that flows into the urinary space and then into the 
tubular portion of the nephron. In the tubular structure, the unwanted substances are 
passed in the formation of urine, while most of the water and many other solutes are 
reabsorbed. Most of the soluble components of the blood pass through the filtration 
mechanisms of the glomerulus and are present in the primary filtrate. Electrolytes are 
reabsorbed with water according to homeostatic demands. Larger serum proteins are 
normally not allowed passage into the tubular space.  One of the smallest of plasma 
proteins, as compared to fibrinogen at 340 kD or immunoglobulins at 150-900 kD, is 
albumin with a molecular weight of 69 kD. Albumin is normally not allowed passage 
through the GBM into the urinary space. While small amounts of proteins are present in 
the proximal tubule, with normal kidney function, these proteins are cleared during urine 
formation. Small proteins that may pass through the ultrafiltration processes undergo 
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pinocytosis via cells of the proximal tubule. Proteinuria refers to the presence of protein 
in the urine. Hematuria refers to the presence of erythrocytes or cell structures (cell 
casts) in the urine. Neither is present in normal urine. A wide range of pathologies, many 
of which will be described in later sections, are associated with abnormalities in the 
filtration process.  
The structure and function of the mammalian kidney has long been a subject of 
fascination and experimentation. An experimental model of nephritis was established in 
1900 by Lindemann by introducing serum from a guinea pig immunized with rat kidney 
that became nephrotoxic when injected into rabbits. This experimental model was 
refined further when sonicated preparations of GBM were used in the initial 
immunization helping to establish the GBM at the target site for nephrogenic antigens 
(Rohrbach, 1991). Electron microscopy had been used for many purposes, but it was not 
until 1948 when a method described by Pease and Baker was used to make fine 
sectioning of biological tissues that this powerful tool could be used to examine fine 
tissue structure (Pease and Baker, 1950). Their method allowed an ultrathin sectioning of 
.05 microns and their survey resulted in many findings. They were able to describe the 
“brush border” of the proximal tubule, the fenestrated nature of the glomerular 
endothelium and detailed descriptions of the glomerular basement membrane. They 
describe the GBM as “pictorially most spectacular”. They described the GBM as thin 
(300-350 nm) and existing as a continuous layer around the fenestrated endothelium that 
is in direct contact with the epithelial cells of the glomerulus. These studies, among 
others, have shown the GBM to be a specialized structure in the kidney. The molecular 
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composition of the GBM has been described above.  The role of the GBM with respect 
to ultrafiltration and the importance of changes in the GBM associated with disease will 
be discussed below. 
 
 
Mechanisms of Glomerular Permselectivity 
 
The mechanisms of glomerular permeability have been an object of discussion 
for some time. In 1960, a seminal study was done by Farquhar et al. describing ferritin 
transfer across the glomerular capillary wall to explore the mechanisms of glomerular 
ultrafiltration (Farquhar et al., 1961). Although the structure of the renal glomerulus had 
been described, little was known about the mechanisms involved in the transport of 
substances from the capillary to the urinary space. At that time two prevailing 
hypotheses had been established for glomerular filtration. One was that the glomerular 
basement membrane acted as the main filter of the kidney since the majority of the 
electron microscopists had described the GBM as the only continuous layer around the 
capillary wall. The other hypothesis indicated that the spaces between the foot processes 
of the epithelial cells acted as slit pores allowing for the free passage of water and small 
molecules but restricted the passage of proteins. The approach of Farquhar et al to 
explore the mechanisms of glomerular permeability was to directly observe the pathways 
of glomerular filtration across the capillary wall by introducing a particulate tracer able 
to be seen by electron microscopy. Their main conclusion, held for many decades, was 
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that the glomerular basement membrane was the main filter of the kidney in that there 
were no identified channels across the foot processes. They observed, however, that the 
filtration was not perfect and that any small molecules, especially proteins, would be 
absorbed through pinocytosis in the epithelium. They further concluded that the function 
of the GBM is probably dependent on both the epithelium and endothelial layers and any 
agent that would interfere with these cells could affect the chemical composition and 
therefore the permeability of the basement membrane. This group reinforced their 
conclusions with a report using graded dextrans to determine the molecular weight 
limitations of glomerular filtration (Caulfield and Farquhar, 1974). These results found 
that the size limitations of glomerular filtration using dextran sulfate were 40-50 kD. 
While 14 kD dextran was cleared from the bloodstream easily, progressive size resulted 
in decreased clearance until approximately 55-60 kD where there was a sharp decline of 
clearance. This corresponded to the clearance of albumin, which at a molecular weight 
of 68 kD does not cross the GBM. In other words, they identified the size limitation of 
the filtration of the GBM at 10A° while the size of albumin is 36A°. Their results helped 
to reinforce that the GBM is the primary filtration barrier to plasma proteins. Thus, the 
size and weight of molecules is important for glomerular permselectivity and further 
studies showed that the charge of a molecule is also significant in determining “charge-
selectivity” (Chang et al., 1975). Again, using the normally neutrally charged dextran 
sulfate in the previous research, charges were added to the molecules to make it either 
positive or negatively charged. Their results showed that positively charged molecules 
pass through the GBM much faster than a neutrally charged molecule and that a 
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negatively charged molecule is inhibited from crossing. It is interesting to note that 
albumin is a negatively charged molecule. The mechanisms of charge and filtration is 
based on the fact that the heparine sulfate glycosaminoglycans (GAGs) that are 
imbedded in the GBM are anionic (Kanwar and Farquhar, 1979a). In fact, the loss of 
these anionic sites is associated with some forms of nephrosis (Caulfield and Farquhar, 
1978; Rohrbach et al., 1983) and the removal of GAGs using GAG-degrading enzymes 
allows albumin to pass through the GBM (Rosenzweig and Kanwar, 1982). In more 
recent reports, an acute, selective proteinurea could be induced in rats by a single 
intraveinous injection of a monoclonal antibody directed against the most abundant 
HSPG in the GBM, agrin (van den Born et al., 1992).  
Some of the first evidence for an alternative view of glomerular ultrafiltration 
came from studies using peroxidase molecules as tracers (Graham and Karnovsky, 
1966). The peroxidase molecules were twice the size of human albumin and large 
enough to be retained by the glomerular structure. These studies found that a greater 
concentration of reaction product was retained in the portion of the basement membrane 
adjacent to the epithelial foot processes. They further reported that much of the product 
was retained on the epithelial membranes and between the foot processes adjacent to 
mesangial areas and more specifically in the epithelial slits. Only after some time did the 
peroxidase product stain the glomerular basement membrane. There was little 
disagreement that filtrate passed from the capillary lumen through the endothelial 
fenstrae, across the basement membrane, and through the epithelial slits into the urinary 
space, but these studies suggested the restriction of passage occurred at the epithelial 
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slits. This challenged the hypothesis that the GBM was the principle glomerular filter 
and suggested that the main filter barrier is distal to the GBM located at the epithelial 
slits; that the GBM was regulated in function as a “course filter” and that the epithelial 
slits are the principle filtration barrier.  
During this early stage of research, however, the structural evidence for a 
mechanism at the slit pore was unknown, but the use of new staining techniques 
identified structures in support of this hypothesis. With the use of tannic acid fixative for 
electron microscopy, a structure termed the “slit diaphragm” was identified at the 
epithelial slits between the foot processes (Rodewald and Karnovsky, 1974). The slit 
diaphragm was identified as an isoporous structure with rectangular pores of 
approximately 40A° across, 140A° through the slit diaphragm and 70A° in length. The 
dimensions of the pores found in the slit diaphragm were smaller than the 70A° width of 
albumin, and supported the hypothesis that the slit diaphragm was the principal filtration 
barrier to plasma proteins. Furthermore, these studies showed that the slit diaphragm was 
a continuous, two-dimensional band that extended to all foot processes so it is a 
necessary structure for molecules to cross this in the filtration process and diminished 
the uniqueness of the GBM in this regard. Detailed analysis of the electo-imagery 
reported in this same investigation described another new “zipper-like” spacing of cross 
bridges within the slit diaphragm although the molecular nature of these novel structures 
could not be revealed until recently.  
 Mapping the genetic defect in congenital nephrotic syndrome of the Finnish 
(NPHS1) type, an autosomal recessive disorder in humans, identified the first of these 
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molecules in the slit diaphragm. Congenital nephrotic syndrome (CNS) is a 
heterogeneous group of renal diseases that result in increased postnatal glomerular 
permeability and proteinurea early in life. Mapping of NSPH1 using positional cloning 
localized the gene to a 150 kb region on chromosome 19q13.1 and sequencing of this 
region revealed 11 candidate genes, one of which was mutated in affected families 
(Kestila et al., 1998). Over 30 different mutations in the NSPH1 gene (Nphs1) have been 
identified (Lenkkeri et al., 1999).  Nphs1 codes for nephrin, a large transmembrane 
glycoprotein, that is 26 kilobases, has 29 exons, and codes for a 4.3 kb mRNA and is a 
member of the Ig superfamily (Kestila et al., 1998). Rat and mouse nephrin genes have 
also been characterized and show high homology and similar organization to the human 
genes (Putaala et al., 2000).  Nephrin has been specifically located to the slit diaphragm 
in human (Ruotsalainen et al., 1999) and mouse  (Holzman et al., 1999). It is postulated 
that pairs of nephrin molecules compose the molecular zipper between the foot processes 
of podocytes. A model for NPHS1 has been created by inactivation of the Nphs1 gene in 
mice that will provide a powerful system for future studies (Putaala et al., 2001). Also, 
the glomerular specific promoter for the nephrin gene has been inserted into two systems 
that may facilitate the identification of transacting factors that are required for podocyte-
specific expression of GBM molecules. (Moeller et al., 2000; Wong et al., 2000) 
 Another necessary component for slit diaphragm assembly was previously well 
characterized, and yet its function in the kidney has only recently been revealed. The 
CD2-associated protein (CD2AP) is critical for stabilizing contacts between T cells and 
antigen presenting cells and is termed CMS in humans. Knockout mice in this gene were 
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developed in an effort to determine the loss of CD2-associated protein (CD2AP) on 
immune function (Shih et al., 1999). A knockout of the first intracellular SRC homology 
domain (SH3) in blastocysts resulted in a diminished immune capacity, but these mice 
also developed a form of congenital nephrotic syndrome. The cause of renal failure was 
determined to be due to the loss of foot processes in the glomerulus. Further, it was 
shown that the CD2AP co-immunoprecipitated with nephrin (Shih et al., 1999). CD2AP 
is expressed in the slit diaphragm and binds nephrin via a novel c-terminal domain (Shih 
et al., 2001). Because of the known function of CD2AP in T cells, it is suggested that 
CD2AP anchors nephrin to the internal protein fibers that form the podocyte 
cytoskeleton to help form and stabilize the slit diaphragm (Yuan et al., 2002). 
The study of pathologies with apparent filtration barrier defects can provide 
useful models for the discovery of the genes and molecules responsible for normal 
glomerular filtration and the molecular basis of disease. This has been demonstrated in 
the study of focal segmental glomerulosclerosis (FSGS). FSGS is heterogeneous group 
of disorders manifested as non-specific renal lesions secondary to other disorders or as a 
specific inherited condition. FSGS may be defined by the presence of segmental 
sclerosis in some, but not necessarily all glomeruli, and is characterized by increased 
urinary protein excretion and decreased kidney function leading to end-stage renal 
failure (Ichikawa and Fogo, 1996). 
 The steroid-resistant form of FSGS in humans (SRN) is an autosomal recessive 
disorder and has been mapped to chromosome1q25-31 (Fuchshuber et al., 1995). 
Recently, mutations in the Nsph2 gene have been reported in families with SNR (Boute 
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et al., 2000). The product of Nsph2 has been termed podocin because the expression of 
this gene is restricted to fetal and adult podocytes. The podocin gene codes for a 42 kD 
protein from a 1,149bp open reading frame. It is a putative integral membrane protein 
and shows homology to human stromatin, which appears to be an ion channel associated 
with the cytoskeleton. Although the actual function of podocin is unknown, it is possible 
that it may be involved in organizing the cytoskeleton of podocyte foot processes at the 
slit diaphragm and may also interact with other podocyte proteins necessary for slit 
diaphragm assembly. It has been reported that podocin co-localizes with nephrin to the 
actin cytoskeleton protruding from the tips of actin filaments (Saleem et al., 2002). The 
cytoplasmic side of podocin has molecular homology for binding to an SH-3 binding site 
similar to the structure found in the CD2AP above. 
 The gene responsible for the autosomal dominant form of FSGS has been 
mapped to human chromosome 19q13 and mutations in the gene encoding α-actin-4 
(ACTN4), which resides at this locus, have been reported in three families (Kaplan et al., 
2000). Although the exact function of ACTN4 with regards to FSGS is unknown, 
expression of this gene occurs in capillaries, glomerular podocytes and in other tissues 
such as circulating lymphocytes. ACTN4 is an actin crosslinking protein and it is 
postulated that regulation of the actin cytoskeleton of glomerular podocytes may be 
altered in FSGS thus interfering in normal filament assembly in the foot processes. This 
indicates that the actin cytoskeleton in podocytes may be involved in normal glomerular 
ultrafiltration and in the pathogenesis of proteinurea. Because ACTN4 is also expressed 
in capillaries, it is possible that a loss of function in this gene could also change the renal 
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vasculature cytoskeleton and thus alter glomerular hemodynamics leading to the 
described phenotype. Regions relating to other forms of inherited FSGS have been 
mapped in the human, but the specific genes for these syndromes have not yet been 
identified. 
 These studies show a complex design of glomerular ultrafiltration that includes 
the coordinate function of the slit diaphragm and the GBM involving many gene 
products. The function of each of these genes is associated and/or dependent on 
intermolecular and/or intramolecular associations of other GBM components. The loss 
of function of any of these components can, therefore, lead to molecular dissociation and 
subsequent failure of overall glomerular ulatrafiltration processes and, hence, an overall 
loss of kidney function. As will be discussed, the products of the COLIV genes have 
been shown to be specifically involved in these processes. 
 
Alport Syndrome and Other Diseases of the GBM 
 
Although there are many diseases that are aimed at various parts of the nephron, 
like the slit diaphragm pathologies described above, diseases referred to as HN can be 
located directly to components of the GBM. Owing to its similarities to the form of 
hereditary nephritis in English cocker spaniel dogs which is the focus of this 
investigation, Alport Syndrome (AS) will be discussed more fully than other diseases of 
the GBM. 
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In humans, AS is the most common form of HN with an estimated gene 
frequency of 1:5000 (Atkin, 1988). Dr. Cecil Alport in 1927 first reported the symptoms 
associated with a new clinically relevant syndrome, which is now referred to as Alport 
Syndrome (AS) (Alport, 1927). Dr. Alport described an inherited nephrotic condition 
that was associated with deafness where male members of a family progressed to end 
stage renal disease (ESRD). The characteristics of AS have since been shown to be very 
heterogeneous. In 1988 AS was classified into six different types based on clinical 
criteria (Atkin, 1988). Type I was classified as juvenile Alport with deafness, type II was 
X-linked with deafness, type III was X-linked adult with deafness, type IV was X-linked 
adult without deafness, type V was autosomal with deafness and thrombocytopathy and 
type VI was autosomal with deafness. 
The most common and identifiable characteristic of AS are renal abnormalities. 
In individuals with hereditary nephritis, the lamina of the GBM show structural 
abnormalities including overall thickening and splitting that can be seen by electron 
microscopy (Churg and Grishman 1972; Hinglais et al. 1972; Spear and Slusser 1972). 
AS can be diagnosed when the characteristic splitting of the GBM is observed 
(Heptinstall, 1992). 
The most common extra-renal defect associated with AS is deafness, which is 
frequent, but not universal, and occurs in approximately 50% of all patients (Wester et 
al., 1995). While renal disorders are not always accompanied with hearing loss in AS, 
members with hearing loss in families diagnosed with AS always have accompanied 
renal disorders (Gubler et al., 1981).  Also, there have been no reports of deaf males 
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without kidney disease transmitting AS to any offspring (Gubler et al., 1981). While the 
exact mechanism for the loss of hearing in AS patients has not yet been determined, the 
defect has been isolated to areas of the inner ear (cochlea).   
Other common extra renal abnormalities associated with AS include a variety of 
ocular defects. While ocular defects may be present in less than half of all AS cases 
(Chance and Stanley, 1977), a condition known as anterior lenticonus is virtually 
pathognmonic of AS (Nielsen, 1978).  Anterior lenticonus is the protrusion of the central 
portion of the lens into the anterior capsule and is most associated with AS families with 
deafness and with rapid progression to end stage renal disease. Other ocular defects seen 
in patients with AS include changes in various basement membranes of the eye including 
Bruch’s membrane, Descemet’s membrane and corneal basement membranes (Govan, 
1983; Rhys et al., 1997; Teekhasaenee et al., 1991).  
Other extra renal abnormalities associated with AS include leiomyomatosis 
(hyperplasia of smooth muscle) (Cochat et al., 1988), and hematological defects such as 
thrombocytopenia (Epstein et al., 1972). The presence of hematological defects in AS is 
interesting because unlike the tissues described above, blood cells do not have classic 
basement membrane architecture. 
Since the diagnosis of AS has been based on certain clinical findings, confusion 
over diagnostic procedures and AS classification is understandable given the 
heterogeneity described above. Further complications over the proper diagnosis and 
classification of AS can be attributed to heterogeneity within a particular type of AS. 
The severity of symptoms varies from person to person and small kindereds contain too 
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few individuals to meet many of the clinical and histologic criteria for proper 
classification. Precise diagnosis and classification of AS is important for several reasons 
including genetic counseling and the establishment of individual prognoses. 
Furthermore, there are many diseases that can be confused with AS. 
Although difficulties in the diagnosis of AS have been reported, a core of traits 
can be associated with all types of AS that have been described above. These include a 
hereditary disease with chronic hematuria that is progressive and characterized 
ultrastructurally by irregular GBM structure. Furthermore, AS can be differentiated from 
immune related glomerulonephritic diseases. Most importantly, AS can be generally 
classified as having either X-linked or autosomal inheritance.  
Of the many types of AS that have been classified, the molecular basis of disease 
was first identified for X-linked AS (XLAS). In the initial investigation of the molecular 
basis of XLAS, it was known that basement membrane ultrastructural aberrations were 
pathognomonic of AS and that collagen type IV made up the structural framework of the 
GBM (Churg and Sherman, 1973; Hinglais et al., 1972; Spear and Slusser, 1972). Also, 
the genetic element responsible for XLAS had been mapped to the X chromosome 
(Atkin et al., 1988; Szpiro-Tapia et al., 1988).  The identification of the minor species of 
type IV collagen including the COLIVA5 gene (Hostikka et al., 1990; Pihlajaniemi et 
al., 1990) and the mapping of COLIVA5 to the X-chromosome (Hostikka et al., 1990) 
identified COLIVA5 as a strong candidate gene. These reports focussed efforts toward 
the screening of this gene in families with X-linked AS. The first mutations in the 
COLIVA5 gene were reported in 1990 (Barker et al., 1990). Since that time, hundreds of 
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different mutations have been found in all parts of the COLIVA5 gene in affected 
families (Martin et al., 2000). These genetic abnormalities include deletions, insertions, 
and splice mutations. All of these mutations have been found to alter the COLIVA5 gene 
producing nonsense mutations that introduce premature stop codons or missense 
mutations that result in the substitution of amino acids. Frequently these missense 
mutations result in the substitution of a glycine residue. As discussed previously, glycine 
is necessary at every third residue for proper collagen folding and function. Major 
rearrangements in the COLIVA5 gene are very rare (Boye et al., 1991; Renieri et al., 
1992). Even though linkage to the COLIVA5 gene has been established, mutations in the 
COLIVA5 gene can not always be found (Kawai et al., 1996). 
Proper folding and subsequent trimer formation is essential for collagen type IV 
function. The loss of function is visualized in immunohistochemical studies that show 
the absence of staining of the product in target tissues. The collagen type IV molecules 
create distinct networks to form the structural framework of the basement membranes. 
The COLIVA5 product, which is usually present in the GBM, Bowman’s capsule and 
distal tubule basement membrane, is absent in patients with X-linked AS (Nakanishi et 
al., 1994). COLIVA5 is also normally expressed in the lens capsule and Decemet’s 
membrane of the eye, in the cochlea of the ear and in the skin. In patients with X-linked 
AS COLIVA5 is also reduced or absent in these tissues. Females who are heterozygous 
for COLIVA5 mutations frequently show abnormal staining of tissues expressing 
COLIVA5 (Kleppel et al., 1989a; Yoshioka et al., 1994) (Yoshioka et al., 1994). It is 
suggested that the variations in histochemical staining patterns in females heterozygous 
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for COLIVA5 mutations is due to differential lyonization in these tissues of the 
COLIVA5 locus. It is important to note that the absence of COLIVA5 staining in X-
linked AS correlates with the absence of COLIVA3 and COLIVA4 staining in tissues 
where these genes are also normally expressed including the GBM (Nakanishi et al., 
1994).  
Mutations in the COLIVA3 and COLIVA4 genes are responsible for autosomal 
recessive AS. The first study to show aberrations in the COLIVA3 and COLIVA4 genes 
reported findings from four families (Mochizuki et al., 1994).  Two of the families had 
mutations in the COLIVA3 gene and two had mutations in the COLIVA4 gene. Both of 
the mutations in the COLIVA3 gene were found in young females diagnosed with 
juvenile AS and each of these patients had GBM  structures characteristic of AS. Both 
patients also had sensorineural loss of hearing. One of the COLIVA3 mutations found 
was a five base deletion that resulted in a premature stop codon in the NC-1 domain. The 
other COLIVA3 mutation was also a nonsense mutation in the NC-1 domain, but 
resulted from a single C to T transition. Mutations in the COLIVA4 gene were also 
identified from young female patients with juvenile AS from two other families, but 
unlike the positioning of the mutations in the NC-1 domain of the COLIVA3 genes 
above, both of the COLIVA4 mutations were found in areas coding for collagenous 
sequences. One COLIVA4 mutation was a G-A transition that changed a glycine to a 
serine and the other, found in a different region, was a single C-A transversion that 
resulted in a premature stop codon. Several other mutations have been reported in the 
COLIVA3 and COLIVA4 genes in patients diagnosed with autosomal AS (Boye et al., 
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1998; Ding et al., 1995; Heidet et al., 2001; Lemmink et al., 1994; Longo et al., 2002). 
The above studies show that like the mutations in the COLIVA5 gene in X-linked AS 
described above, mutations in the COLIVA3 and COLIVA4 have been found in all parts 
of these genes and are not confined to any one area. 
Thin basement membrane disease (TBMD) is also known as benign familial 
hamaturia and, as the name suggests, is characterized by a thinning of the GBM and is 
inherited as an autosomal dominant trait in humans (Gauthier et al., 1989; Rogers et al., 
1973). TBMD has been linked to the COLIVA3/COLIVA4 locus (Buzza et al., 2001b; 
Lemmink et al., 1996). Twelve different mutations in the COLIVA4 gene in twelve 
different families with TBMD have been identified (Buzza et al., 2001a; Lemmink et al., 
1996; Ozen et al., 2001)(Buzza 2003). Mutations in the COLIVA3 gene in families with 
TBMD have also been reported (Longo et al., 2002). Again, the mutations in these genes 
include nonsense mutations resulting from deletions and insertions, or missense 
mutations resulting in glycine substitutions that disrupt the triple helical nature of the 
molecule and the mutations are not localized and have been found throughout these 
genes. Mutations in either the COLIVA3 and COLIVA4 genes exist as heterozygotes in 
individuals with TBMD and mutations in both genes existing simultaneously have not 
been reported. Carriers of X-linked AS may also show thinning of the GBM (Rumpelt et 
al., 1974). The heterozygous nature of the mutations suggests that individuals diagnosed 
with TBMD may be carriers of autosomal recessive AS.   
An autosomal dominant form of AS has been described in humans (Feingold et 
al., 1985). These families have a less severe phenotype with a slower rate of progression 
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as compared to patients with X-linked AS (Pochet et al., 1989). Analysis of a large 
family with autosomal dominant AS showed strong linkage with the 
COLIVA3/COLIVA4 locus, exclusion of the COLIVA5 gene and segregation of a 
COLIVA3 haplotype with the disease (Jefferson et al., 1997). In this family, a splice site 
mutation resulting in the skipping of exon 21 of the COLIVA3 gene has been reported 
(van der Loop et al., 2000). This mutation exists as a heterozygote with one normal 
allele present. The splice mutation of the affected gene does not alter the reading frame, 
but does result in a COLIVA3 chain with an internal deletion. Since the NC-1 domain is 
intact, this chain may be incorporated into the GBM and its presence may disrupt the 
intermolecular framework and interfere with the basement membrane architecture.  
Goodpasture’s syndrome (GS) is an autoimmune disorder that is characterized by 
circulating IgG antibodies targeting the GBM (Weber, 1993). Although the disease was 
first identified in 1919 by Dr. Earnest Goodpasture, it was not until 1987 that the target 
of the circulating antibodies was identified as a novel chain of type IV collagen 
(Butkowski et al., 1987).  In fact, the colIVα3 molecule was first identified by co-
immunoprecipitation with circulating GS antibodies and subsequent biochemical 
characterization (Saus et al., 1988). The specific epitope of the anit-GBM antibodies in 
GS has been identified as a cryptic epitope within the NC-1 region of ColIVα3 
molecules (Netzer et al., 1999a). Although no outright cause of GP has been reported, it 
is possible that this epitope is revealed after exposure to GBM damaging agents 
including the inhalation of gasoline or acute infections. 
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Nail patella syndrome (NPS)  is a pleiotropic disorder affecting nails, skeletal 
system, eyes and kidneys in humans (Beals and Eckhardt, 1969). NPS is also known as 
hereditary onychodysplasia (HOOD), Fong’s disease, Turner-Kiesler syndrome or 
Osterreicher-Turner syndrome. In NPS, renal pathology involves defects in the GBM 
and the first sign of renal involvement in NPS is usually proteinuria with or without 
haematuria and is the main cause of death in these patients. (Gubler et al., 1980). GBM 
changes in NPS include irregular thickening with electron lucent loci resulting in a 
“moth eaten” appearance. The cause of NPS in humans is associated with defects in the 
LMX1B gene (Dreyer et al., 1998). The LMX1B gene has been identified as a 
transcription factor responsible for increased COLIVA3 and COLIVA4 expression that 
has binding activity in the first exon of the COLIVA4 gene, and LMX1B knockout mice 
show a decrease in COLIVA3 and COLIVA4 expression (Morello et al., 2001). 
Transcriptional induction of genes transcribed by LMX1B is required in podocyte 
differentiation as indicated by LMX1B knockout mice (Miner et al., 2002).  
The above studies show that although the COLIVA3, COLIVA4 and COLIVA5 
chains are referred to as the “minor” species of collagen, they have important structural 





Canine Hereditary Nephritis 
 
Several models for HN have been described with specific indications of GBM 
involvement. The models that will be discussed have been reported as progressive 
kidney disorders with end stage renal disease (ESRD) and have other characteristics 
similar to human AS.  
 An example of HN has been described in kindred Samoyed dogs (Jansen et al., 
1984). In this model, males spontaneously develop renal failure and their GBM 
architecture has extensive multilamellar splitting when examined by electron microscopy 
similar to humans diagnosed with AS (Jansen et al., 1986a; Jansen et al., 1986b). 
Affected male Samoyed dogs have glomerular changes that are associated with increased 
proteinuria that increases with the age of the dog and terminates in renal failure by 15 
months of age. Carrier female Samoyed dogs were identified on the basis of having 
given birth to affected males. The carrier females do not regularly develop ESRD 
(although some cases have been reported after five years of age) and GBM structural 
analysis by electron microscopy show less extensive aberrations with focal lamellation 
which does not progress over time.  
 The rate of progression in the Samoyed model was studied using a selective 
breeding program (Jansen et al., 1986a). In early development, affected males and 
carrier females appeared healthy. Proteinuria was not detected until 2-3 months of age in 
either population, but all affected male dogs died by 15 months of age. The 
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predominance of affected males indicated an X-linked mode of inheritance which was 
confirmed with a later study (Jansen et al., 1986b).  
 An interesting study that would foretell many aspects of GBM physiology was 
conducted to determine the immunohistochemical nature of Samoyed HN (Thorner et 
al., 1987). This study was conducted without the knowledge of the existence of the 
minor species of collagen, but these investigators used Goodpasture syndrome (GS) 
antibodies, along with antibodies directed against laminin, collagen type IV and 
fibronectin. The only COLIV molecules known at that time were products of the 
COLIVA1 and COLIVA2 genes. The above antibodies were used in 
immunohistochemical studies with electron microscopy evaluation to characterize 
staining patterns in normal adult dogs, neonatal dogs, female carriers of Samoyed HN 
and male Samoyeds affected with HN. The results for laminin and COLIV antibodies 
showed strong staining of these products in the GBM in all of the populations above. 
Fibronectin staining in the GBM was positive for neonatal dogs and affected male 
Samoyeds, but was focal in carrier females and negative in normal dogs. This is an 
important finding in that with our current knowledge of GBM components, fibronectin is 
absent from normal GBM and agrin is the predominant HSPG in mature GBM. GS 
antibodies did not stain neonatal tissue, only stained in focal areas of carrier female 
GBM, was greatly reduced in affected males, but did stain normal dog GBM. We now 
know that the target of GS antibodies is an NC-1 epitope of the colIVα3 molecule. Also, 
it is now recognized that the colIVα3, colIVα4 and colIVα5 chains are negative for 
staining in patients with AS (Nakanishi et al., 1994). These and other studies indicated 
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that Samoyed HN was a model for X-linked AS in humans (Baumal et al., 1991; Thorner 
et al., 1989). After the molecular basis of X-linked AS was revealed to be caused by 
mutations of the COLIVA5 gene on the X chromosome (Barker et al., 1990), an 
investigation of this gene was directed against this gene in the Samoyed HN model 
(Zheng et al., 1994). This study was conducted using the known human COLIVA5 
sequence and, using these sequences, primers were developed for the amplification, 
cloning, and sequencing of the canine COLIVA5 gene. The result was the identification 
of a single G-T transversion that resulted in a premature stop codon in exon 35 of the 
gene, thus confirming Samoyed HN as a model for human X-linked AS.  
 A second form of X-linked HN in a mixed breed of dogs has also been described 
(Lees et al., 1999). Because this kindred is of a mixed breed and originates from 
Navasota, Texas, this population has been termed NAV dogs. Individuals of this 
population were referred to the Texas A&M Veterinary Medical Center for evaluation 
because of kidney failure. The NAV model of HN has many features similar to the 
Samoyed model above. Pedigree analysis of the NAV dogs indicated an X-linked form 
of transmission. Male NAV dogs affected with HN exhibit proteinuria at three months of 
age and usually die before 15 months of age. Carrier females have proteinuria but do not 
usually progress to renal failure. Ultrastructurally, GBM aberrations of affected NAV 
dogs include thickening and multilamellar splitting. Since the NAV dogs were of mixed 
breed origin, migration of the Samoyed allele responsible for HN into the NAV 
population could not be excluded. The COLIVA5 locus responsible for HN in the 
Samoyed model was sequenced in affected males and determined not to be responsible 
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for HN in the NAV population. Thus, a different mutation responsible for HN in NAV 
dogs was suggested and established NAV HN as a separate model from Samoyed HN.  
 A form of HN in bull terriers has also been reported (Hood et al., 1995). 
Proteinuria is progressive and a high content of albumin in the urine strongly suggests 
involvement of the GBM. Glomerular changes in Bull terriers affected with HN have 
been reported. Chronic renal disease in this breed ranges from one to eight years of age 
(Robinson et al., 1989). Unlike other canine models, bull terrier HN is inherited as an 
autosomal dominant trait  (Hood et al., 1990). Almost equal proportions of affected 
males and female bull terrier HN have been reported. Although autosomal dominant 
Alport syndrome in one human family has been determined to be caused by a splice site 
mutation in the COLIVA3 gene, immunohistochemical analysis of the GBM in bull 
terriers affected with HN show the presence of the COLIVα3 chain (Hood et al., 1995). 
A similar model for ADAS has been identified in a naturally occurring kindred in 
Dalmatians (Hood et al., 2002). Defects in the colIVα4 chain have been implicated in 
these models.  
 A form of NH has been described in English cocker spaniel dogs (ECS) that was 
initially termed familial nephropathy (Robinson et al., 1985; steward, 1984). These 
studies were initiated after presentation of clinical cases were referred to small animal 
practices and included both affected males and females. They described a rapid 
progression and proteinuria. Although no EM was attempted to characterize the GBM, 
the urine protein was determined to be of glomerular origin due to the presence of 
albumin and globulin (Steward, 1984). A study to characterize HN in ECS reported 
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findings by EM in affected dogs that indicated the extensive thickening and 
multilamellar splitting of the GBM characteristic of AS in humans (Lees et al., 1997). 
Although previous studies reported ultrastructural changes in the GBM associated with 
canine glomerulonephritis, these studies were not specific to HN in ECS (Macdougall et 
al., 1986; Murray and Wright, 1974). To study the early features and progression of ECS 
HN, known carriers were identified and two litters were produced by selective breeding 
(Lees et al., 1998b). The result of this breeding included one litter with a single male and 
one litter with one male and two females. Two of the dogs from this breeding (both 
females) developed HN , and the third dog (a single male) was normal at 30 months of 
age when this study was completed. After onset of proteinuria, loss of kidney function 
progressed rapidly and all of the affected dogs demonstrated renal lesions by electron 
microscopy. 
 Further investigation indicated ESC HN as a model for autosomal recessive AS 
(Lees et al., 1998b). This study included normal dogs, obligate carrier ECS dogs and 
affected ECS dogs. Proteinuria was first detected at five to six months of age in affected 
ECS dogs, however the rate of progression varied in this population. The development of 
azotemia in affected dogs varied from two to nine months and two dogs that were 
identified as affected had proteinuria that was significant, but transient. The pattern of 
immunohistochemical staining, however, was the same for every affected ECS dog. 
Laminin staining was universal in normal, ECS carriers and in affected ECS dogs. In 
affected ECS dogs, the GBM staining of the colIVα1 and colIVα2 chain was increased, 
while the colIVα5 staining was greatly decreased and the colIVα3 and colIVα4 chains 
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were totally absent. By contrast, staining of normal dog GBM showed a predominance 
of  colIVα3, colIVα4 and colIVα5 chains and lesser staining for the colIVα1 and 
colIVα2 chains. Obligate carriers had a decreased colIVα5 staining. This is the same 
pattern of expression reported in the GBM of humans diagnosed with autosomal 
recessive AS (Gubler et al., 1995). Interestingly, the colIVα6 chain appeared to be 
faintly expressed in both normal and affected ECS dogs.  
 The detection of the colIVα6 chain in the canine GBM prompted further 
investigation (Lees et al., 2000). Immunolabeling using antibodies monospecific for the 
colIVα6 chain showed positive staining in the GBM of dogs less than 30 months of age, 
but positive in dogs more than 45 months of age. The population of dogs in this study 
were individuals from many breeds showing that the colIVα6 chain is not breed 
dependent. Human subjects were also included in this investigation, but regardless of 
age (30 years of age to 100 years of age), the colIVα6 chain was not detected. In humans 
an isoform switch that occurs during fetal development has been reported (Kalluri et al., 
1997). In fetal GBM, the colIVα1 and colIVα2 chains are the only colIV isoforms 
present, but during development, the colIVα3, colIVα4 and colIVα5 chains are 
produced and, eventually, become the predominant isoform species in the mature GBM. 
It is suggested that the identification of the colVα6 chain in the GBM of older dogs 
represents a second isoform switch in this species. Because the colIVα6 chain was 
detected in the GBM of ECS dogs affected with HN less that 25 months of age, it is also 
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suggested that the isoform switch can occur at an earlier age in response to glomerular 





  Six different isoforms of Type IV collagen (colIVα1-6) have been identified. The 
individual isoforms of colIV are termed alpha chains and are translated from six 
different colIV genes (COLIVA1-A6). Collagen Type IV gene products compose the 
structural framework of basement membranes. The glomerular basement membrane 
(GBM) is a specialized basement membrane involved in the ultrafiltration processes of 
the kidney.  The colIVα1-α5 chains are expressed in the human GBM while the colIV 
α1-α6 chains are expressed in the canine GBM. Many inherited diseases of the kidney 
have been reported and mutations in genes regulating kidney function have been 
identified. Alport syndrome (AS) is the most common form of human hereditary 
nephritis (HN). AS is defined as an inherited progressive kidney disorder associated with 
sensoneural deafness and is characterized by extensive thickening and multilamminar 
splitting of the GBM when examined by electron microscopy. AS has both X-linked 
(XLAS) and autosomal (ARAS) modes of inheritance. Mutations in the COLIVA5 gene 
are responsible for XLAS. A form of HN with characteristic splitting of the GBM with 
X-linked inheritance has been described in Samoyed dogs. A specific mutation in the 
COLIVA5 gene has been identified in Samoyed dogs affected with HN. Mutations in the 
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COLIVA3 and COLIVA4 genes are responsible for ARAS. A form of HN has been 
identified in English cocker spaniel dogs (ECS) that has been described as autosomal in 
inheritance and includes GBM abnormalities including extensive lammination 
characteristic of ARAS. The HN in ECS has been hypothesized to be a model for human 
ARAS. As such, we have isolated and characterized canine COLIVA3 and COLIVA4 
sequences from normal dogs and ECS dogs affected with HN and compared the coding 










Collagens are found in all vertebrate species as well as in Drosophila, sea urchins 
and nematodes (Blumberg et al., 1988). As molecules, the collagens are described as 
triple helical collagenous domains with the amino acid glycine at every third residue that 
are expressed extracellularly where they perform structural roles. To date, 19 different 
types of collagen have been identified (Uitto et al., 1986). Six different isoforms of type 
IV collagen (colIVα1-α6) have been described (Hudson et al., 1993). The individual 
isoforms of colIV are termed alpha chains and are translated from six different genes 
(COLIVA1-6).  
 Collagen type IV gene products compose the structural framework of basement 
membranes. Other basement membrane components include laminin, entactin/nidogen 
and heparine sulfate proteoglycan (HSPG). The glomerular basement membrane (GBM) 
is a specialized structure created predominately by epithelial podocytes in the kidney. 
The GBM is an important structure for the ultrafiltration processes of the kidney.  
 Hereditary nephritis (HN) refers to a group of inherited glomerular diseases of 
collagen type IV that often progress to renal failure. In humans, Alport syndrome (AS) is 
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the most common form of HN (Grunfeld, 1985). About 85% of AS families show X 
chromosome-linked inheritance (XLAS); the remainder show autosomal recessive  
(ARAS) or autosomal dominant inheritance (ADAS) (Reeders, 1992). 
 Several forms of canine HN have been described. HN in the Samoyed breed of 
dog has been described as a model of XLAS and a mutation in the COLIVA5 gene has 
been identified as causative for this disease (Zheng et al., 1994). In bull terriers, an 
autosomal dominant form of HN has been reported, although the molecular basis of 
disease has yet to be described (Hood et al., 1995).  
 A form of HN has also been described in English cocker spaniel (ECS) dogs 
(Lees et al., 1998a). ECS HN is characterized as a progressive kidney disease with 
proteinuria that often results in chronic renal failure. In ECS HN, the GBM has extensive 
thickening and splitting that increases with the progression of the disease. Humans with 
ARAS also have extensive thickening and splitting of the GBM. Mutations in the 
COL4A3 and COL4A4 genes have been identified in individuals with ARAS. 
 The similarities of the glomerular changes and the autosomal recessive mode of 
inheritance in both ECS HN and humans with ARAS suggest genetic similarities. As 
such, we have hypothesized that COL4A3 and COL4A4 are candidate genes in ECS HN. 
We have isolated and characterized the coding regions of these candidate genes in 
normal dogs (without HN) and compared these sequences from ECS dogs diagnosed 
with HN. This chapter describes the isolation and characterization of the COL4A3 
coding regions in these populations.  
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Materials and Methods 
 
Identification of Affected and Normal Populations. Each affected ECS dog met two 
criteria for the diagnosis of HN. First, the kidney disease exhibited clinicopathalogic 
features identical to those described previously as familial nephropathy in ECS. Second, 
glomerular examination with transmission electron microscopy (TEM) that exhibited 
extensive thickening and multilammellar splitting was determined to be pathogmonic of 
HN. The form of HN in ECS has been determined to be a breed specific disease (Lees et 
al., 1998b). Three individual dogs older than two years of age from non-ECS breeds 
were identified for the normal population for this study. The dogs in the normal 
population included a mixed breed female, a female bloodhound and a male Labrador 
retriever. ECS dogs are a rare breed in the United States with a registered population of 
~5,000 individuals. Because of the rarity and structured breeding practices of the ECS 
population, it is unlikely that alleles causing ECS-HN would be present in mixed bred 
populations.  
 
Tissue Isolation. Affected dogs and two normal dogs (a female bloodhound and mixed 
breed) were sacrificed and ~1g sections of kidneys containing the renal cortex were snap 
frozen in liquid nitrogen, transported on dry ice and stored at –80°C. Tissue from one 
normal dog was from a testicle of a Labrador retriever obtained in the College of 
Veterinary Medicine Texas A&M University from a standard neutering procedure.  
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RNA Preparation. Total RNA was isolated from frozen tissue using Trizol (Sigma, St 
Louis, MO) according to manufacturers protocol. Briefly, ~1g of snap frozen tissue was 
ground in a metal beaker embedded in dry ice and ~100mg was added to 1ml of Trizol in 
a pyrex test tube. A plastic coated dounce homogenizer was used to macerate the tissue 
in the tube. The dounce was manipulated manually for approximately one minute at 
room temperature. To prevent shearing of the RNA, mechanical methods of dounce 
manipulation were avoided. The Trizol/tissue mixture was transferred to a 1.8ml 
microcentrifuge tube, allowed to rest at room temperature for ~5 minutes and 
centrifuged at 1,000xg for one minute to pellet any unsolubilized material. Occasionally 
this mixture was stored at –80°C, but immediate use is recommended.  
 To a new 1.8 ml microcentrifuge tube, .5 ml of the Trizol/tissue mixture and 
100ul of cloroform was combined. The tube was briefly vortexed (< 5 seconds) and then 
centrifuged at 10,000xg for 10 minutes. 400ul of the clear upper liquid was transferred to 
a new 1.8ml microcentrufuge tube and 200ul of isopropanol was added, mixed briefly 
and centrifuged at 10,000xg for 10 minutes. The isopropanol was removed and the pellet 
was washed with 1ml of 75% ethanol. After the removal of ethanol, the pellet was 
resuspended in 50ul of RNAse free water and 3ul of RNAse inhibitor (Promega, 
Madison, WI) was added.  
 A portion of the RNA was run on a 1% agarose gel in TAE buffer and visualized 
by staining with ethidium bromide for qualitative analysis. For quantitative purposes, a 
portion of the RNA was also used for spectroscopic analysis at 280A° and 260A°.  
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cDNA Synthesis. The synthesis of cDNA was performed using the Superscript II first 
strand synthesis system (Invitrogen, Carlsbad, California) according to manufacturers 
suggestions. Briefly, 5 ug of total RNA was incubated with an oligo dT primer and 1uL 
of 10mM dNTP’s at 70°C for 5 minutes, chilled on iced, and then combined with 4 uL 
5X first strand buffer, 2 uL .1M DTT and10 units of Superscript reverse transcriptase at 
45°C for one hour. The resulting product was used directly in PCR amplification 
reactions.  
 
PCR Amplification. To assure the accuracy of the amplification process, the enzyme 
used for PCR amplification of the cDNA was AccuTaq LA DNA Polymerase (Sigma, 
St. Louis, MO) which has 3’ proofreading ability. According to manufacturers 
suggestions, the amplification reaction contained 5 uL 10X PCR buffer, 2.5 uL 10mM 
dNTP mix, 600 nmol of each primer, .1 units of AccuTaq LA DNA Polymerase in a 50 
uL reaction. As a template, 2 uL of the cDNA was also included. The amplification 
conditions for all reactions were an initial denaturation at 98°C for 30 seconds followed 
by repeated denaturation at 94°C for 30 seconds, annealing at 65°C for 30 seconds and a 
5 minute extension at 68°C for 35 cycles. A 7 ul sample of the final reaction was 
analyzed on a 1% agarose gel using TAE buffer to check for the quality of the reaction.  
 
Amplification Primers. Primers were designed from a human COLIVA3 sequence 
(Genebank Accession: NM000091). Primers for the targeted areas were analyzed using 
OLIGO 4.0 software (National Biosciences, Plymouth, MN) for dimerization, the 
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presence of hairpin loops and internal stability. Three sets of primers were used to 
amplify the canine COLIVA3 cDNA. The NC-1 region was amplified using COLIVA3 
NC-1 Forward 5’CTG GAG AAA AAG GAC GTG ATG3’ and COLIVA3 NC-1 
Reverse 5’ CAG CTT TCA CAG TTG ATG GAA TAG5’ primers. The 5’ region (to ~ 
260 bases of the start codon) was amplified using COLIVA3 Forward 5’CCG ACT TGT 
CGG TGT ACC AGG ATG3’ and COLIVA3 Reverse 5’CTC TCC TTC TTC CCC 
CTT GGC TCC3’ primers. The intervening sequence was amplified using the COLIVA3 
Forward 5’GTG ATT GGG ATG ATG GGC TAT C3’ and COLIVA3 Reverse 5’TCT 
CCA ATT GGC CCA GGA GTT C3’ primers. 
 
Gel Purification. Amplified products were run on a 1% agarose gel and desired 
fragments were visualized with low intensity ultra violet light. Desired products were cut 
out of the gel using a clean razor blade and placed into a 1.8 ml microcentrifuge tube. 
The PCR product was purified using the QIAquick gel purification system (Qiagen, 
Valencia, CA) and eluted with 50 uL water.  
 
Cloning. The gel purified amplification products were concentrated in a speed vacuum 
under centrifugation until the 50 uL of eluted product was reduced to approximatetly 
5uL. The gel purified products were cloned into pT7 cloning vectors using perfectly 
blunt cloning kits (Novagen, Madison, WI) using T4 ligase. The cloned products were 
transformed into chemically competent cells and plated on LB media containing 50 ug/ 
ml ampicillin, 20 ug/ml tetracycline and 20 ug/ml IPTG that had been overlayed with 20 
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uL of 50 ug/ml X-gal.  The presence of gene fragments in subsequent plasmids was 
confirmed by the presence of white colonies and restriction digestion using EcoRI and 
HindIII.  
 
Sequencing. Sequencing reactions contained 4 uL Big Dye V3.0  (Applied Biosystems, 
Foster City, CA), 400 ng plasmid DNA and 50 nM primer in a 10 uL total reaction 
volume. The parameters for the sequencing reactions included incubation at 95°C for 10 
seconds, 50°C for 5 seconds and 60°C for 4 minutes in a thermocycler for 44 cycles. The 
resulting reaction was purified on BioMax SPIN-50 mini-columns (BioMax, Odenton, 
MD). Briefly, the columns were placed in a microcentrifuge at 1000xg for 3 minutes. 
The columns were transferred to a new 1.8 ml microcentrifuge tube and the sequencing 
reaction placed on the column. The BioMax spin columns were again centrifuged at 
1000xg for 3 minutes. The columns were discarded and the recovered sample was dried 
in a speed vacuum for 40 minutes at room temperature under darkened conditions. The 
sequencing reactions were then analyzed in a commercial sequencing facility. 
 
Sequence Analysis. Chromatograms of the resulting sequence were collected and the 
sequences were downloaded into MacVector V4.0 software (Eastman Kodak Company, 
Rochester, NY). The sequences were alligned with the human COLIVA3 sequence 
(NM000091) to determine its relative position with respect to the human isoform. 
Canine sequences that were confirmed to be of COLIVA3 origin were transferred into 
AssemblyLine V1.0 software files (Accelrys, Princeton, NJ) for sequence alignment. 
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Consensus sequences were then transferred to SDSC Biology Workbench  




Sequences representing the coding regions of the normal canine COLIVA3 gene 
have been isolated by PCR amplification from cDNA derived from total RNA 
(Appendix 1). A total of 4,643 bases have been characterized by sequence analysis 
representing 92.6% of the human coding sequence. The complete COL4A3 cDNA from 
the human is 8,050 bases and has a coding region of 5,010 bases (Genbank 
accession:NM000091). The mouse COL4A3 cDNA has also been characterized and 
contains 7,765 bases with a 5,010 base coding region (Genbank accession: NM007734). 
While the remaining ~275 nucleotides of the 5’ end of the canine COL4A3 coding 
region have yet to be characterized, the 4,643 bases represents a majority of this 
sequence. Nucleic acid alignment using LALINE sequence analysis 
(workbench.sdsc.edu) show 83.4% homology between the canine COL4A3 and 
humanCOL4A3 sequences and 80.0% homology between the canine COL4A3 and 
mouse COL4A3 sequences. The human COL4A3 and mouse COL4A3 sequences share 
81.4% homology (Appendix 2).  
 The canine COL4A3 sequences that have been isolated code for 1,547 amino 
acids. The human COL4A3 gene codes for 1,671 amino acids and the mouse COL4A3 
gene codes for 1,670 amino acids. Using LALINE sequence analysis 
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(workbench.sdsc.edu), the amino acid sequence homology between the normal canine 
COL4A3 sequences and the human COL4A3 sequences is 83.4% and 79.8% 
homologous to the mouse COL4A3 sequences (Appendix 3). The translated coding 
regions of the human and mouse COL4A3 gene have 78.8% homology.  
 Interruptions in the collagenous region are characteristic of type IV collagen 
molecules. The human has 23 interruptions and the mouse has 21 interruptions in this 
region. Twenty interruptions have been identified in the canine COL4A3 sequences in 
the collagenous domain. The presence of glycine at every third residue defines the 
collagenous sequence. Glycine represents 27.3% of the human COL4A3 coding 
sequences and 27.6% of the mouse COL4A3 coding sequences. The canine COL4A3 
coding region contains 27.2% glycine. Proline is another common amino acid in 
collagenous seuences. Proline represents 19.2% of the human COL4A3 sequences, 
20.6% of the mouse COL4A3 sequences and 20.5% of the canine COL4A3 sequences. 
The codons for glycine are very rich in guanine (GGG, GGA,GGC,GGT) and the codons 
for  proline are very rich in cystosine (CCC, CCT, CCG, CCA). Thus, collagenous 
sequences are very GC rich. The canine COL4A3 coding region contains 57.1% GC 
while the human and mouse COL4A3 sequences each contain 56.3% and 57.2% GC 
respectively. 
 COL4A3 sequences have also been isolated from ECS dogs diagnosed with HN 
from cDNA derived from total RNA isolated from fresh frozen kidney. A 4,645 base 
COL4A3 consensus sequence has been characterized in this affected population 
representing 1,547 amino acids. The COL4A3 sequences from this population are almost 
 61
identical at the nucleotide level. The specific nature of these sequences will be the focus 









Collagens are found in all vertebrate species as well as in Drosophila, sea urchins 
and nematodes (Blumberg et al., 1988). As molecules, the collagens are described as 
triple helical collagenous domains with the amino acid glycine at every third residue that 
are expressed extracellularly where they perform structural roles. To date, 19 different 
types of collagen have been identified (Uitto et al., 1986). Six different isoforms of type 
IV collagen (colIVα1-α6) have been described (Hudson et al., 1993). The individual 
isoforms of colIV are termed alpha chains and are translated from six different genes 
(COLIVA1-6).  
 Collagen type IV gene products compose the structural framework of basement 
membranes. Other basement membrane components include laminin, entactin/nidogen 
and heparine sulfate proteoglycan (HSPG). The glomerular basement membrane (GBM) 
is a specialized structure created predominately by epithelial podocytes in the kidney. 
The GBM is an important structure for the ultrafiltration processes of the kidney.  
 Hereditary nephritis (HN) refers to a group of inherited glomerular diseases of 
collagen type IV that often progress to renal failure. In humans, Alport syndrome (AS) is 
 63
the most common form of HN (Grunfeld, 1985). About 85% of AS families show X 
chromosome-linked inheritance (XLAS); the remainder show autosomal recessive  
(ARAS) or autosomal dominant inheritance (ADAS) (Reeders, 1992). 
 Several forms of canine HN have been described. HN in the Samoyed breed of 
dog has been described as a model of XLAS and a mutation in the COLIVA5 gene has 
been identified as causative for this disease (Zheng et al., 1994). In bull terriers, an 
autosomal dominant form of HN has been reported, although the molecular basis of 
disease has yet to be described (Hood et al., 1995).  
 A form of HN has also been described in English cocker spaniel (ECS) dogs 
(Lees et al., 1998a). ECS HN is characterized as a progressive kidney disease with 
proteinuria that often results in chronic renal failure. In ECS HN, the GBM has extensive 
thickening and splitting that increases with the progression of the disease. Humans with 
ARAS also have extensive thickening and splitting of the GBM. Mutations in the 
COL4A3 and COL4A4 genes have been identified in individuals with ARAS. 
 The similarities of the glomerular changes and the autosomal recessive mode of 
inheritance in both ECS HN and humans with ARAS suggest genetic similarities. As 
such, we have hypothesized that COL4A3 and COL4A4 are candidate genes in ECS HN. 
We have isolated and characterized the coding regions of these candidate genes in 
normal dogs (without HN) and compared these sequences from ECS dogs diagnosed 
with HN. This chapter describes the isolation and characterization of the COL4A4 
coding regions in these populations.  
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Materials and Methods 
 
Identification of Affected and Normal Populations. Each affected ECS dog met two 
criteria for the diagnosis of HN. First, the kidney disease exhibited clinicopathalogic 
features identical to those described previously as familial nephropathy in ECS. Second, 
glomerular examination with transmission electron microscopy (TEM) that exhibited 
extensive thickening and multilammellar splitting was determined to be pathogmonic of 
HN. The form of HN in ECS has been determined to be a breed specific disease (Lees et 
al., 1998b). Three individual dogs older than two years of age from non-ECS breeds 
were identified for the normal population for this study. The dogs in the normal 
population included a mixed breed female, a female bloodhound and a male Labrador 
retriever. ECS dogs are a rare breed in the United States with a registered population of 
~5,000 individuals. Because of the rarity and structured breeding practices of the ECS 
population, it is unlikely that alleles causing ECS-HN would be present in mixed bred 
populations.  
 
Tissue Isolation. Affected dogs and two normal dogs (a female bloodhound and mixed 
breed) were sacrificed and ~1g sections of kidneys containing the renal cortex were snap 
frozen in liquid nitrogen, transported on dry ice and stored at –80°C. Tissue from one 
normal dog was from a testicle of a Labrador retriever obtained in the College of 
Veterinary Medicine at Texas A&M University from a standard neutering procedure.  
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RNA Preparation. Total RNA was isolated from frozen tissue using Trizol (Sigma, St 
Louis, MO) according to manufacturers protocol. Briefly, ~1g of snap frozen tissue was 
ground in a metal beaker embedded in dry ice and ~100mg was added to 1ml of Trizol in 
a pyrex test tube. A plastic coated dounce homogenizer was used to macerate the tissue 
in the tube. The dounce was manipulated manually for approximately one minute at 
room temperature. To prevent shearing of the RNA, mechanical methods of dounce 
manipulation were avoided. The Trizol/tissue mixture was transferred to a 1.8ml 
microcentrifuge tube, allowed to rest at room temperature for ~5 minutes and 
centrifuged at 1,000xg for one minute to pellet any unsolubilized material. Occasionally 
this mixture was stored at –80°C, but immediate use is recommended.  
 To a new 1.8 ml microcentrifuge tube, .5 ml of the Trizol/tissue mixture and 
100ul of cloroform was combined. The tube was briefly vortexed (< 5 seconds) and then 
centrifuged at 10,000xg for 10 minutes. 400ul of the clear upper liquid was transferred to 
a new 1.8ml microcentrufuge tube and 200ul of isopropanol was added, mixed briefly 
and centrifuged at 10,000xg for 10 minutes. The isopropanol was removed and the pellet 
was washed with 1ml of 75% ethanol. After the removal of ethanol, the pellet was 
resuspended in 50ul of RNAse free water and 3ul of RNAse inhibitor (Promega, 
Madison, WI) was added.  
 A portion of the RNA was run on a 1% agarose gel in TAE buffer and visualized 
by staining with ethidium bromide for qualitative analysis. For quantitative purposes, a 
portion of the RNA was also used for spectroscopic analysis at 280A° and 260A°.  
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cDNA Synthesis. The synthesis of cDNA was performed using the Superscript II first 
strand synthesis system (Invitrogen, Carlsbad, California) according to manufacturers 
suggestions. Briefly, 5 ug of total RNA was incubated with an oligo dT primer and 1uL 
of 10mM dNTP’s at 70°C for 5 minutes, chilled on iced, and then combined with 4 uL 
5X first strand buffer, 2 uL .1M DTT and10 units of Superscript reverse transcriptase at 
45°C for one hour. The resulting product was used directly in PCR amplification 
reactions.  
 
PCR Amplification. To assure the accuracy of the amplification process, the enzyme 
used for PCR amplification of the cDNA was AccuTaq LA DNA Polymerase (Sigma, 
St. Louis, MO) which has 3’ proofreading ability. According to manufacturers 
suggestions, the amplification reaction contained 5 uL 10X PCR buffer, 2.5 uL 10mM 
dNTP mix, 600 nmol of each primer, .1 units of AccuTaq LA DNA Polymerase in a 50 
uL reaction. As a template, 2 uL of the cDNA was also included. The amplification 
conditions for all reactions were an initial denaturation at 98° Cfor 30 seconds followed 
by repeated denaturation at 94°C for 30 seconds, annealing at 65°C for 30 seconds and a 
5 minute extension at 68°C for 35 cycles. A 7 ul sample of the final reaction was 
analyzed on a 1% agarose gel using TAE buffer to check for the quality of the reaction.  
 
Amplification Primers. Primers were designed from a human COLIVA4 sequence 
(Genebank Accession: NM000092). Primers for the targeted areas were analyzed using 
OLIGO 4.0 software (National Biosciences, Plymouth, MN) for dimerization, the 
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presence of hairpin loops and internal stability. Three sets of primers were used to 
amplify the canine COLIVA4 cDNA. The NC-1 region was amplified using COLIVA4 
NC-1 Forward 5’TTG GCC CTG GAT ACC TCA GTG3’ and COLIVA4 NC-1 Reverse 
5’GGC ACC TGC TGA TTT TCT GG3’ primers. The 5’ region (to -140 bases of the 
start codon in the human) was amplified using COLIVA4 Forward 5’TGA CCC AGA 
ACA CAG AAC CTC AC3’ and COLIVA4 Reverse 5’CCC TTC TCT CCT TTT GGT 
CCA ATT C3’ primers. The intervening sequence was amplified using the COLIVA4 
Forward 5’AGA GGC GCT CCA GGG ATA C3’ and COLIVA4 Reverse 5’CCT TCT 
GGT CCT CTT G3’ primers for the 2,155 base region adjacent to the NC-1. The 1,590 
base region adjacent to the 5’ sequence was amplified with the COL4A4 F 5’GGT CTC 
CGG GTT CCT ATG3’ AND COL4A4 R 5’CTG GCG GCC CAA GAA G3’ primers. 
 
Gel Purification. Amplified products were run on a 1% agarose gel and desired 
fragments were visualized with low intensity ultra violet light. Desired products were cut 
out of the gel using a clean razor blade and placed into a 1.8 ml microcentrifuge tube. 
The PCR product was purified using the QIAquick gel purification system (Qiagen, 
Valencia, CA) and eluted with 50 uL water.  
 
Cloning. The gel purified amplification products were concentrated in a speed vacuum 
under centrifugation until the 50 uL of eluted product was reduced to approximatetly 5 
uL. The gel purified products were cloned into pT7 cloning vectors using perfectly blunt 
cloning kits (Novagen, Madison, WI) using T4 ligase. The cloned products were 
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transformed into chemically competent cells and plated on LB media containing 50 ug/ 
ml ampicillin, 20 ug/ml tetracycline and 20 ug/ml IPTG that had been overlayed with 20 
uL of 50 ug/ml X-gal.  The presence of gene fragments in subsequent plasmids was 
confirmed by the presence of white colonies and restriction digestion using EcoRI and 
HindIII.  
 
Sequencing. Sequencing reactions contained 4 uL Big Dye V3.0  (Applied Biosystems, 
Foster City, CA), 400 ng plasmid DNA and 50 nM primer in a 10 uL total reaction 
volume. The parameters for the sequencing reactions included incubation at 95°C for 10 
seconds, 50°C for 5 seconds and 60°C for 4 minutes in a thermocycler for 44 cycles. The 
resulting reaction was purified on BioMax SPIN-50 mini-columns (BioMax, Odenton, 
MD). Briefly, the columns were placed in a microcentrifuge at 1,000xg for 3 minutes. 
The columns were transferred to a new 1.8 ml microcentrifuge tube and the sequencing 
reaction placed on the column. The BioMax spin columns were again centrifuged at 
1,000xg for 3 minutes. The columns were discarded and the recovered sample was dried 
in a speed vacuum for 40 minutes at room temperature under darkened conditions. The 
sequencing reactions were then analyzed in a commercial sequencing facility. 
 
Sequence Analysis. Chromatograms of the resulting sequence were collected and the 
sequences were downloaded into MacVector V4.0 software (Eastman Kodak Company, 
Rochester, NY). The sequences were alligned with the human COLIVA4 sequence 
(NM000092) to determine its relative position with respect to the human isoform. 
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Canine sequences that were confirmed to be of COLIVA3 origin were transferred into 
AssemblyLine V1.0 software files (Accelrys, Princeton, NJ) for sequence alignment. 
Consensus sequences were then transferred to SDSC Biology Workbench  




Sequences representing the coding regions of the normal canine COLIVA4 gene 
have been isolated by PCR amplification from cDNA derived from total RNA 
(Appendix 5). A total of 5,163 bases have been characterized by sequence analysis 
representing ~98% of the human coding sequence. The complete COL4A4 cDNA from 
the human is 5,726 bases and has a coding region of 5,073 bases (Genbank 
accession:NM000092). The mouse COL4A4 cDNA has also been characterized and 
contains 5,918 bases with a coding region of 5,049 bases  (Genbank accession: 
AF169338). While the remaining ~50 nucleotides of the 3’ end of the canine COL4A4 
coding region have yet to be characterized, the 5,163 bases represents a majority of this 
sequence. Nucleic acid alignment using LALINE sequence analysis 
(workbench.sdsc.edu) show 85.0% homology between the canine COL4A4 and human 
COL4A4 sequences and 79.0% homology between the canine COL4A4 and mouse 
COL4A4 sequences. The human COL4A4 and mouse COL4A4 sequences share 80.7% 
homology (Appendix 6).  
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 The canine COL4A4 sequences that have been isolated code for 1,677 amino 
acids. The human COL4A4 gene codes for 1,691 amino acids and the mouse COL4A4 
gene codes for 1,683 amino acids. Using LALINE sequence analysis 
(workbench.sdsc.edu), the amino acid sequence homology between the normal canine 
COL4A4 sequences and the human COL4A4 sequences is 83.2% and 78.3% 
homologous to the mouse COL4A4 sequences (Appendix 7). The translated coding 
regions of the human and mouse COL4A4 gene have 78.6% homology.  
 Interruptions in the collagenous region are characteristic of type IV collagen 
molecules. The human has 24 interruptions and the mouse has 23 interruptions in this 
region. In the canine COL4A4 sequences, 23 interruptions have been identified in the 
collagenous domain. The presence of glycine at every third residue defines the 
collagenous sequence. Glycine represents 28.0% of the human COL4A4 coding 
sequences and 27.5% of the mouse COL4A4 coding sequences. The canine COL4A4 
coding region contains 27.8% glycine. Proline is another common amino acid in 
collagenous seuences. Proline represents 20.8% of the human COL4A4 sequences, 
20.9% of the mouse COL4A4 sequences and 21.2% of the canine COL4A4 sequences. 
The codons for glycine are very rich in guanine (GGG, GGA,GGC,GGT) and the codons 
for  proline are very rich in cystosine (CCC, CCT, CCG, CCA). Thus, collagenous 
sequences are very GC rich. The canine COL4A4 coding region contains 60.5% GC 
while the human and mouse COL4A4 sequences each contain 59.3% and 59.7% GC 
respectively. 
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 COL4A4 sequences have also been isolated from ECS dogs diagnosed with HN 
from cDNA derived from total RNA isolated from fresh frozen kidney. A 5,011 base 
COL4A4 consensus sequence has been characterized in this affected population 
representing 1,607 amino acids. The COL4A4 sequences from this population are almost 
identical at the nucleotide level. The specific nature of these sequences will be the focus 





SUMMARY AND CONCLUSIONS 
 
The problematic nature of the identification of mutations in ECS HN can be 
derived from studies that have attempted to find mutations in the COL4A3 and COL4A4 
genes in ARAS. While the detection rate of mutations in the COL4A5 coding region in 
XLAS has reached ~90%, it has been reported that perhaps 10% of the mutations are in 
non-coding regions of the CL4A5 gene (Martin et al., 1998). The 90% detection rate of 
mutations in the COL4A5 gene in XLAS does not represent the current rate of detection 
of COL4A3 and COL4A4 mutations in ARAS. In the investigation of the COL4A3 or 
COL4A4 genes in ARAS, the success rate of finding mutations in these genes 
individually is very low. When both the COL4A3 and COL4A4 genes have been 
analyzed together in ARAS, the identification of causal mutations is increased, but does 
not reach 100% detection in these genes. Together, two studies that analyzed both the 
COL4A3 and COL4A4 genes in ARAS have shown less than a 30% rate of detection of 
mutations in these genes. This low rate of detection may represent the limitations in the 
methodology of exon screening which, when applied to the COL4A5 gene in XLAS, has 
an equally low rate of detection. 
 In both studies, diagnosis of AS had been made including the splitting of the 
GBM, and exclusion of the COL4A5 gene had been determined. Although selective 
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criteria were used to diagnose ARAS in these studies, this methodology represents a 
more permissive basis of diagnosis as compared to the strict interpretation of ECS-HN. 
In one study (Mochizuki et al., 1994), mutations in the COL4A3 and COL4A4 genes in 
4 of 7 families was reported. These included two mutations in the COL4A3 gene (both 
nonsense mutations) and two mutations in the COL4A4 gene (one glycine substitution 
and one nonsense mutation). In another study (Longo et al., 2002), 8 mutations were 
identified in 30 probands. This study included six probands with ADAS presumed to be 
of COL4A3 or COL4A4 origin. While Mochizuki et al. reported an equal number of 
COL4A3 and COL4A4 mutations, Longo et al. reported seven COL4A3 mutations (two 
nonsense mutations, three microdeletions a glycine substitution, and a missense at the 
start codon) and only one COL4A4 mutation (one glycine substitution). The combined 
detection rate in these studies for mutations in either the COL4A3 or COL4A4 genes is 
12/37. This low rate of detection suggests that either mutations in the COL4A3 and 
COL4A4 genes in ARAS are difficult to identify or, possibly, the presence of another 
genetic locus responsible for this pathology.  
 Indication of the latter possibility is represented in a study of haplotype 
segregation in thin basement membrane disease (TBMD) (Buzza et al., 2001b). While it 
is possible to perform linkage analysis of haplotype segregation of the 
COL4A3/COL4A4 locus, it is difficult to differentiate segregation patterns to any one of 
these loci. In both man and mouse, the COL4A3 and COL4A4 genes lie head to head 
where they share a common promoter and therefore can be considered to be examples of 
very close linkage. Haplotype segregation of genomic microsatellites of the 
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COL4A3/COL4A4 locus and the COL4A5 locus were studied in the families of 22 
individuals diagnosed with TBMD. In this study, 35% of the families showed linkage to 
the COL4A3/COL4A4 locus, 18% showed linkage to the COL4A5 locus, but 45% of the 
families failed to show linkage to either locus. TBMD is often inherited as an autosomal 
dominant trait and, as the name indicates, is characterized by a thinned GBM 
(Blumenthal et al., 1988). Heterozygous carriers for causal mutations in ARAS 
(Lemmink et al., 1996) and female carriers of XLAS (Rumpelt et al., 1974) have 
clinocopathalogic symptoms identical to those of TBMD including a thinning of the 
GBM. It is suggested that TBMD represents a carrier state for ARAS or XLAS (Netzer 
et al., 1999b). Incomplete penetrance or improper diagnosis may have affected the lack 
of segregation of the either the COL4A3, COL4A4 or COL4A5 genes with TBMD. 
These results do not preclude, however, the presence of another locus responsible for 
TBMD: a recognized disease of the GBM. The possibility of another genetic locus 
responsible for ARAS might be resolved with similar haplotype analysis to determine 
the frequency of segregation of the COL4A3/COL4A4 locus in these families. Similarly, 
haplotype analysis could help to determine COL4A3/COL4A4 segregation in ECS HN.  
Implication of either the COL4A3 or COL4A4 gene in ECS HN by analysis of 
haplotype segregation in our current study is very difficult. The experimental design in 
this study was to determines sequences in alleles not responsible for ECS HN and 
compare these sequences in ECS-HN populations. Optimally, haplotype analysis would 
be conducted in individuals of the same breed. This is possible in the analysis of the X-
linked HN in the Samoyed breed. In this case, it is possible to positively identify affected 
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males, normal males and carrier females. Similar haplotype analysis is complicated in 
our study because of the presumed autosomal nature of ECS HN. It is presumed that 
affected individuals are homozygous recessive in ECS HN populations. Because the 
total ECS population in the United States is less than 5,000 individuals, there exists a 
possibility that any one individual may be a heterozygous carrier of ECS HN alleles. 
ECS HN has been reported to be breed specific. No other autosomal recessive HN has 
been reported in any other canine populations. For these reasons, non-ECS populations 
were selected for the absence of ECS HN alleles. Therefore, haplotype analysis in this 
study may represent breed specific ECS haplotypes and not represent markers specific 
for ECS HN.  Segregation of haplotypes is often used for the analysis of quantitative 
trait loci (QTL). The experimental design for these studies involving haplotype 
segregation is very different from the approach of our study. Haplotype analysis of QTL 
does not frequently use genetic elements derived from cDNA that has been cloned. 
While the vast majority of the COL4A3 and COL4A4 coding regions have been 
identified, it is possible that mutations exist in other areas yet to be characterized. These 
include ~250 bases at the 5’ end and ~30 bases at the 3’ end of the COL4A3 coding 
region, and ~50 bases at the 5’ end and ~50 bases at the 3’ end of the COL4A4 coding 
region. Other regions of interest include promoter elements, 5’ and 3’ UTRs, exon/intron 
junctions and intronic sequences. 
Several differences have been identified between the normal and ECS-HN 
COL4A3 sequences. The effects of these individual nucleotide changes with regards to 
codon changes are summarized in Appendix 9. Several differences have also been 
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identified between the normal and ECS-HN COL4A4 sequences. The effects of these 
individual nucleotide changes with regards to codon changes are summarized in 
Appendix 10.  
The most significant differences between normal canine populations and ECS-
HN populations in the COL4A3 and COL4A4 sequences are two base changes in the 
COL4A3 allele. One difference that has been identified is a G-A transition that results in 
an amino acid change at position ~3,250 (See Appendix 7). While the codon for the 
normal sequence is AGG and codes for arginine, the G-A transition results in an AAG 
codon that codes for lysine. The sequence difference has been identified in every 
affected ECS examined (N=3) from 4 different clones and was present in each of 14 
sequence reactions. This transition was identified in two normal non-ECS individuals 
from 4 clones in 7 sequencing reactions. Another significant difference identified in the 
COL4A3 sequences is another single base change at position ~3,220 (See Appendix 7). 
While the normal sequence is AGC and codes for serine, a G-T transversion has been 
identified that changes the codon in ECS alleles to ATC to code for isoleucine. This 
transversion was identified in three ECS-HN individuals from 4 different clones and was 
present in each of 12 sequencing reactions. The normal sequence has been confirmed in 
two normal individuals from four clones in 6 sequencing reactions. It is difficult to 
determine if these differences are causal mutations for ECS HN. If identification of 
heterozygosity in known carriers in these regions could be determined between normal 
and affected populations, these markers could be very informative. Based on these 
sequences, primers have been designed from regions flanking areas of interest to amplify 
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these regions from genomic DNA (gDNA) isolated from circulating lymphocytes for the 
identification of heterozygous alleles at this locus. The process has been difficult 
because the primary gDNA sequence of these genes has not been determined. Based on 
corresponding human sequences, both the COL4A3 and COL4A4 genes should each 
cover over 150 kb each and contain approximately 50 introns. Because the position and 
size of introns and exons are unknown for the canine genes, it is difficult to design 
parameters for amplification reactions. Although this does not preclude the possibility of 
isolating these sequences from gDNA, the process has proven difficult. An alternative 
approach to identify heterozygosity in these loci from known carrier populations is to 
isolate these sequences from the coding regions of these genes. This could include the 
amplification, cloning and sequencing of these regions from cDNA derived from total 
RNA. Because of the difficulties involved in the specific amplification of collagen 
genes, direct sequencing of amplification products with the primers that have been 
designed has proven difficult. Once the primary sequence of the gDNA has been 
determined, more specific primers for these areas of interest can be synthesized for 
direct sequencing of gDNA amplification reactions. Since both alleles may be equally 
expressed, it is possible to identify the two alleles by sequencing cloned sequences from 
products amplified from cDNA. Using the binomial equation ([N!/X!(N-X)!](Px)∧x(PN-
x)∧N-x), greater than 95% detection of heterozygous loci can be determined when 5 
clones are analyzed from products of individual amplification reactions.  
The question as to the origin of the ECS-HN allele is an interesting topic for 
discussion. Clinically, ECS-HN is not indicated by spontaneous mutation, but rather by 
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an established genetic aberration in the germ line of this population. ECS-HN has been 
reported to date to be a breed specific pathology indicating that the ECS-HN allele is not 
present in other purebred populations and, within the ECS breed, is restricted to “party 
colored” individuals. Purebred canine populations exist as groups indicating a common 
origin. Examples of purebred groups include hounds, terriers and retrievers among 
others. Examples of purebred spaniel populations include the ECS as well as the 
American cocker spaniel, the Brittany spaniel, and Springer spaniel. No indication of the 
ECS-HN allele, however, is present in these populations. It is difficult to determine 
whether the ECS-HN allele was present during the establishment of the ECS population 
or originated during ECS breed development. If the ECS-HN allele was present during 
the establishment of the population, then this causal mutation might have also been 
present in other populations. If the ECS-HN allele was present in other populations, 
especially other spaniel populations, many factors could have caused its disappearance 
in non-ECS breeds. Selective forces could have eliminated the allele in non-ECS 
populations since the ECS-HN allele causes a decreased fitness. However, the perpetual 
nature of the ECS-HN allele in ECS populations could be due to the recessive nature of 
the allele that would mask its presence in heterozygous populations making selection 
difficult. Because these populations are small and because inbreeding tends toward 
genetic homozygosity, the ECS-HN allele could also have been lost by genetic drift. 
Alternatively, the ECS-HN allele could have been introduced in the evolution of this 
population.  
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 Recessive alleles could be perpetuated through breeding practices inherent in the 
establishment and growth of purebred canine populations. Most purebred canine 
populations arise from a small number of individuals. Often there is a major sire that 
may be bred to many females. This practice can lead to a high frequency of alleles from 
a small portion of the breeding population. In this case, the frequency of the ECS-HN 
allele may have been amplified in this population by the founder effect. This would 
suggest that the ECS-HN allele, by whatever means of introduction, would be identical 
by descent. In pure genetic terms, identity by decent infers loss of all genetic 
heterogeneity to create identical alleles. This does not necessarily have to be a strict 
definition. Identity by decent could also infer homozygosity at one locus causing a 
particular phenotype, but genetic polymorphism at other allelic loci arising from 
subsequent mutations. The COL4A3 and COL4A4 sequences we have characterized 
from ECS-HN populations are very homozygous as are the sequences generated from 
non-ECS populations. Decreased homozygosity is expected in small-inbred populations. 
The polymorphisms that have been identified in the ECS-HN populations do not 
preclude, however, homozygosity at the ECS-HN locus. Although the ECS population 
has been recently established (less than 500 years ago), many hundreds of generations 
may have occurred thus creating the opportunity for the introduction of polymorphisms. 
The theory of the molecular clock suggests a constant rate of molecular evolution. 
Although studies on the molecular clock frequently focus on populations separated 
genetically over extreme time periods, it is not inconceivable that a causal mutations for 
ECS-HN may have been introduced into the population’s, albeit, brief history.  
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It is difficult to establish the transitional change that substitutes an arginine for a 
lysine as the causal mutation in ECS-HN. This change does not result in a nonsense 
mutation, does not occur at an essential structural element such as glycine and does not 
drastically effect a proline residue adjacent to a glycine or substitute a non-conserved 
amino acid. The neutral theory of molecular evolution, first established by Kimura, 
suggests that most mutations are neutral. The neutrality theory is indicated at two levels. 
First, that genetic mutations often do not change the amino acid (due to the wobble 
effect), and, second, when mutations do change the coding sequence they often 
substitute neutral changes that do not effect protein structure or function. The theory is 
based on the three types of mutations, namely, deleterious mutations, neutral mutations 
and advantageous mutations. Deleterious mutations are frequently eliminated from 
populations, advantageous mutations are exceedingly rare, therefore, most mutations 
perpetuated in a population are neutral. Kimura’s neutral theory of molecular evolution 
has recently been reformulated with the tremendous amount of sequence data that has 
been derived from investigation into specific genetic systems and genome projects.  
 Many supposedly neutral mutations have been reevaluated as functional 
polymorphisms. Polymorphic analysis working with the “relative clinical observed 
likelihood” (RCOL) has established the relevance of polymorphisms with regards to 
clinical relevance (Cooper, 2002). Clinically relevant polymorphisms include a change 
in a functional amino acid, an evolutionarily conserved amino acid, a biochemically non-
conserved amino acid and reversion of phenotype with substitution. Although the 
arginine-lysine substitution does not meet many of the criteria, it does confer with other 
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characteristics of clinically relevant phenotypes. It segregates with the clinical 
phenotype, is present in all individuals tested and is not present in two normal dogs from 
two different breeds and substitutes a conserved amino acid from both mouse and man. 
The serine-isoleucine substitution also segregates with the affected phenotype but may 
be more clinically significant. The substitution changes a hydrophilic amino acid for a 
hydrophobic amino acid. Although not evolutionarily conserved in the human where the 
corresponding amino acid is an asparagine (another hydrophilic amino acid), it is 
conserved in the corresponding position in the mouse. 
 Folding of the colIV molecules into a trimer for incorporation into the basement 
membrane network is essential for colIV function. ColIV timer assembly begins at the 
C-terminus and proceeds to the N-terminus. Any disruption in the winding together of 
these chains can disrupt the normal molecular assembly. 
 the spectrum of COL4A5 mutations is represented in an investigation of the 
natural history of 195 XLAS kindreds (Jais et al., 2000). Of the 195 COL4A5 mutations 
reported, ~20% were large rearrangements, ~15% were microinsertions or 
microdeletions, ~27% were nonsense mutations and ~15% were splice mutations. 
Missense mutations were found in 74/195 kindreds and represented ~38% of all 
mutations in this study. Although the majority of the missense mutations (59/74) were 
glycine substitutions, 16/74 of the missense mutations were substitutions that involved 
amino acids other than glycine. 
 An earlier investigation described many of these non-glycine substitutions in 
XLAS (Lemmink et al., 1997). Non-glycine substitutions in the COL4A5 gene in this 
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study were identified as causal mutations in 11/160 kindreds. Two non-glycine 
substitutions changed a conserved arginine. Six mutations were identified as 
hydrophobic to hydrophillic changes and three of these changed an isoleucine to a 
serine. The serine to isoleucine substitution in the COL4A3 gene identified in ECS-HN 
individuals is a hydrophillic to hydrophobic change, but this report shows that changes 
in the hydrophobicity of individual amino acids in the COL4A5 gene have been shown 
to create the XLAS phenotype. Similar changes have yet to be shown in ARAS, but this 
may be because of the scarcity of reported mutations in these COL4A3 and COL4A4 
genes. 
 While it is more difficult to establish causality of amino acid substitutions on 
phenotype, we propose that the aberrations identified in the COL4A3 coding region in 
ECS-HN individuals inhibits the incorporation of the colIVA3 chain into mature colIV 
trimers. The winding of these molecules could be disrupted by a kink in a collagenous 
region resulting from a substitution of a hydrophillic amino acid (serine) with a 
hydrophobic amino acid (isoleucine). The serine-isoleucine subsitution lies adjacent to a 
glycine molecule and it is possible that the change to a hydrophobic amino acid causes a 
kink in the chain inhibiting the folding of the glycine into the α3α4α5 helix. Each amino 
acid interacts with other amino acids in corresponding chains. It is now impossible to 
determine the intramolecular associations between the α3α4α5 chains at this specific 
locus, however, the substitution of a larger hydrophobic amino acid at this position may 
inhibit the folding of these chains into a mature functional trimer.  
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 Another factor inhibiting the winding of the colIVα3α4α5 trimer is the 
substitution of the conserved arginine near the substituted serine. For whatever reason, 
this colIVA3 arginine is conserved in mouse and man. These two mutations may act 
synergistically to inhibit the molecular interactions necessary for trimer assembly. 
The ultimate goal of molecular medicine is to be able to predict a clinical 
phenotype associated with a specific genotype. The identification of a specific base 
change in ECS COL4A3 and COL4A4 alleles, especially with regards to an amino acid 
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    Canine COL4A3 nucleotide sequence 
 
    Sequence Range: 1 to 4643 
 
                     10          20          30          40          50 
            AACTT TAAGA AGGAG ATATA CCATG GCGAT GGTGT ACCAG GATGC AATGG 
            TTGAA ATTCT TCCTC TATAT GGTAC CGCTA CCACA TGGTC CTACG TTACC 
 
                     60          70          80          90         100 
            TTCTA AGGGT GAGCA AGGGT TTCCA GGCCT TCCAG GGACA CCAGG CTACC 
            AAGAT TCCCA CTCGT TCCCA AAGGT CCGGA AGGTC CCTGT GGTCC GATGG 
 
                    110         120         130         140         150 
            CAGGG ATCCC GGGTG CTGTT GGCCT GAAAG GAGAA AAAGG TGCTC CTGCC 
            GTCCC TAGGG CCCAC GACAA CCGGA CTTTC CTCTT TTTCC ACGAG GACGG 
 
                    160         170         180         190         200 
            ACAGA AGGTA TAGAA CTTGA TGGAA GAGGT GACCC TGGGT TGCCA GGAGC 
            TGTCT TCCAT ATCTT GAACT ACCTT CTCCA CTGGG ACCCA ACGGT CCTCG 
 
                    210         220         230         240         250 
            TCCAG GATTC CAGGG TTTAC CAGGC CTTCC AGGCT TTCCG GGACC TGCTG 
            AGGTC CTAAG GTCCC AAATG GTCCG GAAGG TCCGA AAGGC CCTGG ACGAC 
 
                    260         270         280         290         300 
            GTCCA CCTGG CCCTC CGGGA TTCTT AGGCT TTCCA GGAGC CATGG GACCT 
            CAGGT GGACC GGGAG GCCCT AAGAA TCCGA AAGGT CCTCG GTACC CTGGA 
 
                    310         320         330         340         350 
            CCAGG ACCTA AGGGT CAAAT GGGCG ATAAA GTGAT AGGAC AAAAA GGAGA 
            GGTCC TGGAT TCCCA GTTTA CCCGC TATTT CACTA TCCTG TTTTT CCTCT 
 
                    360         370         380         390         400 
            GCGGG GTGTG AAAGG ATTAA CAGGA CCTCC CGGAC CACCA GGAAC AGTTA 
            CGCCC CACAC TTTCC TAATT GTCCT GGAGG GCCTG GTGGT CCTTG TCAAT 
 
                    410         420         430         440         450 
            TTGTG ACGCT AACCG GCCCT GATAA CAGAA CGGAC CTCAA GGGGG AGAAG 
            AACAC TGCGA TTGGC CGGGA CTATT GTCTT GCCTG GAGTT CCCCC TCTTC 
 
                    460         470         480         490         500 
            GGAGA CAAGG GAGCC ATGGG GAAGC CTGGA CCTCC TGGGC CCTTG GGACC 
            CCTCT GTTCC CTCGG TACCC CTTCG GACCT GGAGG ACCCG GGAAC CCTGG 
 
                    510         520         530         540         550 
            GCCTG GAGAA TCCTA TGGAT CTGAA AAAGG TGCTC CTGGA GAACC TGGCC 
            CGGAC CTCTT AGGAT ACCTA GACTT TTTCC ACGAG GACCT CTTGG ACCGG 
 
                    560         570         580         590         600 
            CGCAG GGAAA ACCTG GCAAA GATGG TGCCC CTGGT TTCCC TGGCA CTGAG 




                    610         620         630         640         650 
            GGGCC CAAAG GCAAC AGAGG CTTCC CTGGG TTACG GGGTG AAGAC GGCAT 
            CCCGG GTTTC CGTTG TCTCC GAAGG GACCC AATGC CCCAC TTCTG CCGTA 
 
                    660         670         680         690         700 
            TAAGG GGTGG AAAGG GGACA TTGGC CCGCC AGGAT TTCGT GGTCC AACAG 
            ATTCC CCACC TTTCC CCTGT AACCG GGCGG TCCTA AAGCA CCAGG TTGTC 
 
                    710         720         730         740         750 
            AATAT TATGA TGCAT ACCAG GAAAA GGGTG ATGAA GGAAT TCCAG GCCCA 
            TTATA ATACT ACGTA TGGTC CTTTT CCCAC TACTT CCTTA AGGTC CGGGT 
 
                    760         770         780         790         800 
            CCAGG CCCCA AAGGA GCTCG TGGCC CCCAG GGTCC CAGCG GTCCC CCTGG 
            GGTCC GGGGT TTCCT CGAGC ACCGG GGGTC CCAGG GTCGC CAGGG GGACC 
 
                    810         820         830         840         850 
            AGTTC TTGGA AGTGC TGGGT CATCA AAGCC TGGCC TCAGA GGAGC TCCTG 
            TCAAG AACCT TCACG ACCCA GTAGT TTCGG ACCGG AGTCT CCTCG AGGAC 
 
                    860         870         880         890         900 
            GATCT CCAGG CATGA AAGGA CGTAA AGGGG AACAA GGGCC CCCGG GAAAG 
            CTAGA GGTCC GTACT TTCCT GCATT TCCCC TTGTT CCCGG GGGCC CTTTC 
 
                    910         920         930         940         950 
            AATGC AGTGG GGCCT CCTGG GTCCC CAGGT TGTCC TGGTT CACCA GGCCC 
            TTACG TCACC CCGGA GGACC CAGGG GTCCA ACAGG ACCAA GTGGT CCGGG 
 
                    960         970         980         990        1000 
            CATAG GGCTG CCGGG ATATC CAGGA CCACC AGGTG ACATC GTGTT TCGCA 
            GTATC CCGAC GGCCC TATAG GTCCT GGTGG TCCAC TGTAG CACAA AGCGT 
 
                   1010        1020        1030        1040        1050 
            AAGGT CCACC TGGGG TTGGT GGACT CCCCG GCCAT GTTGG GTTTC CAGGC 
            TTCCA GGTGG ACCCC AACCA CCTGA GGGGC CGGTA CAACC CAAAG GTCCG 
 
                   1060        1070        1080        1090        1100 
            ATCCC AGGAG TCGAG GGGCC CAAAG GGGAA CCAGG CCTCT TGTGC GTACA 
            TAGGG TCCTC AGCTC CCCGG GTTTC CCCTT GGTCC GGAGA ACACG CATGT 
 
                   1110        1120        1130        1140        1150 
            GTGTG CTTAT ATCCC AGGGC GTCCA GGTCT CCCAG GACTG CCAGG GTTGG 
            CACAC GAATA TAGGG TCCCG CAGGT CCAGA GGGTC CTGAC GGTCC CAACC 
 
                   1160        1170        1180        1190        1200 
            ATGGC ATAAA AGGAA TCCCA GGAGG ACAAG GGGCA GCTGG CATTA AAGGA 
            TACCG TATTT TCCTT AGGGT CCTCC TGTTC CCCGT CGACC GTAAT TTCCT 
 
                   1210        1220        1230        1240        1250 
            AGCCC AGGGT CCCCA GGAAG TGCGG GTCTT CCAGG ATTTC CAGGA TTCCC 
            TCGGG TCCCA GGGGT CCTTC ACGCC CAGAA GGTCC TAAAG GTCCT AAGGG 
 
                   1260        1270        1280        1290        1300 
            GGGTG CTCCG GGTGC TCCAG GACTT AAAGG AGAAA AAGGA GAAAC ATCTG 




                   1310        1320        1330        1340        1350 
            AGCCT GAGGG ACAGG TGGGT GCTCC AGGGG ACCCC GGGCT CAGAG GCCAT 
            TCGGA CTCCC TGTCC ACCCA CGAGG TCCCC TGGGG CCCGA GTCTC CGGTA 
 
                   1360        1370        1380        1390        1400 
            CCTGG AAGAA AGGGC TTGGA TGGAA TTCCT GGAAC TCCTG GAATT AAAGG 
            GGACC TTCTT TCCCG AACCT ACCTT AAGGA CCTTG AGGAC CTTAA TTTCC 
 
                   1410        1420        1430        1440        1450 
            ACCAC CAGGA CCCAA AGGTG AACCG GCCCT GAGTG GTGAG AAGGG GGACC 
            TGGTG GTCCT GGGTT TCCAC TTGGC CGGGA CTCAC CACTC TTCCC CCTGG 
 
                   1460        1470        1480        1490        1500 
            AGGGT CCTCC AGGGG ATCCT GGGAT CCCAG GGTCC CCAGG ACCTG CAGGA 
            TCCCA GGAGG TCCCC TAGGA CCCTA GGGTC CCAGG GGTCC TGGAC GTCCT 
 
                   1510        1520        1530        1540        1550 
            CCACC TGGAC CACCA AACTA TGGAC CACAG GGAGA GCCTG GTCCA AAGGG 
            GGTGG ACCTG GTGGT TTGAT ACCTG GTGTC CCTCT CGGAC CAGGT TTCCC 
 
                   1560        1570        1580        1590        1600 
            CACCC AAGGA GTTCC TGGAG CCCCT GGACC ACCTG GAGAA GCCGG TCCTA 
            GTGGG TTCCT CAAGG ACCTC GGGGA CCTGG TGGAC CTCTT CGGCC AGGAT 
 
                   1610        1620        1630        1640        1650 
            AGGGA GAATT CGGTA TTTCG ACACC AGTCC CAGGG CCCCC AGGAC CTCCA 
            TCCCT CTTAA GCCAT AAAGC TGTGG TCAGG GTCCC GGGGG TCCTG GAGGT 
 
                   1660        1670        1680        1690        1700 
            GGGCC CCCTG GTTAT GCTGG CCCCC GAGGT CCACC TGGTA TCCCT GGATC 
            CCCGG GGGAC CAATA CGACC GGGGG CTCCA GGTGG ACCAT AGGGA CCTAG 
 
                   1710        1720        1730        1740        1750 
            CATAG GAAAA TGTGG TGATC CGGGT CTTCC TGGGC CTGAT GGTGA ACCAG 
            GTATC CTTTT ACACC ACTAG GCCCA GAAGG ACCCG GACTA CCACT TGGTC 
 
                   1760        1770        1780        1790        1800 
            GAATT CCAGG AATTG GCTTC CCTGG GCCCC CTGGA CCTAA GGGAG ACCAA 
            CTTAA GGTCC TTAAC CGAAG GGACC CGGGG GACCT GGATT CCCTC TGGTT 
 
                   1810        1820        1830        1840        1850 
            GGTTT TCCAG GAGCA AAAGG AGCAC CGGGT TGTCC AGGAG AAATG GGGAA 
            CCAAA AGGTC CTCGT TTTCC TCGTG GCCCA ACAGG TCCTC TTTAC CCCTT 
 
                   1860        1870        1880        1890        1900 
            GCCCG GGTCA CCTGG AGAAC CAGGT CTCCC AGGAG CCAAG GGAGA ACCAG 
            CGGGC CCAGT GGACC TCTTG GTCCA GAGGG TCCTC GGTTC CCTCT TGGTC 
 
                   1910        1920        1930        1940        1950 
            GACTA GCCAT ACCTG GAGAA CCAGG AATAC CAGGT TTTCC AGGAG AAAGA 
            CTGAT CGGTA TGGAC CTCTT GGTCC TTATG GTCCA AAAGG TCCTC TTTCT 
 
                   1960        1970        1980        1990        2000 
            GGCAA TTCTG GGGAA AATGG AGAAA TTGGA CTCCC TGGAC TTCCA GGTCT 




                   2010        2020        2030        2040        2050 
            CCCTG GAATT CCAGG AACTG GAGGG CTTGA TGGAC CACCA GGGGA TCCAG 
            GGGAC CTTAA GGTCC TTGAC CTCCC GAACT ACCTG GTGGT CCCCT AGGTC 
 
                   2060        2070        2080        2090        2100 
            GGAAG CCTGG ACCAC CTGGA GAAAA AGGAC CCCCA GGAAG TTGCA CAGAG 
            CCTTC GGACC TGGTG GACCT CTTTT TCCTG GGGGT CCTTC AACGT GTCTC 
 
                   2110        2120        2130        2140        2150 
            GGTCC CAGAG GAGCC CACGG ACTTC CAGGA TTAAA TGGAT TGGAA GGGCA 
            CCAGG GTCTC CTCGG GTGCC TGAAG GTCCT AATTT ACCTA ACCTT CCCGT 
 
                   2160        2170        2180        2190        2200 
            ACCAG GCAGA AGAGG TGAAA CAGGG CCAAA AGGAG ACCCA GGTAT TCCAG 
            TGGTC CGTCT TCTCC ACTTT GTCCC GGTTT TCCTC TGGGT CCATA AGGTC 
 
                   2210        2220        2230        2240        2250 
            GCTTG GATAG ATCAG GCTTT CCTGG AGAAC CTGGA CCACC AGGAA TGCCA 
            CGAAC CTATC TAGTC CGAAA GGACC TCTTG GACCT GGTGG TCCTT ACGGT 
 
                   2260        2270        2280        2290        2300 
            GGTCA TCGAG GTGAG ATAGG ACCAC CTGGC CAAAA AGGAT ATCCA GGAAA 
            CCAGT AGCTC CACTC TATCC TGGTG GACCG GTTTT TCCTA TAGGT CCTTT 
 
                   2310        2320        2330        2340        2350 
            TCCGG GATTT TTAGG ACTAC CAGGT GAAGA TGGAG TGATT GGGAT GATGG 
            AGGCC CTAAA AATCC TGATG GTCCA CTTCT ACCTC ACTAA CCCTA CTACC 
 
                   2360        2370        2380        2390        2400 
            GCTAT CCAGG AAACA CTGGC CCTCC TGGGC CTCCC GGGAT CCCAG GCACC 
            CGATA GGTCC TTTGT GACCG GGAGG ACCCG GAGGG CCCTA GGGTC CGTGG 
 
                   2410        2420        2430        2440        2450 
            CCAGG ACAGA GGGGT AGCTT TGGAA TTCCA GGTGC AAAGG GTGAG AAAGG 
            GGTCC TGTCT CCCCA TCGAA ACCTT AAGGT CCACG TTTCC CACTC TTTCC 
 
                   2460        2470        2480        2490        2500 
            GCCCC CAGGA GCCAA GGGGG AAGAA GGAGA GAAAG GACCT ATGGG GCCTT 
            CGGGG GTCCT CGGTT CCCCC TTCTT CCTCT CTTTC CTGGA TACCC CGGAA 
 
                   2510        2520        2530        2540        2550 
            GTCAA ATAAC CAGCT CAGTG GGGGA CAAAG GAGAA CCAGG CCTCA AAGGG 
            CAGTT TATTG GTCGA GTCAC CCCCT GTTTC CTCTT GGTCC GGAGT TTCCC 
 
                   2560        2570        2580        2590        2600 
            TTTGC AGGAA AGCCG GGTGA AAAAG GAAAC AGAGG CATTC CAGGG TTACC 
            AAACG TCCTT TCGGC CCACT TTTTC CTTTG TCTCC GTAAG GTCCC AATGG 
 
                   2610        2620        2630        2640        2650 
            AGGTT TGAAA GGATT CGAAG GGCCA CCTGG ACCAC CAGGC CCACC AGGCC 
            TCCAA ACTTT CCTAA GCTTC CCGGT GGACC TGGTG GTCCG GGTGG TCCGG 
 
                   2660        2670        2680        2690        2700 
            CCCGA GGAGA TCCAG GCAGC ATTGG GAATC CTGGA GAAGC AGGAC CACGT 




                   2710        2720        2730        2740        2750 
            GGAAG TCCAG GAAAC ATGGG GAACA TGGGG ATGCC AGGTC TTAAA GGACA 
            CCTTC AGGTC CTTTG TACCC CTTGT ACCCC TACGG TCCAG AATTT CCTGT 
 
                   2760        2770        2780        2790        2800 
            CAGGG GACCT TTGGG ACTAC CAGGT GTCAC TGGAA GACCA GGCCT CCCAG 
            GTCCC CTGGA AACCC TGATG GTCCA CAGTG ACCTT CTGGT CCGGA GGGTC 
 
                   2810        2820        2830        2840        2850 
            GTGTT CACGG TCTCC AAGGA GACAA GGGAG AGCCA GGTTA TTCAG CAGGT 
            CACAA GTGCC AGAGG TTCCT CTGTT CCCTC TCGGT CCAAT AAGTC GTCCA 
 
                   2860        2870        2880        2890        2900 
            ACAAG GCCAG GACCA CCGGG ACTAA AGGGA GATCC AGGAT TACCA GGTGC 
            TGTTC CGGTC CTGGT GGCCC TGATT TCCCT CTAGG TCCTA ATGGT CCACG 
 
                   2910        2920        2930        2940        2950 
            CATGG GAAGG AAAGG AGAAA GAGGG CTACC TGGCA CCCCT GGCCA TTCGG 
            GTACC CTTCC TTTCC TCTTT CTCCC GATGG ACCGT GGGGA CCGGT AAGCC 
 
                   2960        2970        2980        2990        3000 
            GGCCT GCTGG AACTG AGGGA GCCCC TGGAC ATCCC GGAAG TCCTG GCCAC 
            CCGGA CGACC TTGAC TCCCT CGGGG ACCTG TAGGG CCTTC AGGAC CGGTG 
 
                   3010        3020        3030        3040        3050 
            CCAGG AAAGC CAGGC CCTGA TGGAG ATTTG GGGTT AAAAG GCATC AAAGG 
            GGTCC TTTCG GTCCG GGACT ACCTC TAAAC CCCAA TTTTC CGTAG TTTCC 
 
                   3060        3070        3080        3090        3100 
            CTTCC CTGGG TCCCC AGGAG TCAAA GGACC TCCAG GACCT CCAGG AATCC 
            GAAGG GACCC AGGGG TCCTC AGTTT CCTGG AGGTC CTGGA GGTCC TTAGG 
 
                   3110        3120        3130        3140        3150 
            TAGGA TCTCC TGGAC CTATG GGCAT GAGAG GCAAC CAGGG CCGTG ATGGA 
            ATCCT AGAGG ACCTG GATAC CCGTA CTCTC CGTTG GTCCC GGCAC TACCT 
 
                   3160        3170        3180        3190        3200 
            ATCCC TGGTC CCCCA GGAGA AAAGG GAGAA ACAGG TTTGC TGGGG GCACA 
            TAGGG ACCAG GGGGT CCTCT TTTCC CTCTT TGTCC AAACG ACCCC CGTGT 
 
                   3210        3220        3230        3240        3250 
            TCCAG GCCCA GGAGG GAGCC CTGGT CCTCC AGGAG CCAAA GGAGA CAGGG 
            AGGTC CGGGT CCTCC CTCGG GACCA GGAGG TCCTC GGTTT CCTCT GTCCC 
 
                   3260        3270        3280        3290        3300 
            GCGCC CCAGG CCTAC CAGGC CCCCC AGGCA GGAAA GGGGC AGTGG GAGAT 
            CGCGG GGTCC GGATG GTCCG GGGGG TCCGT CCTTT CCCCG TCACC CTCTA 
 
                   3310        3320        3330        3340        3350 
            GCCGG GCCAC GGGGA CCCAC TGGCA TGACG GGACT CCCAG GGCCA CCAGG 
            CGGCC CGGTG CCCCT GGGTG ACCGT ACTGC CCTGA GGGTC CCGGT GGTCC 
 
                   3360        3370        3380        3390        3400 
            TTTTC CTGGT GCAGT CATCC CTGGC CAGAA AGGAA ATCAA GGTCC ACCAG 




                   3410        3420        3430        3440        3450 
            GCTTC AGAGG AAACC CAGGT GAGCC TGGTC CTCCA GGCCC TCCAG GGAGC 
            CGAAG TCTCC TTTGG GTCCA CTCGG ACCAG GAGGT CCGGG AGGTC CCTCG 
 
                   3460        3470        3480        3490        3500 
            CACGT GAAAG GCATA AAAGG AGACA AGGGA CTCAT GGGTG AGCCT GGCCC 
            GTGCA CTTTC CGTAT TTTCC TCTGT TCCCT GAGTA CCCAC TCGGA CCGGG 
 
                   3510        3520        3530        3540        3550 
            CAGAG GTCTA CCTGG AACTG TGGGA GACAA GGGGC CACCG GGTCA ACCGG 
            GTCTC CAGAT GGACC TTGAC ACCCT CTGTT CCCCG GTGGC CCAGT TGGCC 
 
                   3560        3570        3580        3590        3600 
            GAGCA CCAGG GAGCC CAGGT CTGCC AGGGC TCAGG GGCGA TCCTG GATTC 
            CTCGT GGTCC CTCGG GTCCA GACGG TCCCG AGTCC CCGCT AGGAC CTAAG 
 
                   3610        3620        3630        3640        3650 
            TATGG ATTTC CAGGT GTTAA AGGAG AGAAG GGTAA CCCAG GATTT CCGGG 
            ATACC TAAAG GTCCA CAATT TCCTC TCTTC CCATT GGGTC CTAAA GGCCC 
 
                   3660        3670        3680        3690        3700 
            ACCAG CTGGA CCTCC AGGGC AAATT GGGCC AAAAG GACCA CCTGG TGTCC 
            TGGTC GACCT GGAGG TCCCG TTTAA CCCGG TTTTC CTGGT GGACC ACAGG 
 
                   3710        3720        3730        3740        3750 
            GTGGA GACCC TGGCA CAGTT AAGAT CATCT CCCTT CCAGG AAGCC CAGGG 
            CACCT CTGGG ACCGT GTCAA TTCTA GTAGA GGGAA GGTCC TTCGG GTCCC 
 
                   3760        3770        3780        3790        3800 
            CCACC TGGCC GTGCT GGAGG ACCGG GGATG CCAGG AGAAC CAGGG CCACC 
            GGTGG ACCGG CACGA CCTCC TGGCC CCTAC GGTCC TCTTG GTCCC GGTGG 
 
                   3810        3820        3830        3840        3850 
            AGGGC CACCA GGAAT CCTAG GACCC TGTGG ACCAA GAGGT AAACC AGGCA 
            TCCCG GTGGT CCTTA GGATC CTGGG ACACC TGGTT CTCCA TTTGG TCCGT 
 
                   3860        3870        3880        3890        3900 
            TGGAT GGAAT ACCAG GAACT CCTGG GCCAA TTGGA GAAAA AGGCA ACAAA 
            ACCTA CCTTA TGGTC CTTGA GGACC CGGTT AACCT CTTTT TCCGT TGTTT 
 
                   3910        3920        3930        3940        3950 
            GGTTG TAAAG GCGAG CAAGG ACCAC CTGGA TTAGA TGGAC TGCCA GGCTT 
            CCAAC ATTTC CGCTC GTTCC TGGTG GACCT AATCT ACCTG ACGGT CCGAA 
 
                   3960        3970        3980        3990        4000 
            GAAGG GGAGA CCTGG AGACC CTGGA CCACC TGCAA CTGGG ACCAT GAAGA 
            CTTCC CCTCT GGACC TCTGG GACCT GGTGG ACGTT GACCC TGGTA CTTCT 
 
                   4010        4020        4030        4040        4050 
            GGGGC TTTAT CTTCA CCAGG CATAG TCAGA CCACA GTGAT TCCTT CCTGT 
            CCCCG AAATA GAAGT GGTCC GTATC AGTCT GGTGT CACTA AGGAA GGACA 
 
                   4060        4070        4080        4090        4100 
            CCAGA AGGGA CAGCG CCACT CTATA GTGGC TTTTC TCTTC TTTTC ATACA 




                   4110        4120        4130        4140        4150 
            AGGAA ATGAA CAAGC CCATG GACAA GACTT GGGAA CTCTC GGCAG CTGCC 
            TCCTT TACTT GTTCG GGTAC CTGTT CTGAA CCCTT GAGAG CCGTC GACGG 
 
                   4160        4170        4180        4190        4200 
            TGCAG CGATT TACCA CAATG CCATT CTTGT TCTGT AACAT CAACA ATGTC 
            ACGTC GCTAA ATGGT GTTAC GGTAA GAACA AGACA TTGTA GTTGT TACAG 
 
                   4210        4220        4230        4240        4250 
            TGTAA TTTTG CATCT CGAAA TGACT ACTCA TACTG GCTGT CAACA CCAGC 
            ACATT AAAAC GTAGA GCTTT ACTGA TGAGT ATGAC CGACA GTTGT GGTCG 
 
                   4260        4270        4280        4290        4300 
            TCTGA TGCCA ATGGA CATGG CTCCA ATTAC TGGCA GGGCC CTGGA GCCTT 
            AGACT ACGGT TACCT GTACC GAGGT TAATG ACCGT CCCGG GACCT CGGAA 
 
                   4310        4320        4330        4340        4350 
            ATATT AGCAG ATGCA CTGTC TGTGA AGGTC CTACG ATTGC CATAG CCATT 
            TATAA TCGTC TACGT GACAG ACACT TCCAG GATGC TAACG GTATC GGTAA 
 
                   4360        4370        4380        4390        4400 
            CACAG CCAAA CCACT GACAT TCCCT CATGT CCCAA TGGCT GGATT TCTCT 
            GTGTC GGTTT GGTGA CTGTA AGGGA GTACA GGGTT ACCGA CCTAA AGAGA 
 
                   4410        4420        4430        4440        4450 
            CTGGA AAGGA TTTTC GTTTA TCATG TTCAC AAGTG CAGGT TCTGA GGGTG 
            GACCT TTCCT AAAAG CAAAT AGTAC AAGTG TTCAC GTCCA AGACT CCCAC 
 
                   4460        4470        4480        4490        4500 
            CTGGG CAAGC ACTGG CCTCC CCCGG CTCCT GCCTG GAAGA GTTCC GAGCC 
            GACCC GTTCG TGACC GGAGG GGGCC GAGGA CGGAC CTTCT CAAGG CTCGG 
 
                   4510        4520        4530        4540        4550 
            AGTCC GTTTA TAGAA TGTCA CGGAA GAGGA ACGTG CAACT ACTAT TCAAA 
            TCAGG CAAAT ATCTT ACAGT GCCTT CTCCT TGCAC GTTGA TGATA AGTTT 
 
                   4560        4570        4580        4590        4600 
            TTCCT ACAGT TTCTG GTTGG CTTCG TTAAA CCCCC AAAGA ATGTT CAGAA 
            AAGGA TGTCA AAGAC CAACC GAAGC AATTT GGGGG TTTCT TACAA GTCTT 
 
                   4610        4620        4630        4640     
            AACCT ATTCC ATCAA CTGTG AAAGC TGAAT CCATA TGACT AGT 









Canine COL4A3 nucleotide alignments 
 
 
Consensus key (see documentation for details) 
* - single, fully conserved residue 
  - no consensus 
 
 
CLUSTAL W (1.81) multiple sequence alignment 
 
 
Canine_Normal_5-18      ------------------------------------------------------------ 
Human_COL4A3            ATGAGCGCCCGGACCGCCCCCAGGCCGCAGGTGCTCCTGCTGCCGCTCCTGCTGGTGCTC 
Mouse_COL4A3            ATGCACTCCAAGACTGCTCCAAGGTTCCTGGTGTTCCTGCTGCTTACCCTGCTGCTACTC 
 
 
Canine_Normal_5-18      ------------------------------------------------------------ 
Human_COL4A3            CTGGCGGCGGCGCCCGCAGCCAGCAAGGGTTGTGTCTGTAAAGACAAAGGCCAGTGCTTC 
Mouse_COL4A3            CTGGCTGCCTCTCCTGTGGCTAGCAAGGGCTGTGTCTGCAAAGGCAAAGGACAATGCCTC 
 
 
Canine_Normal_5-18      ------------------------------------------------------------ 
Human_COL4A3            TGTGACGGGGCCAAAGGGGAGAAGGGGGAGAAGGGCTTTCCTGGACCCCCCGGTTCTCCT 
Mouse_COL4A3            TGCGCGGGGACCAAAGGGGAGAAGGGGGAGAAAGGGGTTCCTGGTTCCCCTGGATTTCCT 
 
 
Canine_Normal_5-18      ------------------------------------------------------------ 
Human_COL4A3            GGCCAGAAAGGATTCACAGGTCCTGAAGGCTTGCCTGGACCGCAGGGACCCAAGGGCTTT 
Mouse_COL4A3            GGCCAGAAAGGATTTCCAGGTCCTGAAGGCTTGCCTGGACCACAGGGACCCAAGGGCTCC 
 
 
Canine_Normal_5-18      ------------------------------------------------------------ 
Human_COL4A3            CCAGGACTTCCAGGACTCACGGGTTCCAAAGGTGTAAGGGGAATAAGTGGATTGCCAGGA 
Mouse_COL4A3            CCAGGACTTCCGGGACTCACTGGCCCCAAAGGCATCAGGGGAATAACTGGATTACCAGGG 
 
 
Canine_Normal_5-18      --------------------------AACTTTAAGAAG----GAGATATACCATGGCGAT 
Human_COL4A3            TTTTCTGGTTCTCCTGGACTTCCAGGCACCCCAGGCAATACCGGGCCTTACGGACTTGTC 
Mouse_COL4A3            TTTGCAGGTCCTCCTGGACTTCCAGGCCTCCCAGGCCACCCTGGGCCTCGTGGGCTGGCT 
                                                        * *       * *            *   
 
Canine_Normal_5-18      GGTGTACCAGGATGCAATGGTTCTAAGGGTGAGCAAGGGTTTCCAGGCCTTCCAGGGACA 
Human_COL4A3            GGTGTACCAGGATGCAGTGGTTCTAAGGGTGAGCAGGGGTTTCCAGGACTCCCAGGGACA 
Mouse_COL4A3            GGTTTACCAGGATGCAACGGATCTAAGGGTGAACAAGGATTCCCGGGCTTTCCCGGCACA 
                        *** ************  ** *********** ** ** ** ** **  * ** ** *** 
 
Canine_Normal_5-18      CCAGGCTACCCAGGGATCCCGGGTGCTGTTGGCCTGAAAGGAGAAAAAGGTGCTCCTGCC 
Human_COL4A3            CCGGGCTACCCAGGGATCCCGGGTGCTGCTGGTTTGAAAGGACAAAAGGGTGCTCCTGCT 
Mouse_COL4A3            CCAGGCTATGCAGGGCTCCCAGGTCCTGATGGCTTGAAAGGACAAAAGGGTGAGCCTGCT 
                        ** *****  ***** **** *** *** ***  ******** **** ****  *****  
 
Canine_Normal_5-18      ACAG---AAGGTATAGAACTTGATGGAAGAGGTGACCCTGGGTTGCCAGGAGCTCCAGGA 
Human_COL4A3            AAAGGAGAAGATATAGAACTTGATGCAAAAGGCGACCCCGGGTTGCCAGGGGCTCCAGGA 
Mouse_COL4A3            CAAGGAGAAGACAGGGGATTCAATGGAAAAGGTGACCCTGGGCCTCCAGGGGTTCCAGGC 
                          **   ***  *  * * *  *** ** *** ***** ***   ***** * ******  
 
Canine_Normal_5-18      TTCCAGGGTTTACCAGGCCTTCCAGGCTTTCCGGGACCTGCTGGTCCACCTGGCCCTCCG 
Human_COL4A3            CCCCAGGGTTTGCCAGGCCCTCCAGGTTTTCCTGGGCCTGTTGGCCCACCTGGTCCTCCG 
Mouse_COL4A3            TTCCAGGGTTTTCCGGGACTCCCAGGTTTTCCAGGGCCTGCCGGTCCACCAGGACCTCCG 
                          ********* ** ** *  ***** ***** ** ****  ** ***** ** ****** 
 
Canine_Normal_5-18      GGATTCTTAGGCTTTCCAGGAGCCATGGGACCTCCAGGACCTAAGGGTCAAATGGGCGAT 
Human_COL4A3            GGATTCTTTGGCTTTCCAGGAGCCATGGGACCTAGAGGACCTAAGGGTCACATGGGTGAA 
Mouse_COL4A3            GGATTTTTTGGTTTACCAGGAGCAATGGGACCCAGAGGACCCAAAGGCCACATGGGCGAT 
                        ***** ** ** ** ******** ********   ****** ** ** ** ***** **  
 116
 
Canine_Normal_5-18      AAAGTGATAGGACAAAAAGGAGAGCGGGGTGTGAAAGGATTAACAGGACCTCCCGGACCA 
Human_COL4A3            AGAGTGATAGGACATAAAGGAGAGCGGGGTGTGAAAGGGTTAACAGGACCCCCGGGACCA 
Mouse_COL4A3            AGCGTGATAGGACAAAAAGGAGAAAGGGGTATGAAAGGATTAACAGGACCTCCTGGGCCA 
                        *  *********** ********  ***** ******* *********** ** ** *** 
 
Canine_Normal_5-18      CCAGGAACAGTTATTGTGACGCTAACCGGCCCTGATAACAGAACGGACCTCAAGGGGGAG 
Human_COL4A3            CCAGGAACAGTTATTGTGACCCTAACTGGCCCAGATAACAGAACGGACCTCAAGGGGGAA 
Mouse_COL4A3            CCAGGAACAGTGATTTTTACACTCACCCAGCCATACAACAAATCGGACTTCAAGGGAGAG 
                        *********** *** * ** ** **    **  * **** * ***** ******* **  
 
Canine_Normal_5-18      AAGGGAGACAAGGGAGCCATGGGGAAGCCTGGACCTCCTGGGCCCTTGGGACCGCCTGGA 
Human_COL4A3            AAGGGAGACAAGGGAGCAATGGGCGAGCCTGGACCTCCTGGACCCTCAGGACTGCCTGGA 
Mouse_COL4A3            AAAGGAGATGAGGGAGAGAGGGGTGAACCCGGACCTCCTGGACCCTCGGGGCCACCTGGA 
                        ** *****  ******  * ***  * ** *********** ****  ** *  ****** 
 
Canine_Normal_5-18      GAATCCTATGGATCTGAAAAAGGTGCTCCTGGAGAACCTGGCCCGCAGGGAAAACCTGGC 
Human_COL4A3            GAATCATATGGATCTGAAAAGGGTGCTCCTGGAGACCCTGGCCTGCAGGGAAAACCCGGA 
Mouse_COL4A3            GACTCCTATGGATCAGAAAAGGGTGCGCCTGGAGAGCCTGGTCCTCGGGGCAAACCTGGA 
                        ** ** ******** ***** ***** ******** ***** *  * *** ***** **  
 
Canine_Normal_5-18      AAAGATGGTGCCCCTGGTTTCCCTGGCACTGAGGGGCCCAAAGGCAACAGAGGCTTCCCT 
Human_COL4A3            AAAGATGGTGTTCCTGGCTTCCCTGGAAGTGAGGGAGTCAAGGGCAACAGGGGTTTCCCT 
Mouse_COL4A3            AAAGATGGTGCCCCTGGCTTCCCTGGCACTGAGGGAGCCAAAGGCAACAGGGGCTTTCCT 
                        **********  ***** ******** * ******   *** ******** ** ** *** 
 
Canine_Normal_5-18      GGGTTACGGGGTGAAGACGGCATTAAGGGGTGGAAAGGGGACATTGGCCCGCCAGGATTT 
Human_COL4A3            GGGTTAATGGGTGAAGATGGCATTAAGGGACAGAAAGGGGACATTGGCCCTCCAGGATTT 
Mouse_COL4A3            GGGTTGAGGGGTGAAGCTGGCATTAAGGGAAGGAAAGGAGACATTGGCCCCCCAGGATTT 
                        *****   ********  ***********   ****** *********** ********* 
 
Canine_Normal_5-18      CGTGGTCCAACAGAATATTATGATGCATACCAGGAAAAGGGTGATGAAGGAATTCCAGGC 
Human_COL4A3            CGTGGTCCAACAGAATATTATGACACATACCAGGAAAAGGGAGATGAAGGCACTCCAGGC 
Mouse_COL4A3            CCTGGTCCAACAGAATATTATGACGCATACCTGGAAAAGGGAGAGAGAGGAATGCCAGGC 
                        * *********************  ****** ********* **   *** *  ****** 
 
Canine_Normal_5-18      CCACCAGGCCCCAAAGGAGCTCGTGGCCCCCAGGGTCCCAGCGGTCCCCCTGGAGTTCTT 
Human_COL4A3            CCACCAGGGCCCAGAGGAGCTCGTGGCCCACAAGGTCCCAGTGGTCCCCCCGGAGTTCCT 
Mouse_COL4A3            CTTCCTGGGCCCAAAGGAGCCCGTGGCCCACAGGGTCCAAGTGGTCCCCCTGGAGTCCCT 
                        *  ** ** **** ****** ******** ** ***** ** ******** ***** * * 
 
Canine_Normal_5-18      GGAAGTGCTGGGTCATCAAAGCCTGGCCTCAGAGGAGCTCCTGGATCTCCAGGCATGAAA 
Human_COL4A3            GGAAGTCCTGGATCATCAAGGCCTGGCCTCAGAGGAGCCCCTGGATGGCCAGGCTTGAAA 
Mouse_COL4A3            GGAAGTCCTGGACTGTCAAGGCCTGGCCTCAGAGGACCCATTGGATGGCCAGGCTTGAAA 
                        ****** ****    **** **************** *   *****  ****** ***** 
 
Canine_Normal_5-18      GGACGTAAAGGGGAACAAGGGCCCCCGGGAAAGAATGCAGTGGGGCCTCCTGGGTCCCCA 
Human_COL4A3            GGAAGTAAAGGGGAACGAGGCCGCCCAGGAAAGGATGCCATGGGGACTCCTGGGTCCCCA 
Mouse_COL4A3            GGGAGTAAAGGAGAGAGAGGACCCCCTGGAAAAGACACTGTGGGCCCTCCTGGACCCCTG 
                        **  ******* **   *** * *** *****  *  *  ****  *******  ***   
 
Canine_Normal_5-18      GGTTGTCCTGGTTCACCAGGCCCCATAGGGCTGCCGGGATATCCAGGACCACCAGGTGAC 
Human_COL4A3            GGTTGTGCTGGTTCACCAGGTCTTCCAGGATCACCGGGACCTCCAGGACCGCCAGGTGAC 
Mouse_COL4A3            GGATGTCCTGGCTCACCAGGTCCACCAGGCCCTCCAGGACCTCCAGGATGTCCAGGTGAC 
                        ** *** **** ******** *    ***    ** ***  *******   ********* 
 
Canine_Normal_5-18      ATCGTGTTTCGCAAAGGTCCACCTGGGGTTGGTGGACTCCCCGGCCATGTTGGGTTTCCA 
Human_COL4A3            ATCGTTTTTCGCAAGGGTCCACCTGGAGATCACGGACTGCCAGGCTATCTAGGGTCTCCA 
Mouse_COL4A3            ATTGTTTTT---AAATGTTCCCCTGGTGAGCATGGAATGCCAGGTGACACAGGACCTCCA 
                        ** ** ***   **  ** * ***** *     *** * ** **  *    **   **** 
 
Canine_Normal_5-18      GGCATCCCAGGAGTCGAGGGGCCCAAAGGGGAACCAGGCCTCTTGTGCGTACAGTGTGCT 
Human_COL4A3            GGAATCCCAGGAGTTGATGGGCCCAAAGGAGAACCAGGCCTCCTGTGTACACAGTGCCCT 
Mouse_COL4A3            GGAGTTCCAGGACTTGATGGACCCAAAGGAGAACCAGGCAGTCCATGCACCGAGTGTCAC 




Canine_Normal_5-18      TATATCCCAGGGCGTCCAGGTCTCCCAGGACTGCCAGGGTTGGATGGCATAAAAGGAATC 
Human_COL4A3            TATATCCCAGGGCCTCCCGGTCTCCCAGGATTGCCAGGGTTACATGGTGTAAAAGGAATC 
Mouse_COL4A3            TGCTTCCCAGGGCCCCCTGGAGTCCCAGGATTTCCAGGATTAGATGGTATCAAAGGAATC 
                        *   *********  ** **  ******** * ***** **  ****  * ********* 
 
Canine_Normal_5-18      CCAGGAGGACAAGGGGCAGCTGGCATTAAAGGAAGCCCAGGGTCCCCAGGAAGTGCGGGT 
Human_COL4A3            CCAGGAAGACAAGGCGCAGCTGGCTTGAAAGGAAGCCCAGGGTCCCCAGGAAATACAGGT 
Mouse_COL4A3            CCAGGAGGACGAGGTGTGCCTGGTCTGAAGGGAAACCCAGGGTCCCCAGGAAGTGCAGGT 
                        ****** *** *** *   ****  * ** **** ***************** * * *** 
 
Canine_Normal_5-18      CTTCCAGGATTTCCAGGATTCCCGGGTGCTCCGGGTGCTCCAGGACTTAAAGGAGAAAAA 
Human_COL4A3            CTTCCAGGATTTCCAGGTTTCCCAGGTGCCCAGGGTGACCCAGGACTTAAAGGAGAAAAA 
Mouse_COL4A3            CTCCCAGGATTTGCAGGATTCCCAGGTGACCAAGGGCATCCAGGACTTAAAGGGGACAAA 
                        ** ********* **** ***** ****  *  **    ************** ** *** 
 
Canine_Normal_5-18      GGAGAAACATCTGAGCCTGAGGGACAGGTGGGTGCTCCAGGGGACCCCGGGCTCAGAGGC 
Human_COL4A3            GGTGAAACACTTCAGCCTGAGGGGCAAGTGGGTGTCCCAGGTGACCCGGGGCTCAGAGGC 
Mouse_COL4A3            GGGGATACACCTCTACCCTGGGGGCAAGTGGGTAATCCAGGTGATCCTGGACTCAGAGGC 
                        ** ** ***  *   **   *** ** ******   ***** ** ** ** ********* 
 
Canine_Normal_5-18      CATCCTGGAAGAAAGGGCTTGGATGGAATTCCTGGAACTCCTGGAATTAAAGGACCACCA 
Human_COL4A3            CAACCTGGGAGAAAGGGCTTGGATGGAATTCCTGGAACTCTGGGAGTGAAAGGATTACCA 
Mouse_COL4A3            CTGCCCGGGAGAAAGGGCTTCGATGGAACTCCTGGAGGTCCAGGAGCGAAAGGACCACCA 
                        *  ** ** *********** ******* *******  **  ***   ******  **** 
 
Canine_Normal_5-18      GGACCCAAAGGTGAACCGGCCCTGAGTGGTGAGAAGGGGGACCAGGGTCCTCCAGGGGAT 
Human_COL4A3            GGACCTAAAGGCGAACTGGCTCTGAGTGGTGAGAAAGGGGACCAAGGTCCTCCAGGGGAT 
Mouse_COL4A3            GGACCTCAGGGCGAACCGGCCCTGAGTGGAAGGAAAGGGGACCAAGGACCTCCAGGACCT 
                        *****  * ** **** *** ********   *** ******** ** ********   * 
 
Canine_Normal_5-18      CCTGGGATCCCAGGGTCCCCAGGACCTGCAGGACCACCTGGACCACCAAACTATGGACCA 
Human_COL4A3            CCTGGCTCCCCTGGGTCCCCAGGACCTGCAGGACCAGCTGGACCACCTGGCTACGGACCC 
Mouse_COL4A3            CCTGGATTCCCTGGACCCCCAGGACCTGCAGGACCAGCTGGACCACCAGGCTATGGACCT 
                        *****   *** **  ******************** **********   *** *****  
 
Canine_Normal_5-18      CAGGGAGAGCCTGGTCCAAAGGGCACCCAAGGAGTTCCTGGAGCCCCTGGACCACCTGGA 
Human_COL4A3            CAAGGAGAACCTGGTCTCCAGGGCACGCAAGGAGTTCCTGGGGCCCCCGGACCACCCGGA 
Mouse_COL4A3            CAAGGAGAGCCAGGTCCAAAGGGAGCCCAAGGAGTCCCCGGCGTCCTGGGACCACCTGGA 
                        ** ***** ** ****   ****  * ******** ** ** * **  ******** *** 
 
Canine_Normal_5-18      GAAGCCGGTCCTAAGGGAGAATTCGGTATTTCGACACCAGTCCCAGGGCCCCCAGGACCT 
Human_COL4A3            GAAGCCGGCCCTAGGGGAGAGCTCAGTGTTTCAACACCAGTTCCAGGCCCTCCAGGACCT 
Mouse_COL4A3            GAAGCCGGTCTTAAAGGAGAACCCAGTACATCAACTCCAGATCTAGGTCCCCCAGGCCCT 
                        ******** * **  *****   * **   ** ** ****  * *** ** ***** *** 
 
Canine_Normal_5-18      CCAGGGCCCCCTGGTTATGCTGGCCCCCGAGGTCCACCTGGTATCCCTGGATCCATAGGA 
Human_COL4A3            CCAGGGCCCCCTGGCCATCCTGGCCCCCAAGGTCCACCTGGTATCCCTGGATCCCTGGGG 
Mouse_COL4A3            CCAGGGCCCCCTGGTCAGGCTGGCCCCAGAGGTCTACCTGGTTTGCCTGGACCGGTGGGA 
                        **************  *  ********  ***** ******* * ****** *  * **  
 
Canine_Normal_5-18      AAATGTGGTGATCCGGGTCTTCCTGGGCCTGATGGTGAACCAGGAATTCCAGGAATTGGC 
Human_COL4A3            AAATGTGGAGATCCTGGTCTTCCAGGGCCTGATGGTGAACCAGGAATTCCAGGAATTGGA 
Mouse_COL4A3            AAATGTG---ATCCTGGTCTTCCTGGACCTGATGGTGAGCCAGGAATTCCAGAAGCTGGA 
                        *******   **** ******** ** *********** ************* *  ***  
 
Canine_Normal_5-18      TTCCCTGGGCCCCCTGGACCTAAGGGAGACCAAGGTTTTCCAGGAGCAAAAGGAGCACCG 
Human_COL4A3            TTTCCTGGGCCACCTGGACCTAAGGGAGACCAAGGTTTTCCAGGTACAAAAGGATCACTG 
Mouse_COL4A3            TGCCCAGGGCCTCCAGGACCTAAGGGAAATCAAGGTTTCCCAGGGACAAAAGGATCACCT 
                        *  ** ***** ** ************ * ******** *****  ******** ***   
 
Canine_Normal_5-18      GGTTGTCCAGGAGAAATGGGGAAGCCCGGGTCACCTGGAGAACCAGGTCTCCCAGGAGCC 
Human_COL4A3            GGTTGTCCTGGAAAAATGGGAGAGCCTGGGTTACCTGGAAAGCCAGGCCTCCCAGGAGCC 
Mouse_COL4A3            GGTTGTCCTGGGGAAATGGGAAAGCCTGGCCGTCCTGGAGAACCAGGCATCCCAGGAGCC 
                        ******** **  *******  **** **    ****** * *****  *********** 
 
 118
Canine_Normal_5-18      AAGGGAGAACCAGGACTAGCCATACCTGGAGAACCAGGAATACCAGGTTTTCCAGGAGAA 
Human_COL4A3            AAGGGAGAACCAGCAGTAGCCATGCCTGGAGGACCAGGAACACCAGGTTTTCCAGGAGAA 
Mouse_COL4A3            AAGGGAGAACCATCCGTAGGCAGGCCTGGGAAACCAGGGAAACCAGGCTTTCCAGGAGAA 
                        ************    *** **  *****   ****** * ****** ************ 
 
Canine_Normal_5-18      AGAGGCAATTCTGGGGAAAATGGAGAAATTGGACTCCCTGGACTTCCAGGTCTCCCTGGA 
Human_COL4A3            AGAGGCAATTCTGGGGAACATGGAGAAATTGGACTCCCTGGACTTCCAGGTCTCCCTGGA 
Mouse_COL4A3            AGAGGCAATGCCGGGGAAAATGGAGATATTGGACTCCCTGGGCTTCCAGGCCTCCCTGGA 
                        ********* * ****** ******* ************** ******** ********* 
 
Canine_Normal_5-18      ATTCCAGGAACTGGAGGGCTTGATGGACCACCAGGGGATCCAGGGAAGCCTGGACCACCT 
Human_COL4A3            ACTCCAGGAAATGAAGGGCTTGATGGACCACGAGGAGATCCAGGGCAGCCTGGACCACCT 
Mouse_COL4A3            ACTCCAGGAAGAGGCGGGCTTGACGGGCCTCCAGGAGACCCAGGACAGCCTGGATCACCT 
                        * ********  *  ******** ** ** * *** ** *****  ******** ***** 
 
Canine_Normal_5-18      GGAGAAAAAGGACCCCCAGGAAGTTGCACAGAGGGTCCCAGAGGAGCCCACGGACTTCCA 
Human_COL4A3            GGAGAACAAGGACCCCCAGGAAGGTGCATAGAGGGTCCCAGGGGAGCCCAAGGACTTCCA 
Mouse_COL4A3            GGAGCAAAAGGATCCCCAGGAAGGTGCATACCAGGACCCAGGGGCACCCAAGGACTTCCC 
                        **** * ***** ********** **** *   ** ***** **  **** ********  
 
Canine_Normal_5-18      GGATTAAATGGATTGGAAGGGCAACCAGGCAGAAGAGGTGAAACAGGGCCAAAAGGAGAC 
Human_COL4A3            GGCTTAAATGGATTGAAAGGGCAACAAGGCAGAAGAGGTAAAACGGGGCCAAAGGGAGAC 
Mouse_COL4A3            GGCTTGAATGGATTGAAAGGGCAACCAGGTCGAAGAGGTGATACCGGGCCAAAGGGAGAC 
                        ** ** ********* ********* ***  ******** * ** ******** ****** 
 
Canine_Normal_5-18      CCAGGTATTCCAGGCTTGGATAGATCAGGCTTTCCTGGAGAACCTGGACCACCAGGAATG 
Human_COL4A3            CCAGGAATTCCAGGCTTGGATAGATCAGGATTTCCTGGAGAAACTGGATCACCAGGAATT 
Mouse_COL4A3            CCTGGCATCCCAGGCATGGACAGGTCTGGGGTCCCCGGAGATCCTGGACCACCAGGAACA 
                        ** ** ** ****** **** ** ** **  * ** *****  ***** *********   
 
Canine_Normal_5-18      CCAGGTCATCGAGGTGAGATAGGACCACCTGGCCAAAAAGGATATCCAGGAAATCCGGGA 
Human_COL4A3            CCAGGTCATCAAGGTGAAATGGGACCACTGGGTCAAAGAGGATATCCAGGAAATCCGGGA 
Mouse_COL4A3            CCAGGTTGTCCTGGTGAGATGGGACCACCTGGACAAAAAGGATATCCGGGAGCTCCAGGA 
                        ******  **  ***** ** *******  ** **** ********* ***  *** *** 
 
Canine_Normal_5-18      TTTTTAGGACTACCAGGTGAAGATGGAGTGATTGGGATGATGGGCTATCCAGGAAACACT 
Human_COL4A3            ATTTTAGGGCCACCAGGTGAAGATGGAGTGATTGGGATGATGGGATTTCCTGGAGCCATT 
Mouse_COL4A3            TTCCCAGGACCACCAGGCGAGAAAGGAGAGGTTGGAATGATGGGCTATCCTGGAACCACT 
                         *   *** * ****** **  * **** * **** ******** * *** ***  ** * 
 
Canine_Normal_5-18      GGCCCTCCTGGGCCTCCCGGGATCCCAGGCACCCCAGGACAGAGGGGTAGCTTTGGAATT 
Human_COL4A3            GGCCCTCCAGGGCCCCCTGGGAACCCAGGCACACCAGGGCAGAGGGGGAGCCCTGGAATT 
Mouse_COL4A3            GGCCCTCCGGGGCTTCCTGGGAAACCAGGCTCACAGGGGCAGCGAGGTAGCCTCGGAATC 
                        ******** ****  ** ****  ****** * *  ** *** * ** ***   *****  
 
Canine_Normal_5-18      CCAGGTGCAAAGGGTGAGAAAGGGCCCCCAGGAGCCAAGGGGGAAGAAGGAGAGAAAGGA 
Human_COL4A3            CCAGGAGTAAAGGGCCAGAGAGGAACCCCAGGAGCCAAGGGGGAACAAGGAGATAAAGGA 
Mouse_COL4A3            CCAGGAATGAAAGGGGAAAAAGGACGCCCAGGAGCCAAAGGCGAACGAGGAGAGAAAGGA 
                        *****    ** **  * * ***   ************ ** ***  ****** ****** 
 
Canine_Normal_5-18      CCTATGGGGCCTTGTCAAATAACCAGCTCAGTGGGGGACAAAGGAGAACCAGGCCTCAAA 
Human_COL4A3            AATCCCGGGCCTTCAGAGATATCCCACGTAATAGGGGACAAAGGAGAACCAGGTCTCAAA 
Mouse_COL4A3            AAACCAGGGCCTTCTCAAACAACACTCTTAAAGGGAGACAAAGGAGAGCCTGGACTTAAA 
                              *******   * * * *   *  *   ** *********** ** ** ** *** 
 
Canine_Normal_5-18      GGGTTTGCAGGAAAGCCGGGTGAAAAAGGAAACAGAGGCATTCCAGGGTTACCAGGTTTG 
Human_COL4A3            GGATTCGCAGGAAATCCAGGTGAGAAAGGAAACAGAGGCGTTCCAGGGATGCCAGGTTTA 
Mouse_COL4A3            GGATTTGTTGGGAATCCAGGTGAGAAAGGAAACAGAGGCAACCCAGGGTTACCAGGTCCG 
                        ** ** *  ** ** ** ***** ***************   ****** * ******    
 
Canine_Normal_5-18      AAAGGATTCGAAGGGCCACCTGGACCACCAGGCCCACCAGGCCCCCGAGGAGATCCAGGC 
Human_COL4A3            AAGGGCCTCAAAGGACTACCCGGACCAGCAGGACCACCAGGCCCCAGAGGAGATTTGGGC 
Mouse_COL4A3            AAAGGCCTCGAGGGATTGCCTGGGCTACCAGGTCCTCCAGGCCCTAGAGGAGATACGGGA 




Canine_Normal_5-18      AGCATTGGGAATCCTGGAGAAGCAGGACCACGTGGAAGTCCAGGAAACATGGGGAACATG 
Human_COL4A3            AGCACTGGGAATCCTGGAGAACCAGGACTCCGTGGTATACCAGGAAGCATGGGGAACATG 
Mouse_COL4A3            AGCAGAGGAAATCCTGGAAGACCAGGACCACACGGCATGCCAGGAAGCATGGGGATCATG 
                        ****  ** *********  * ******  *  ** *  ******* ******** **** 
 
Canine_Normal_5-18      GGGATGCCAGGTCTTAAAGGACACAGGGGACCTTTGGGACTACCAGGTGTCACTGGAAGA 
Human_COL4A3            GGCATGCCAGGTTCTAAAGGAAAAAGGGGAACTTTGGGATTCCCAGGTCGAGCAGGAAGA 
Mouse_COL4A3            GGGGTGCCAGGCCCTAAAGGGAGAAAAGGAACTTCAGGGCTTCCAGGTCTAGCTGGAAGA 
                        **  *******   ******    *  *** ***  **  * ******    * ****** 
 
Canine_Normal_5-18      CCAGGCCTCCCAGGTGTTCACGGTCTCCAAGGAGACAAGGGAGAGCCAGGTTATTCAGCA 
Human_COL4A3            CCAGGCCTCCCAGGTATTCATGGTCTCCAGGGAGATAAGGGAGAGCCAGGTTATTCAGAA 
Mouse_COL4A3            CCAGGCCGGACAGGGATCCATGGTCCCCAAGGAGATAAGGGGGAGCCGGGTTATTCAGAA 
                        *******   ****  * ** **** *** ***** ***** ***** ********** * 
 
Canine_Normal_5-18      GGTACAAGGCCAGGACCACCGGGACTAAAGGGAGATCCAGGATTACCAGGTGCCATGGGA 
Human_COL4A3            GGTACAAGGCCAGGACCACCGGGACCAACGGGGGATCCAGGACTGCCGGGTGATATGGGA 
Mouse_COL4A3            GGTGCAAGACCAGGACCACCAGGACCAAAGGGCGATCCAGGATTGCCAGGTGACAAAGGA 
                        *** **** *********** **** ** *** ********* * ** ****  *  *** 
 
Canine_Normal_5-18      AGGAAAGGAGAAAGAGGGCTACCTGGCACCCCTGGCCATTCGGGGCCTGCTGGAACTGAG 
Human_COL4A3            AAGAAAGGAGAAATGGGGCAACCTGGCCCACCTGGACATTTGGGGCCTGCTGGACCTGAG 
Mouse_COL4A3            AAGAAAGGAGAAAGAGGCGTACCTGGGCCACCTGGACAATCGGGGCCTGCCGGACCTGAT 
                        * ***********  **   ******  * ***** ** * ********* *** ****  
 
Canine_Normal_5-18      GGAGCCCCTGGACATCCCGGAAGTCCTGGCCACCCAGGAAAGCCAGGCCCTGATGGAGAT 
Human_COL4A3            GGAGCCCCTGGAAGTCCTGGAAGTCCTGGCCTCCCAGGAAAGCCAGGTCCTCATGGTGAT 
Mouse_COL4A3            GGAGCCCCTGGGAGTCCTGGGAGTCCTGGTCACCCAGGAAAACCAGGTCCTGCTGGTGAT 
                        ***********   *** ** ******** * ********* ***** ***  *** *** 
 
Canine_Normal_5-18      TTGGGGTTAAAAGGCATCAAAGGCTTCCCTGGGTCCCCAGGAGTCAAAGGACCTCCAGGA 
Human_COL4A3            TTGGGTTTTAAAGGAATCAAAGGCCTCCTGGGCCCTCCAGGAATCAGAGGCCCTCCAGGT 
Mouse_COL4A3            TTGGGTCTGAAAGGACAGAAAGGCTTCCCAGGCCCTCCAGGAAGCACTGGCCCTCCAGGC 
                        *****  * *****    ****** ***  **  * ******  **  ** ********  
 
Canine_Normal_5-18      CCTCCAGGAATCCTAGGATCTCCTGGACCTATGGGCATGAGAGGCAACCAGGGCCGTGAT 
Human_COL4A3            CTTCCAGGATTTCCAGGATCTCCTGGACCAATGGGTATAAGAGGTGACCAAGGACGTGAT 
Mouse_COL4A3            CCTCCAGGACTCCCAGGACTTCCTGGGCCAATGGGTATGAGAGGTGACCAAGGACGTGAT 
                        * ******* * * ****  ****** ** ***** ** *****  **** ** ****** 
 
Canine_Normal_5-18      GGAATCCCTGGTCCCCCAGGAGAAAAGGGAGAAACAGGTTTGCTGGGGGCACATCCAGGC 
Human_COL4A3            GGAATTCCTGGTCCAGCCGGAGAAAAGGGAGAAACGGGTTTATTGAGGGCCCCTCCAGGC 
Mouse_COL4A3            GGAATTCCTGGTCCTCCAGGAGAAAAAGGAGAAACAGGCTTGCTGGGGGCCTACCCAGGC 
                        ***** ********  * ******** ******** ** **  ** ****    ****** 
 
Canine_Normal_5-18      CCAGGAGGGAGCCCTGGTCCTCCAGGAGCCAAAGGAGACAGGGGCGCCCCAGGCCTACCA 
Human_COL4A3            CCAAGAGGGAACCCTGGTGCTCAAGGAGCCAAAGGAGACAGGGGAGCCCCAGGTTTTCCT 
Mouse_COL4A3            CCAAAAGGGAGCCCTGGTGTACCAGGTGCCAAAGGAGACAGGGGAGTTCCAGGCTTGTCT 
                        ***  ***** *******   * *** ***************** *  *****  *  *  
 
Canine_Normal_5-18      GGCCCCCCAGGCAGGAAAGGGGCAGTGGGAGATGCCGGGCCACGGGGACCCACTGGCATG 
Human_COL4A3            GGCCTCCCGGGCAGAAAAGGGGCCATGGGAGATGCTGGACCTCGAGGACCCACAGGCATA 
Mouse_COL4A3            GGCCTTCCCGGCAGGAAGGGGGTTATGGGGGATGTTGGACCCCAAGGACCCCCAGGCACT 
                        ****  ** ***** ** ****   **** ****  ** ** *  ****** * ****   
 
Canine_Normal_5-18      ACGGGACTCCCAGGGCCACCAGGTTTTCCTGGTGCAGTCATCCCTGGCCAGAAAGGAAAT 
Human_COL4A3            GAAGGATTCCCAGGGCCACCAGGTCTGCCCGGTGCAATTATCCCTGGCCAGACAGGAAAT 
Mouse_COL4A3            GCTGGACTCCCAGGGCCACCAGGTCTACCTGGGGCAATTATCCCTGGCCCCAAAGGAGAC 
                           *** ***************** * ** ** *** * **********  * **** *  
 
Canine_Normal_5-18      CAAGGTCCACCAGGCTTCAGAGGAAACCCAGGTGAGCCTGGTCCTCCAGGCCCTCCAGGG 
Human_COL4A3            CGTGGTCCACCAGGCTCAAGAGGAAGCCCAGGTGCGCCTGGTCCCCCTGGACCTCCAGGG 
Mouse_COL4A3            AGAGGTCTTCCTGGCTTAAGAGGAAATCCAGGTGAGCCAGGTCCCCCTGGACCTCCAGGA 
                           ****  ** ****  *******  ******* *** ***** ** ** ********  
 
 120
Canine_Normal_5-18      AGCCACGTGAAAGGCATAAAAGGAGACAAGGGACTCATGGGTGAGCCTGGCCCCAGAGGT 
Human_COL4A3            AGTCATGTAATAGGCATAAAAGGAGACAAAGGGTCTATGGGCCACCCTGGCCCAAAAGGT 
Mouse_COL4A3            CCTATCGGAAAAGGCATAAAAGGTGACAAAGGATTTATGGGCCCACCTGGCCCCAAAGGC 
                              *  * ************ ***** **    *****    ******** * ***  
 
Canine_Normal_5-18      CTACCTGGAACTGTGGGAGACAAGGGGCCACCGGGTCAACCGGGAGCACCAGGGAGCCCA 
Human_COL4A3            CCACCTGGAACTGCAGGAGACATGGGACCACCAGGTCGTCTGGGAGCACCAGGTACTCCA 
Mouse_COL4A3            CTGCCTGGAACTGTAGGGGACATGGGCCCACCAGGTTTCCCGGGAGCACCAGGTACCCCC 
                        *  **********  ** **** *** ***** ***   * ************ *  **  
 
Canine_Normal_5-18      GGTCTGCCAGGGCTCAGGGGCGATCCTGGATTCTATGGATTTCCAGGTGTTAAAGGAGAG 
Human_COL4A3            GGTCTTCCAGGACCCAGAGGTGATCCTGGATTCCAGGGGTTTCCAGGCGTGAAAGGAGAA 
Mouse_COL4A3            GGTCTTCCCGGTGTCAGAGGTGATCCAGGATTCCCTGGATTTCCAGGCATAAAAGGAGAA 
                        ***** ** **   *** ** ***** ******   ** ********  * ********  
 
Canine_Normal_5-18      AAGGGTAACCCAGGATTTCCGGGACCAGCTGGACCTCCAGGGCAAATTGGGCCAAAAGGA 
Human_COL4A3            AAGGGTAATCCTGGATTTCTAGGATCCATTGGACCTCCAGGACCAATTGGGCCAAAAGGA 
Mouse_COL4A3            AAGGGTAACCCTGGATTTCTTGGGCCAATTGGACATCCAGGACCAGTTGGGCCCAAAGGA 
                        ******** ** *******  **  *   ***** ****** * * ******* ****** 
 
Canine_Normal_5-18      CCACCTGGTGTCCGTGGAGACCCTGGCACAGTTAAGATCATCTCCCTTCCAGGAAGCCCA 
Human_COL4A3            CCACCTGGTGTACGTGGAGACCCTGGCACACTTAAGATTATCTCCCTTCCAGGAAGCCCA 
Mouse_COL4A3            CCACCAGGTCCACGTGGAAAACCTGGCACTCTTAAGGTCATCTCTCTTCCGGGAAGCCCA 
                        ***** ***   ****** * ********  ***** * ***** ***** ********* 
 
Canine_Normal_5-18      GGGCCACCTGGCCGTGCTGGAGGACCGGGGATGCCAGGAGAACCAGGGCCACCAGGGCCA 
Human_COL4A3            GGGCCACCTGGCACACCTGGAGAACCAGGGATGCAGGGAGAACCTGGGCCACCAGGGCCA 
Mouse_COL4A3            GGGCCACCTGGTGTACCTGGACAGCCAGGAATGAAAGGAGACCCTGGACCCCTGGGACTG 
                        ***********     *****   ** ** ***   ***** ** ** ** *  ** *   
 
Canine_Normal_5-18      CCAGGAATCCTAGGACCCTGTGGACCAAGAGGTAAACCAGGCATGGATGGAATACCAGGA 
Human_COL4A3            CCTGGAAACCTAGGACCCTGTGGGCCAAGAGGTAAGCCAGGCAAGGATGGAAAACCAGGA 
Mouse_COL4A3            CCAGGAATCCCAGGACCCTGTGGGCCAAGAGGTAAACCAGGCAAGGATGGGAAACCAGGA 
                        ** **** ** ************ *********** ******* ****** * ******* 
 
Canine_Normal_5-18      ACTCCTGGGCCAATTGGAGAAAAAGGCAACAAAGGTTGTAAAGGCGAGCAAGGACCACCT 
Human_COL4A3            ACTCCTGGACCAGCTGGAGAAAAAGGCAACAAAGGTTCTAAAGGAGAGCCAGGACCAGCT 
Mouse_COL4A3            ACTCCAGGACCAGCTGGTACAAAGGGCAACAAGGGCTTGAAAGGACAGCAAGGCCCACCT 
                        ***** ** ***  ***   *** ******** ** *  *****  *** *** *** ** 
 
Canine_Normal_5-18      GGATTAGATGGACTGCCAGGCTTGAAGGGGAGACCTGGAGACCCTGGACCACCTGCAACT 
Human_COL4A3            GGATCAGATGGATTGCCAGGTTTGAAAGGAAAACGTGGAGACAGTGGATCACCTGCAACC 
Mouse_COL4A3            GGTCTGGATGGATTGCCAGGCTTAAAGGGAAATCCTGGTGACAGGGGAACGCCGGCCACT 
                        **    ****** ******* ** ** ** *  * *** ***   *** * ** ** **  
 
Canine_Normal_5-18      GGGACCATGAAGAGGGGCTTTATCTTCACCAGGCATAGTCAGACCACAGTGATTCCTTCC 
Human_COL4A3            TGGACAAC---GAGAGGCTTTGTCTTCACCCGACACAGTCAAACCACAGCAATTCCTTCA 
Mouse_COL4A3            GGTACAAGAATGCGAGGCTTCATCTTCACCCGACACAGTCAAACCACGGCCATTCCTTCA 
                         * ** *    * * *****  ******** * ** ***** ***** *  ********  
 
Canine_Normal_5-18      TGTCCAGAAGGGACAGCGCCACTCTATAGTGGCTTTTCTCTTCTTTTCATACAAGGAAAT 
Human_COL4A3            TGTCCAGAGGGGACAGTGCCACTCTACAGTGGGTTTTCTTTTCTTTTTGTACAAGGAAAT 
Mouse_COL4A3            TGCCCTGAAGGAACACAGCCACTCTATAGTGGGTTTTCTCTTCTTTTTGTACAAGGAAAC 
                        ** ** ** ** ***  ********* ***** ****** *******  **********  
 
Canine_Normal_5-18      GAACAAGCCCATGGACAAGACTTGGGAACTCTCGGCAGCTGCCTGCAGCGATTTACCACA 
Human_COL4A3            CAACGAGCCCACGGACAAGACCTTGGAACTCTTGGCAGCTGCCTGCAGCGATTTACCACA 
Mouse_COL4A3            AAACGTGCACATGGACAAGACCTAGGTACTCTGGGCAGCTGCCTGCAGCGATTCACCACA 
                         ***  ** ** ********* * ** ***** ******************** ****** 
 
Canine_Normal_5-18      ATGCCATTCTTGTTCTGTAACATCAACAATGTCTGTAATTTTGCATCTCGAAATGACTAC 
Human_COL4A3            ATGCCATTCTTATTCTGCAATGTCAATGATGTATGTAATTTTGCATCTCGAAATGATTAT 
Mouse_COL4A3            ATGCCGTTCTTATTCTGTAACATCAATAATGTATGTAACTTTGCATCACGAAATGATTAT 




Canine_Normal_5-18      TCATACTGGCTGTCAACACCAGCTCTGATGCCAATGGACATGGCTCCAATTACTGGCAGG 
Human_COL4A3            TCATACTGGCTGTCAACACCAGCTCTGATGCCAATGAACATGGCTCCCATTACTGGCAGA 
Mouse_COL4A3            TCATACTGGCTGTCAACACCAGCTCTGATGCCAATGGACATGGCTCCAATTAGTGGCAGA 
                        ************************************ ********** **** ******  
 
Canine_Normal_5-18      GCCCTGGAGCCTTATATTAGCAGATGCACTGTCTGTGAAGGTCCTACGATTGCCATAGCC 
Human_COL4A3            GCCCTTGAGCCTTATATAAGCAGATGCACTGTTTGTGAAGGTCCTGCGATCGCCATAGCC 
Mouse_COL4A3            GCTCTCGAACCCTATATTAGCAGATGCACCGTCTGTGAAGGTCCAGCAATGGCCATAGCT 
                        ** ** ** ** ***** *********** ** ***********  * ** ********  
 
Canine_Normal_5-18      ATTCACAGCCAAACCACTGACATTCCCTCATGTCCCAATGGCTGGATTTCTCTCTGGAAA 
Human_COL4A3            GTTCACAGCCAAACCACTGACATTCCTCCATGTCCTCACGGCTGGATTTCTCTCTGGAAA 
Mouse_COL4A3            GTTCACAGTCAAACTACTGCTATCCCTCCGTGTCCCCAGGACTGGGTTTCTCTCTGGAAA 
                         ******* ***** ****  ** **  * *****  * * **** ************** 
 
Canine_Normal_5-18      GGATTTTCGTTTATCATGTTCACAAGTGCAGGTTCTGAGGGTGCTGGGCAAGCACTGGCC 
Human_COL4A3            GGATTTTCATTCATCATGTTCACAAGTGCAGGTTCTGAGGGCACCGGGCAAGCACTGGCC 
Mouse_COL4A3            GGTTTTTCTTTCATTATGTTCACAAGTGCAGGCTCTGAGGGTGCTGGACAAGCACTTGCC 
                        ** ***** ** ** ***************** ********  * ** ******** *** 
 
Canine_Normal_5-18      TCCCCCGGCTCCTGCCTGGAAGAGTTCCGAGCCAGTCCGTTTATAGAATGTCACGGAAGA 
Human_COL4A3            TCCCCTGGCTCCTGCCTGGAAGAATTCCGAGCCAGCCCATTTCTAGAATGTCATGGAAGA 
Mouse_COL4A3            TCGCCTGGCTCCTGCCTGGAAGAATTCCGAGCCAGTCCATTTATAGAATGCCATGGACGA 
                        ** ** ***************** *********** ** *** ******* ** *** ** 
 
Canine_Normal_5-18      GGAACGTGCAACTACTATTCAAATTCCTACAGTTTCTGGTTGGCTTCGTTAAACCCCCAA 
Human_COL4A3            GGAACGTGCAACTACTATTCAAATTCCTACAGTTTCTGGCTGGCTTCATTAAACCCAGAA 
Mouse_COL4A3            GGGACATGTAACTACTACTCAAACTCCTACAGTTTCTGGCTGGCTTCGCTGAACCCAGAA 
                        ** ** ** ******** ***** *************** *******  * *****  ** 
 
Canine_Normal_5-18      AGAATGTTCAGAAAACCTATTCCATCAACTGTGAAAGCTG---AATCCATATGACTAGT- 
Human_COL4A3            AGAATGTTCAGAAAGCCTATTCCATCAACTGTGAAAGCTGGGGAATTAGAAAAAATAATA 
Mouse_COL4A3            AGAATGTTCAGAAAACCTATTCCATCAACTGTGAAAGCTGGAGACTTAGAGAAAATCATA 
                        ************** *************************   * *       * *  *  
 
Canine_Normal_5-18      ------------------------------------ 
Human_COL4A3            AGTCGCTGTCAGGTGTGCATGAAGAAAAGACACTGA 












Canine COL4A3 amino acid sequence alignments 
 
 
Consensus key (see documentation for details) 
* - single, fully conserved residue 
: - conservation of strong groups 
. - conservation of weak groups 
  - no consensus 
 
 
CLUSTAL W (1.81) multiple sequence alignment 
 
 
Canine_A3_Normal_5-18_Transl      -------------------------------------------------- 
Human_COL4A3_Translated_-_Fr      MSARTAPRPQVLLLPLLLVLLAAAPAASKGCVCKDKGQCFCDGAKGEKGE 
Mouse_COL4A3_Translated_-_Fr      MHSKTAPRFLVFLLLTLLLLLAASPVASKGCVCKGKGQCLCAGTKGEKGE 
 
 
Canine_A3_Normal_5-18_Transl      -------------------------------------------------- 
Human_COL4A3_Translated_-_Fr      KGFPGPPGSPGQKGFTGPEGLPGPQGPKGFPGLPGLTGSKGVRGISGLPG 
Mouse_COL4A3_Translated_-_Fr      KGVPGSPGFPGQKGFPGPEGLPGPQGPKGSPGLPGLTGPKGIRGITGLPG 
 
 
Canine_A3_Normal_5-18_Transl      ----------NFKKEIYHGDGVPGCNGSKGEQGFPGLPGTPGYPGIPGAV 
Human_COL4A3_Translated_-_Fr      FSGSPGLPGTPGNTGPYGLVGVPGCSGSKGEQGFPGLPGTPGYPGIPGAA 
Mouse_COL4A3_Translated_-_Fr      FAGPPGLPGLPGHPGPRGLAGLPGCNGSKGEQGFPGFPGTPGYAGLPGPD 
                                              :       *:***.**********:******.*:**.  
 
Canine_A3_Normal_5-18_Transl      GLKGEKGAPATGEGIELDGRGDPGLPGAPGFQGLPGLPGFPGPAGPPGPP 
Human_COL4A3_Translated_-_Fr      GLKGQKGAPAKGEDIELDAKGDPGLPGAPGPQGLPGPPGFPGPVGPPGPP 
Mouse_COL4A3_Translated_-_Fr      GLKGQKGEPAQGEDRGFNGKGDPGPPGVPGFQGFPGLPGFPGPAGPPGPP 
                                  ****:** **  *.  ::.:**** **.** **:** ******.****** 
 
Canine_A3_Normal_5-18_Transl      GFLGFPGAMGPPGPKGQMGDKVIGQKGERGVKGLTGPPGPPGTVIVTLTG 
Human_COL4A3_Translated_-_Fr      GFFGFPGAMGPRGPKGHMGERVIGHKGERGVKGLTGPPGPPGTVIVTLTG 
Mouse_COL4A3_Translated_-_Fr      GFFGLPGAMGPRGPKGHMGDSVIGQKGERGMKGLTGPPGPPGTVIFTLTQ 
                                  **:*:****** ****:**: ***:*****:**************.***  
 
Canine_A3_Normal_5-18_Transl      PDNRTDLKGEKGDKGAMGKPGPPGPLGPPGESYGSEKGAPGEPGPQGKPG 
Human_COL4A3_Translated_-_Fr      PDNRTDLKGEKGDKGAMGEPGPPGPSGLPGESYGSEKGAPGDPGLQGKPG 
Mouse_COL4A3_Translated_-_Fr      PYNKSDFKGEKGDEGERGEPGPPGPSGPPGDSYGSEKGAPGEPGPRGKPG 
                                  * *::*:******:*  *:****** * **:**********:** :**** 
 
Canine_A3_Normal_5-18_Transl      KDGAPGFPGTEGPKGNRGFPGLRGEDGIKGWKGDIGPPGFRGPTEYYDAY 
Human_COL4A3_Translated_-_Fr      KDGVPGFPGSEGVKGNRGFPGLMGEDGIKGQKGDIGPPGFRGPTEYYDTY 
Mouse_COL4A3_Translated_-_Fr      KDGAPGFPGTEGAKGNRGFPGLRGEAGIKGRKGDIGPPGFPGPTEYYDAY 
                                  ***.*****:** ********* ** **** ********* *******:* 
 
Canine_A3_Normal_5-18_Transl      QEKGDEGIPGPPGPKGARGPQGPSGPPGVLGSAGSSKPGLRGAPGSPGMK 
Human_COL4A3_Translated_-_Fr      QEKGDEGTPGPPGPRGARGPQGPSGPPGVPGSPGSSRPGLRGAPGWPGLK 
Mouse_COL4A3_Translated_-_Fr      LEKGERGMPGLPGPKGARGPQGPSGPPGVPGSPGLSRPGLRGPIGWPGLK 
                                   ***:.* ** ***:************** **.* *:*****. * **:* 
 
Canine_A3_Normal_5-18_Transl      GRKGEQGPPGKNAVGPPGSPGCPGSPGPIGLPGYPGPPGDIVFRKGPPGV 
Human_COL4A3_Translated_-_Fr      GSKGERGRPGKDMGTPGSPGCAGSPGLPGSPGPPGPPGDIVFRKGPPGD 
Mouse_COL4A3_Translated_-_Fr      GSKGERGPPGKDTVGPPGPLGCPGSPGPPGPPGPPGCPGDIVFKCSP-GE 
                                  * ***:* ***:::*.**. **.****  * ** ** ******: .* *  
 
Canine_A3_Normal_5-18_Transl      GGLPGHVGFPGIPGVEGPKGEPGLLCVQCAYIPGRPGLPGLPGLDGIKGI 
Human_COL4A3_Translated_-_Fr      HGLPGYLGSPGIPGVDGPKGEPGLLCTQCPYIPGPPGLPGLPGLHGVKGI 
Mouse_COL4A3_Translated_-_Fr      HGMPGDTGPPGVPGLDGPKGEPGSPCTECHCFPGPPGVPGFPGLDGIKGI 




Canine_A3_Normal_5-18_Transl      PGGQGAAGIKGSPGSPGSAGLPGFPGFPGAPGAPGLKGEKGETSEPEGQV 
Human_COL4A3_Translated_-_Fr      PGRQGAAGLKGSPGSPGNTGLPGFPGFPGAQGDPGLKGEKGETLQPEGQV 
Mouse_COL4A3_Translated_-_Fr      PGGRGVPGLKGNPGSPGSAGLPGFAGFPGDQGHPGLKGDKGDTPLPWGQV 
                                  ** :*..*:**.*****.:*****.****  * *****:**:*  * *** 
 
Canine_A3_Normal_5-18_Transl      GAPGDPGLRGHPGRKGLDGIPGTPGIKGPPGPKGEPALSGEKGDQGPPGD 
Human_COL4A3_Translated_-_Fr      GVPGDPGLRGQPGRKGLDGIPGTLGVKGLPGPKGELALSGEKGDQGPPGD 
Mouse_COL4A3_Translated_-_Fr      GNPGDPGLRGLPGRKGFDGTPGGPGAKGPPGPQGEPALSGRKGDQGPPGP 
                                  * ******** *****:** **  * ** ***:** ****.********  
 
Canine_A3_Normal_5-18_Transl      PGIPGSPGPAGPPGPPNYGPQGEPGPKGTQGVPGAPGPPGEAGPKGEFGI 
Human_COL4A3_Translated_-_Fr      PGSPGSPGPAGPAGPPGYGPQGEPGLQGTQGVPGAPGPPGEAGPRGELSV 
Mouse_COL4A3_Translated_-_Fr      PGFPGPPGPAGPAGPPGYGPQGEPGPKGAQGVPGVLGPPGEAGLKGEPST 
                                  ** **.******.***.******** :*:*****. ******* :** .  
 
Canine_A3_Normal_5-18_Transl      STPVPGPPGPPGPPGYAGPRGPPGIPGSIGKCGDPGLPGPDGEPGIPGIG 
Human_COL4A3_Translated_-_Fr      STPVPGPPGPPGPPGHPGPQGPPGIPGSLGKCGDPGLPGPDGEPGIPGIG 
Mouse_COL4A3_Translated_-_Fr      STPDLGPPGPPGPPGQAGPRGLPGLPGPVGKC-DPGLPGPDGEPGIPEAG 
                                  ***  ********** .**:* **:**.:*** **************  * 
 
Canine_A3_Normal_5-18_Transl      FPGPPGPKGDQGFPGAKGAPGCPGEMGKPGSPGEPGLPGAKGEPGLAIPG 
Human_COL4A3_Translated_-_Fr      FPGPPGPKGDQGFPGTKGSLGCPGKMGEPGLPGKPGLPGAKGEPAVAMPG 
Mouse_COL4A3_Translated_-_Fr      CPGPPGPKGNQGFPGTKGSPGCPGEMGKPGRPGEPGIPGAKGEPSVGRPG 
                                   ********:*****:**: ****:**:** **:**:*******.:. ** 
 
Canine_A3_Normal_5-18_Transl      EPGIPGFPGERGNSGENGEIGLPGLPGLPGIPGTGGLDGPPGDPGKPGPP 
Human_COL4A3_Translated_-_Fr      GPGTPGFPGERGNSGEHGEIGLPGLPGLPGTPGNEGLDGPRGDPGQPGPP 
Mouse_COL4A3_Translated_-_Fr      KPGKPGFPGERGNAGENGDIGLPGLPGLPGTPGRGGLDGPPGDPGQPGSP 
                                   ** *********:**:*:*********** **  ***** ****:**.* 
 
Canine_A3_Normal_5-18_Transl      GEKGPPGSCTEGPRGAHGLPGLNGLEGQPGRRGETGPKGDPGIPGLDRSG 
Human_COL4A3_Translated_-_Fr      GEQGPPGRCIEGPRGAQGLPGLNGLKGQQGRRGKTGPKGDPGIPGLDRSG 
Mouse_COL4A3_Translated_-_Fr      GAKGSPGRCIPGPRGTQGLPGLNGLKGQPGRRGDTGPKGDPGIPGMDRSG 
                                  * :*.** *  ****::********:** ****.***********:**** 
 
Canine_A3_Normal_5-18_Transl      FPGEPGPPGMPGHRGEIGPPGQKGYPGNPGFLGLPGEDGVIGMMGYPGNT 
Human_COL4A3_Translated_-_Fr      FPGETGSPGIPGHQGEMGPLGQRGYPGNPGILGPPGEDGVIGMMGFPGAI 
Mouse_COL4A3_Translated_-_Fr      VPGDPGPPGTPGCPGEMGPPGQKGYPGAPGFPGPPGEKGEVGMMGYPGTT 
                                  .**:.*.** **  **:** **:**** **: * ***.* :****:**   
 
Canine_A3_Normal_5-18_Transl      GPPGPPGIPGTPGQRGSFGIPGAKGEKGPPGAKGEEGEKGPMGPCQITSS 
Human_COL4A3_Translated_-_Fr      GPPGPPGNPGTPGQRGSPGIPGVKGQRGTPGAKGEQGDKGNPGPSEISHV 
Mouse_COL4A3_Translated_-_Fr      GPPGLPGKPGSQGQRGSLGIPGMKGEKGRPGAKGERGEKGKPGPSQTTLL 
                                  **** ** **: ***** **** **::* ******.*:**  **.: :   
 
Canine_A3_Normal_5-18_Transl      VGDKGEPGLKGFAGKPGEKGNRGIPGLPGLKGFEGPPGPPGPPGPRGDPG 
Human_COL4A3_Translated_-_Fr      IGDKGEPGLKGFAGNPGEKGNRGVPGMPGLKGLKGLPGPAGPPGPRGDLG 
Mouse_COL4A3_Translated_-_Fr      KGDKGEPGLKGFVGNPGEKGNRGNPGLPGPKGLEGLPGLPGPPGPRGDTG 
                                   ***********.*:******** **:** **::* ** .******** * 
 
Canine_A3_Normal_5-18_Transl      SIGNPGEAGPRGSPGNMGNMGMPGLKGHRGPLGLPGVTGRPGLPGVHGLQ 
Human_COL4A3_Translated_-_Fr      STGNPGEPGLRGIPGSMGNMGMPGSKGKRGTLGFPGRAGRPGLPGIHGLQ 
Mouse_COL4A3_Translated_-_Fr      SRGNPGRPGPHGMPGSMGIMGVPGPKGRKGTSGLPGLAGRPGRTGIHGPQ 
                                  * ****..* :* **.** **:** **::*. *:** :**** .*:** * 
 
Canine_A3_Normal_5-18_Transl      GDKGEPGYSAGTRPGPPGLKGDPGLPGAMGRKGERGLPGTPGHSGPAGTE 
Human_COL4A3_Translated_-_Fr      GDKGEPGYSEGTRPGPPGPTGDPGLPGDMGKKGEMGQPGPPGHLGPAGPE 
Mouse_COL4A3_Translated_-_Fr      GDKGEPGYSEGARPGPPGPKGDPGLPGDKGKKGERGVPGPPGQSGPAGPD 
                                  ********* *:****** .*******  *:*** * **.**: ****.: 
 
Canine_A3_Normal_5-18_Transl      GAPGHPGSPGHPGKPGPDGDLGLKGIKGFPGSPGVKGPPGPPGILGSPGP 
Human_COL4A3_Translated_-_Fr      GAPGSPGSPGLPGKPGPHGDLGFKGIKGLLGPPGIRGPPGLPGFPGSPGP 
Mouse_COL4A3_Translated_-_Fr      GAPGSPGSPGHPGKPGPAGDLGLKGQKGFPGPPGSTGPPGPPGLPGLPGP 
                                  **** ***** ****** ****:** **: *.**  **** **: * *** 
 
 125
Canine_A3_Normal_5-18_Transl      MGMRGNQGRDGIPGPPGEKGETGLLGAHPGPGGSPGPPGAKGDRGAPGLP 
Human_COL4A3_Translated_-_Fr      MGIRGDQGRDGIPGPAGEKGETGLLRAPPGPRGNPGAQGAKGDRGAPGFP 
Mouse_COL4A3_Translated_-_Fr      MGMRGDQGRDGIPGPPGEKGETGLLGAYPGPKGSPGVPGAKGDRGVPGLS 
                                  **:**:*********.********* * *** *.**  *******.**:. 
 
Canine_A3_Normal_5-18_Transl      GPPGRKGAVGDAGPRGPTGMTGLPGPPGFPGAVIPGQKGNQGPPGFRGNP 
Human_COL4A3_Translated_-_Fr      GLPGRKGAMGDAGPRGPTGIEGFPGPPGLPGAIIPGQTGNRGPPGSRGSP 
Mouse_COL4A3_Translated_-_Fr      GLPGRKGVMGDVGPQGPPGTAGLPGPPGLPGAIIPGPKGDRGLPGLRGNP 
                                  * *****.:**.**:**.*  *:*****:***:*** .*::* ** **.* 
 
Canine_A3_Normal_5-18_Transl      GEPGPPGPPGSHVKGIKGDKGLMGEPGPRGLPGTVGDKGPPGQPGAPGSP 
Human_COL4A3_Translated_-_Fr      GAPGPPGPPGSHVIGIKGDKGSMGHPGPKGPPGTAGDMGPPGRLGAPGTP 
Mouse_COL4A3_Translated_-_Fr      GEPGPPGPPGPIGKGIKGDKGFMGPPGPKGLPGTVGDMGPPGFPGAPGTP 
                                  * ********.   ******* ** ***:* ***.** ****  ****:* 
 
Canine_A3_Normal_5-18_Transl      GLPGLRGDPGFYGFPGVKGEKGNPGFPGPAGPPGQIGPKGPPGVRGDPGT 
Human_COL4A3_Translated_-_Fr      GLPGPRGDPGFQGFPGVKGEKGNPGFLGSIGPPGPIGPKGPPGVRGDPGT 
Mouse_COL4A3_Translated_-_Fr      GLPGVRGDPGFPGFPGIKGEKGNPGFLGPIGHPGPVGPKGPPGPRGKPGT 
                                  **** ****** ****:********* *. * ** :******* **.*** 
 
Canine_A3_Normal_5-18_Transl      VKIISLPGSPGPPGRAGGPGMPGEPGPPGPPGILGPCGPRGKPGMDGIPG 
Human_COL4A3_Translated_-_Fr      LKIISLPGSPGPPGTPGEPGMQGEPGPPGPPGNLGPCGPRGKPGKDGKPG 
Mouse_COL4A3_Translated_-_Fr      LKVISLPGSPGPPGVPGQPGMKGDPGPLGLPGIPGPCGPRGKPGKDGKPG 
                                  :*:*********** .* *** *:*** * **  ********** ** ** 
 
Canine_A3_Normal_5-18_Transl      TPGPIGEKGNKGCKGEQGPPGLDGLPGLKGRPGDPGPPATGTMKRGFIFT 
Human_COL4A3_Translated_-_Fr      TPGPAGEKGNKGSKGEPGPAGSDGLPGLKGKRGDSGSPATWTTR-GFVFT 
Mouse_COL4A3_Translated_-_Fr      TPGPAGTKGNKGLKGQQGPPGLDGLPGLKGNPGDRGTPATGTRMRGFIFT 
                                  **** * ***** **: **.* ********. ** *.*** *   **:** 
 
Canine_A3_Normal_5-18_Transl      RHSQTTVIPSCPEGTAPLYSGFSLLFIQGNEQAHGQDLGTLGSCLQRFTT 
Human_COL4A3_Translated_-_Fr      RHSQTTAIPSCPEGTVPLYSGFSFLFVQGNQRAHGQDLGTLGSCLQRFTT 
Mouse_COL4A3_Translated_-_Fr      RHSQTTAIPSCPEGTQPLYSGFSLLFVQGNKRAHGQDLGTLGSCLQRFTT 
                                  ******.******** *******:**:***::****************** 
 
Canine_A3_Normal_5-18_Transl      MPFLFCNINNVCNFASRNDYSYWLSTPALMPMDMAPITGRALEPYISRCT 
Human_COL4A3_Translated_-_Fr      MPFLFCNVNDVCNFASRNDYSYWLSTPALMPMNMAPITGRALEPYISRCT 
Mouse_COL4A3_Translated_-_Fr      MPFLFCNINNVCNFASRNDYSYWLSTPALMPMDMAPISGRALEPYISRCT 
                                  *******:*:**********************:****:************ 
 
Canine_A3_Normal_5-18_Transl      VCEGPTIAIAIHSQTTDIPSCPNGWISLWKGFSFIMFTSAGSEGAGQALA 
Human_COL4A3_Translated_-_Fr      VCEGPAIAIAVHSQTTDIPPCPHGWISLWKGFSFIMFTSAGSEGTGQALA 
Mouse_COL4A3_Translated_-_Fr      VCEGPAMAIAVHSQTTAIPPCPQDWVSLWKGFSFIMFTSAGSEGAGQALA 
                                  *****::***:***** **.**:.*:******************:***** 
 
Canine_A3_Normal_5-18_Transl      SPGSCLEEFRASPFIECHGRGTCNYYSNSYSFWLASLNPQRMFRKPIPST 
Human_COL4A3_Translated_-_Fr      SPGSCLEEFRASPFLECHGRGTCNYYSNSYSFWLASLNPERMFRKPIPST 
Mouse_COL4A3_Translated_-_Fr      SPGSCLEEFRASPFIECHGRGTCNYYSNSYSFWLASLNPERMFRKPIPST 
                                  **************:************************:********** 
 
Canine_A3_Normal_5-18_Transl      VKA---ESIL----------- 
Human_COL4A3_Translated_-_Fr      VKAGELEKIISRCQVCMKKRH 
Mouse_COL4A3_Translated_-_Fr      VKAGDLEKIISRCQVCMKKRH 












Canine COL4A4 nucleotide sequence 
 
Sequence Range: 1 to 5163 
 
                     10          20          30          40          50 
            CTAGA GGATC TACTA GTCAT ATGGA TGTGA GAGTC TTCTG GAAGA GAAGA 
            GATCT CCTAG ATGAT CAGTA TACCT ACACT CTCAG AAGAC CTTCT CTTCT 
 
                     60          70          80          90         100 
            GAAAC CTGAC AATCT TTTTT AAGTC CCAAG ACTTG ACTGT GAGGT AATCC 
            CTTTG GACTG TTAGA AAAAA TTCAG GGTTC TGAAC TGACA CTCCA TTAGG 
 
                    110         120         130         140         150 
            ATGCA CATGG CATCA GTAAA GTGTT CATTC AGGTG GATCA AGCCC TTGGC 
            TACGT GTACC GTAGT CATTT CACAA GTAAG TCCAC CTAGT TCGGG AACCG 
 
                    160         170         180         190         200 
            CAGAG ATCCC TGGTC ACTTA TATTT ATCCT CTTTT CTGTA CAACA TGCAT 
            GTCTC TAGGG ACCAG TGAAT ATAAA TAGGA GAAAA GACAT GTTGT ACGTA 
 
                    210         220         230         240         250 
            ATGGG AGTGG AAAGA AGTTT GTCGG CCCCT GTGGA GGAAG AGATT GCTCG 
            TACCC TCACC TTTCT TCAAA CAGCC GGGGA CACCT CCTTC TCTAA CGAGC 
 
                    260         270         280         290         300 
            GTGTG CCATT GCTTT CCTGA AAAAG GGTCT CGGGG TCAAC CAGGA CCGCC 
            CACAC GGTAA CGAAA GGACT TTTTC CCAGA GCCCC AGTTG GTCCT GGCGG 
 
                    310         320         330         340         350 
            GGGGC CACAG GGTCC CATTG GACCC CTGGG ACTGC CAGGA CCCAC AGGAA 
            CCCCG GTGTC CCAGG GTAAC CTGGG GACCC TGACG GTCCT GGGTG TCCTT 
 
                    360         370         380         390         400 
            TTCCA GGAGA GAAAG GGATG AGAGG TGACA GTGGC CCTCC TGGAG CAGCA 
            AAGGT CCTCT CTTTC CCTAC TCTCC ACTGT CACCG GGAGG ACCTC GTCGT 
 
                    410         420         430         440         450 
            GGTGA CAAAG GTGAC AAGGG TCCAA CTGGT GTTCC TGGAT TTCCA GGGTT 
            CCACT GTTTC CACTG TTCCC AGGTT GACCA CAAGG ACCTA AAGGT CCCAA 
 
                    460         470         480         490         500 
            GGATG GCATA CCTGG CCACC CGGGG CCTCC TGGAT CCAGA GGCAA GCCTG 
            CCTAC CGTAT GGACC GGTGG GCCCC GGAGG ACCTA GGTCT CCGTT CGGAC 
 
                    510         520         530         540         550 
            GCATG CATGG CTACA ATGGT TCACG AGGTG ATCCA GGGTT TCCAG GAAAA 
            CGTAC GTACC GATGT TACCA AGTGC TCCAC TAGGT CCCAA AGGTC CTTTT 
 
                    560         570         580         590         600 
            AGAGG AGTTC CTGGC CCAGG AGGCC CCCCA GGCCT TCCTG GGGAA AGGGG 
            TCTCC TCAAG GACCG GGTCC TCCGG GGGGT CCGGA AGGAC CCCTT TCCCC 
 
                    610         620         630         640         650 
            AGAAA AAGGA AATTC AGTGT TCATT TTAGG TGCCA TTAAA GGTAT TCAGG 




                    660         670         680         690         700 
            GAGAC AGGGG GGACC CAGAC CTGCC TGGCT TGCCG GGACC GAAGG GGGCA 
            CTCTG TCCCC CCTGG GTCTG GACGG ACCGA ACGGC CCTGG CTTCC CCCGT 
 
                    710         720         730         740         750 
            GGAGG ACCGG CAGGT CCCAA GGGAC AGCCA GGAGA GCCTG GGTTA ACAGG 
            CCTCC TGGCC GTCCA GGGTT CCCTG TCGGT CCTCT CGGAC CCAAT TGTCC 
 
                    760         770         780         790         800 
            TGCTC CGGGC CATCC TGGGA GACCA GGCTT GAAGG GTAAT CCTGG TGTGG 
            ACGAG GCCCG GTAGG ACCCT CTGGT CCGAA CTTCC CATTA GGACC ACACC 
 
                    810         820         830         840         850 
            GAGTA AAGGG GCAAA TGGGA GACCC GGGTG AGGTT GGCCA GCAGG GTTCT 
            CTCAT TTCCC CGTTT ACCCT CTGGG CCCAC TCCAA CCGGT CGTCC CAAGA 
 
                    860         870         880         890         900 
            CCTGG ACCCA CCTTA TTGGT ACAGC CACCT GATTC CTGTC TGTAT AAAGG 
            GGACC TGGGT GGAAT AACCA TGTCG GTGGA CTAAG GACAG ACATA TTTCC 
 
                    910         920         930         940         950 
            AGAAA AGGGC ATAAA AGGAA TGCCT GGTAT GATTG GACCT CCAGG ACTAC 
            TCTTT TCCCG TATTT TCCTT ACGGA CCATA CTAAC CTGGA GGTCC TGATG 
 
                    960         970         980         990        1000 
            CGGGA CCCAA GGGAG AACCT GGAAT TGGAC CAAAA GGAGA GAAGG GTATT 
            GCCCT GGGTT CCCTC TTGGA CCTTA ACCTG GTTTT CCTCT CTTCC CATAA 
 
                   1010        1020        1030        1040        1050 
            CCTGG GTTCT CAGGA CCTCG GGGTG ATCCG GGTTC CTATG GCTCT CCAGG 
            GGACC CAAGA GTCCT GGAGC CCCAC TAGGC CCAAG GATAC CGAGA GGTCC 
 
                   1060        1070        1080        1090        1100 
            TTTTC CAGGA TTAAA GGGGA AACCA GGACT GTTTG GAGAT CCTGG ATCAT 
            AAAAG GTCCT AATTT CCCCT TTGGT CCTGA CAAAC CTCTA GGACC TAGTA 
 
                   1110        1120        1130        1140        1150 
            TTGGA TTTGT TGGCC CAAAG GGGGA TCCTG GAGAC CGTGG GTACC CAGGA 
            AACCT AAACA ACCGG GTTTC CCCCT AGGAC CTCTG GCACC CATGG GTCCT 
 
                   1160        1170        1180        1190        1200 
            CCACC GGGTG TTCTG GTAAC TCCAT CTGTT CCACT CAAAG GCCCT CCAGG 
            GGTGG CCCAC AAGAC CATTG AGGTA GACAA GGTGA GTTTC CGGGA GGTCC 
 
                   1210        1220        1230        1240        1250 
            GGATC CGGGG CGCCC TGGCC ACTAT GGAGA AATGG GGTCC GTTGG ACCAC 
            CCTAG GCCCC GCGGG ACCGG TGATA CCTCT TTACC CCAGG CAACC TGGTG 
 
                   1260        1270        1280        1290        1300 
            CTGGT CCCCC TGGTC CCCCA GGTCC ACCAG GGGAA GACTG TGCAG GCATG 
            GACCA GGGGG ACCAG GGGGT CCAGG TGGTC CCCTT CTGAC ACGTC CGTAC 
 
                   1310        1320        1330        1340        1350 
            ATGGG ACCCC CTGGA CCAAG AGGAT TTCCT GGTCA TCCAG GATTT CCAGG 




                   1360        1370        1380        1390        1400 
            GGCAG CTGGT ATCCC AGGGA GAGCG GATTT AAGTC CAGGA AAACC AGGGA 
            CCGTC GACCA TAGGG TCCCT CTCGC CTAAA TTCAG GTCCT TTTGG TCCCT 
 
                   1410        1420        1430        1440        1450 
            AACCG GGACC TCCTG GGTTG CCCGG AGCAC CAGGG CTGCA AGGAC CCCCA 
            TTGGC CCTGG AGGAC CCAAC GGGCC TCGTG GTCCC GACGT TCCTG GGGGT 
 
                   1460        1470        1480        1490        1500 
            GGATC AGATG TTATC TATTG TAGTG TTGGG CATCC TGGAC CACAA GGGAT 
            CCTAG TCTAC AATAG ATAAC ATCAC AACCC GTAGG ACCTG GTGTT CCCTA 
 
                   1510        1520        1530        1540        1550 
            AAAAG GCAAA ATGGG TCCTC CAGGA AGAAG AGGCT CGAAA GGAGA AAAAG 
            TTTTC CGTTT TACCC AGGAG GTCCT TCTTC TCCGA GCTTT CCTCT TTTTC 
 
                   1560        1570        1580        1590        1600 
            GAAAT GCGGG GCTCT GTGCC TGTGA GCCTG GTCCC ATGGG CCCAC CAGGC 
            CTTTA CGCCC CGAGA CACGG ACACT CGGAC CAGGG TACCC GGGTG GTCCG 
 
                   1610        1620        1630        1640        1650 
            CCTCC AGGAC TTCCT GGAAG GCAGG GTAGT AAGGG AGACT TGGGG CTCCC 
            GGAGG TCCTG AAGGA CCTTC CGTCC CATCA TTCCC TCTGA ACCCC GAGGG 
 
                   1660        1670        1680        1690        1700 
            TGGGT GGATT GGAGA GAAAG GTCAC CCAGG CCCTC CTGGT GCTGA AGGAT 
            ACCCA CCTAA CCTCT CTTTC CAGTG GGTCC GGGAG GACCA CGACT TCCTA 
 
                   1710        1720        1730        1740        1750 
            CTCCA GGATC ACCAG GAAAA CATGG CGCCT CAGGA CCACC TGGCA GCAAA 
            GAGGT CCTAG TGGTC CTTTT GTACC GCGGA GTCCT GGTGG ACCGT CGTTT 
 
                   1760        1770        1780        1790        1800 
            GGAGA AAAGG GCGAC AGGGT TGTAT CAAGA GTGAA AGGGA AAAAA GGAGA 
            CCTCT TTTCC CGCTG TCCCA ACATA GTTCT CACTT TCCCT TTTTT CCTCT 
 
                   1810        1820        1830        1840        1850 
            AAGAG GTCCT GATGG GCTCC CAGGA TTTCC AGGAC AACAG GGACA AAATG 
            TTCTC CAGGA CTACC CGAGG GTCCT AAAGG TCCTG TTGTC CCTGT TTTAC 
 
                   1860        1870        1880        1890        1900 
            GTCGG GATGG ACTTC CTGGA AAAAA GGGGG ATCCA GGCCC CCCGG GGGGT 
            CAGCC CTACC TGAAG GACCT TTTTT CCCCC TAGGT CCGGG GGGCC CCCCA 
 
                   1910        1920        1930        1940        1950 
            CATGA GGATG CAGCC CCAGG TGCTA AAGGG TCTCC TGGAC CACCG GGGCC 
            GTACT CCTAC GTCGG GGTCC ACGAT TTCCC AGAGG ACCTG GTGGC CCCGG 
 
                   1960        1970        1980        1990        2000 
            CCCAG GCAGA ACAGG ACCCA GGGGA CAACC AGGTC TGGGA TTTCC TGGTC 
            GGGTC CGTCT TGTCC TGGGT CCCCT GTTGG TCCAG ACCCT AAAGG ACCAG 
 
                   2010        2020        2030        2040        2050 
            CACCA GGAGA GAGAG GACAA CCAGG AGCTC CAGGC CGCCC TGGCG AGAGG 




                   2060        2070        2080        2090        2100 
            GGCTT CGGGG GCTTG AAGGG CCAGA AAGGT GATAC AATTT CTTGT AATGT 
            CCGAA GCCCC CGAAC TTCCC GGTCT TTCCA CTATG TTAAA GAACA TTACA 
 
                   2110        2120        2130        2140        2150 
            CACCT ACCCT GGGAG GCCAG GACCC CCAGG TTTTG ATGGA CCTCC AGGAC 
            GTGGA TGGGA CCCTC CGGTC CTGGG GGTCC AAAAC TACCT GGAGG TCCTG 
 
                   2160        2170        2180        2190        2200 
            CAAAG GGATT TCCAG GTCCT CAAGG CGCTC CAGGG TTGAG GTGCT TGGAT 
            GTTTC CCTAA AGGTC CAGGA GTTCC GCGAG GTCCC AACTC CACGA ACCTA 
 
                   2210        2220        2230        2240        2250 
            GGGCC AAAAG GTCAG CGTGG CAAAC CAGGA ATGTC AGAGA TACCC GGTCC 
            CCCGG TTTTC CAGTC GCACC GTTTG GTCCT TACAG TCTCT ATGGG CCAGG 
 
                   2260        2270        2280        2290        2300 
            ACCTG GTTTT CGTGG TGACA TGGGA GATCC GGGTT TTGAA GGTGA AAAGG 
            TGGAC CAAAA GCACC ACTGT ACCCT CTAGG CCCAA AACTT CCACT TTTCC 
 
                   2310        2320        2330        2340        2350 
            GGTCC TCCCT TCTTG GGCCG CCAGG CTTTC CTGGT TCTCG TGGAG CAAAT 
            CCAGG AGGGA AGAAC CCGGC GGTCC GAAAG GACCA AGAGC ACCTC GTTTA 
 
                   2360        2370        2380        2390        2400 
            GGTCA GAAAG GAATG ATGGG AGACA TTGCC TATGG CCTCC CAGGC CCCCC 
            CCAGT CTTTC CTTAC TACCC TCTGT AACGG ATACC GGAGG GTCCG GGGGG 
 
                   2410        2420        2430        2440        2450 
            AGGAA AGAGA GGTCC TTCCG GAGTG CCAGG GTCCA AAGGA CACAG AGGTG 
            TCCTT TCTCT CCAGG AAGGC CTCAC GGTCC CAGGT TTCCT GTGTC TCCAC 
 
                   2460        2470        2480        2490        2500 
            ATTCA GGACG TCCAG GGTTT GCAGG GCCAG CCGGC AAGCC TGGAT CCCCA 
            TAAGT CCTGC AGGTC CCAAA CGTCC CGGTC GGCCG TTCGG ACCTA GGGGT 
 
                   2510        2520        2530        2540        2550 
            GGTCT CAAAG GTCCC AGAGG CAGAG AGGGA AGTGC TGGGT TTCAA GGTAT 
            CCAGA GTTTC CAGGG TCTCC GTCTC TCCCT TCACG ACCCA AAGTT CCATA 
 
                   2560        2570        2580        2590        2600 
            CCCGG GTCCA CCTGG CCATT CCTGC AAAAG AGGCG CTCCA GGGAT ACCAG 
            GGGCC CAGGT GGACC GGTAA GGACG TTTTC TCCGC GAGGT CCCTA TGGTC 
 
                   2610        2620        2630        2640        2650 
            GGCAA CCGGG GCTCC CTGGG GCCCC GGGGA GTCCA GGTGC CCCAG GTTGG 
            CCGTT GGCCC CGAGG GACCC CGGGG CCCCT CAGGT CCACG GGGTC CAACC 
 
                   2660        2670        2680        2690        2700 
            AAAGG ACAGC GAGGG GATGT GGGGC CTCCG GGTCC AGCTG GAATG AAAGG 
            TTTCC TGTCG CTCCC CTACA CCCCG GAGGC CCAGG TCGAC CTTAC TTTCC 
 
                   2710        2720        2730        2740        2750 
            CCTCC CTGGA GTCCC TGGAC GGCCA GGGGC AGAGG GACCC CTAGG ATTCC 




                   2760        2770        2780        2790        2800 
            CAGGA GTCCC AGGCC CCTTA GGGGA TGATG GGCTG CCTGG TCTTC CAGGC 
            GTCCT CAGGG TCCGG GGAAT CCCCT ACTAC CCGAC GGACC AGAAG GTCCG 
 
                   2810        2820        2830        2840        2850 
            CCGAA GGGAC CCCAG GGGCT GCCTG GCTTC CCCGG TTTTC CAGGG GAGAG 
            GGCTT CCCTG GGGTC CCCGA CGGAC CGAAG GGGCC AAAAG GTCCC CTCTC 
 
                   2860        2870        2880        2890        2900 
            AGGAA AGCCT GGCCC AGAGG GACGC CCTGG CAGCA AGGGG GAACC AGGAG 
            TCCTT TCGGA CCGGG TCTCC CTGCG GGACC GTCGT TCCCC CTTGG TCCTC 
 
                   2910        2920        2930        2940        2950 
            AGGAT GGTCG GCCTG GCTTC TTCGG AGACC AAGGG GTGAA AGGTG CCAAA 
            TCCTA CCAGC CGGAC CGAAG AAGCC TCTGG TTCCC CACTT TCCAC GGTTT 
 
                   2960        2970        2980        2990        3000 
            GGAGC GAGAG GACCC CCAGG AGATG AAGGA GAGAT GGCGG TCTTT TCCCA 
            CCTCG CTCTC CTGGG GGTCC TCTAC TTCCT CTCTA CCGCC AGAAA AGGGT 
 
                   3010        3020        3030        3040        3050 
            AAAAG GGAAA ACCGG GGAAC CTGGA CCTCC AGGAG ATGAT GGATT CCCAG 
            TTTTC CCTTT TGGCC CCTTG GACCT GGAGG TCCTC TACTA CCTAA GGGTC 
 
                   3060        3070        3080        3090        3100 
            GAGAA GAAGG TGATA AAGGC AATCC AGGGA TGCCG GGGAG GAGAG GAGAG 
            CTCTT CTTCC ACTAT TTCCG TTAGG TCCCT ACGGC CCCTC CTCTC CTCTC 
 
                   3110        3120        3130        3140        3150 
            CCTGG AAGAT TCGGA GCACC TGGAT TTCAC AGAGG GGAGC CCGGG AGAAC 
            GGACC TTCTA AGCCT CGTGG ACCTA AAGTG TCTCC CCTCG GGCCC TCTTG 
 
                   3160        3170        3180        3190        3200 
            CGGGC AGCCA GGGCT TCCTG GCCCC CCAGG CCCCC CAGGC TCACC TGGGC 
            GCCCG TCGGT CCCGA AGGAC CGGGG GGTCC GGGGG GTCCG AGTGG ACCCG 
 
                   3210        3220        3230        3240        3250 
            TGAGA GGGAT TATTG GTTTT CCGGG ATTTC CAGGT GACCA GGGTG AGCCA 
            ACTCT CCCTA ATAAC CAAAA GGCCC TAAAG GTCCA CTGGT CCCAC TCGGT 
 
                   3260        3270        3280        3290        3300 
            GGTTC TCCAG GGTCT CCTGG ACTTT CAGGA ATTGA TGGAA TGAGA GGACC 
            CCAAG AGGTC CCAGA GGACC TGAAA GTCCT TAACT ACCTT ACTCT CCTGG 
 
                   3310        3320        3330        3340        3350 
            TAAAG GAAGC AAAGG TGACC CTGCA AGTCA GTTCG GCCCA CCTGG TCCAA 
            ATTTC CTTCG TTTCC ACTGG GACGT TCAGT CAAGC CGGGT GGACC AGGTT 
 
                   3360        3370        3380        3390        3400 
            AGGGT GAACC AGGTA GCCCT GGATG TCCAG GACAA GTTGG AGCAC CTGGA 
            TCCCA CTTGG TCCAT CGGGA CCTAC AGGTC CTGTT CAACC TCGTG GACCT 
 
                   3410        3420        3430        3440        3450 
            GAGCA GGGCT TGCCT GGTGT TCAAG GGCTC AGAGG ACCAC CTGGA AGGCC 




                   3460        3470        3480        3490        3500 
            AGGAT TACCT GGCTC CTCCG GACCA CCAGG GTGTC CAGGT AATCA AGGGG 
            TCCTA ATGGA CCGAG GAGGC CTGGT GGTCC CACAG GTCCA TTAGT TCCCC 
 
                   3510        3520        3530        3540        3550 
            TGCCT GGGCT GACAG GGCCT CCAGG AGAAA CAGGG GATCC TGGGC CAAGA 
            ACGGA CCCGA CTGTC CCGGA GGTCC TCTTT GTCCC CTAGG ACCCG GTTCT 
 
                   3560        3570        3580        3590        3600 
            GGCAT GATGG GAGAT CCAGG GCCAC CAGGT CTTCC AGGAA TAAAA GGTCC 
            CCGTA CTACC CTCTA GGTCC CGGTG GTCCA GAAGG TCCTT ATTTT CCAGG 
 
                   3610        3620        3630        3640        3650 
            CTCCG GGTCG CCGGG TCTGA ATGGC TTGCA TGGTT TAAAG GGTCA GAAAG 
            GAGGC CCAGC GGCCC AGACT TACCG AACGT ACCAA ATTTC CCAGT CTTTC 
 
                   3660        3670        3680        3690        3700 
            GAGCC AAAGG TGCTT CAGGT TTGCA CGAAG TGGGC CCACC CGGTC CAGTG 
            CTCGG TTTCC ACGAA GTCCA AACGT GCTTC ACCCG GGTGG GCCAG GTCAC 
 
                   3710        3720        3730        3740        3750 
            GGCGT ACCTG GGCTG AAAGG GGAGC CGGGA GACCC TGGGA GCCCA GGAAT 
            CCGCA TGGAC CCGAC TTTCC CCTCG GCCCT CTGGG ACCCT CGGGT CCTTA 
 
                   3760        3770        3780        3790        3800 
            TTCTC CCCCA GGCCT TTCTG GAGAA AGAGG CCCCC CCGGC CCCCC AGGGA 
            AAGAG GGGGT CCGGA AAGAC CTCTT TCTCC GGGGG GGCCG GGGGG TCCCT 
 
                   3810        3820        3830        3840        3850 
            GACCT GGAGC CCCTG GTCCT GCAGG TGCCA CAGGA AGAGC TGCTG AAGGT 
            CTGGA CCTCG GGGAC CAGGA CGTCC ACGGT GTCCT TCTCG ACGAC TTCCA 
 
                   3860        3870        3880        3890        3900 
            CACGT TCCTG ACCCA GGTCC ACCCG GAGAT GTGGG TCCTC CTGGC CCCGA 
            GTGCA AGGAC TGGGT CCAGG TGGGC CTCTA CACCC AGGAG GACCG GGGCT 
 
                   3910        3920        3930        3940        3950 
            TGGTC CGAGA GGAGC GCCCG GGCCC CCAGG CCCCC CTGGG AGCGT TGACC 
            ACCAG GCTCT CCTCG CGGGC CCGGG GGTCC GGGGG GACCC TCGCA ACTGG 
 
                   3960        3970        3980        3990        4000 
            TTCTG AGAGG GGAAC CAGGA GACTG TGGGC CGCCG GGGCC TCCAG GTCCC 
            AAGAC TCTCC CCTTG GTCCT CTGAC ACCCG GCGGC CCCGG AGGTC CAGGG 
 
                   4010        4020        4030        4040        4050 
            CCGGG CCCAC CCGGC CCTCC AGGAC ACCAA GGCTT CCCAG GATGC GATGG 
            GGCCC GGGTG GGCCG GGAGG TCCTG TGGTT CCGAA GGGTC CTACG CTACC 
 
                   4060        4070        4080        4090        4100 
            AAAAG ACGGC CAGAA AGGAC CAATA GGATT CCCGG GGCTG CAGGG GCCTC 
            TTTTC TGCCG GTCTT TCCTG GTTAT CCTAA GGGCC CCGAC GTCCC CGGAG 
 
                   4110        4120        4130        4140        4150 
            AGGGA CTTCC TGGGC TCCCT GGGGA GAAGG GTCTG CTGGG CATTC CAGGC 




                   4160        4170        4180        4190        4200 
            CGGCG AGGGC ACCCC GGTCC TCCAG GTTCC AGAGG TGAAC CAGGG CCTCC 
            GCCGC TCCCG TGGGG CCAGG AGGTC CAAGG TCTCC ACTTG GTCCC GGAGG 
 
                   4210        4220        4230        4240        4250 
            TGCAG ATGTG GATTC GTGCC CCCGC ATCCC CGGGC TTCCT GGGGT ACCAG 
            ACGTC TACAC CTAAG CACGG GGGCG TAGGG GCCCG AAGGA CCCCA TGGTC 
 
                   4260        4270        4280        4290        4300 
            GCCCA AGAGG ACCAG AAGGA GCCAT GGGGG TCCCT GGAAG GAGAG GGCCC 
            CGGGT TCTCC TGGTC TTCCT CGGTA CCCCC AGGGA CCTTC CTCTC CCGGG 
 
                   4310        4320        4330        4340        4350 
            CCAGG ACCAG GGTGC AAAGG AGAGC CGGGA CTGGA GGGCA GGAGG GGCGA 
            GGTCC TGGTC CCACG TTTCC TCTCG GCCCT GACCT CCCGT CCTCC CCGCT 
 
                   4360        4370        4380        4390        4400 
            GGCCG GCCTC CCAGG ACCTC CGGGG CCTCC CGGAA GCACA GGGGA CGCAG 
            CCGGC CGGAG GGTCC TGGAG GCCCC GGAGG GCCTT CGTGT CCCCT GCGTC 
 
                   4410        4420        4430        4440        4450 
            GAGAA GCCGG TTGCC CCGGA GCACC AGGGC CCCCC GGGCC CATTG GGGAC 
            CTCTT CGGCC AACGG GGCCT CGTGG TCCCG GGGGG CCCGG GTAAC CCCTG 
 
                   4460        4470        4480        4490        4500 
            CCCGG GCCCA GAGGG TTTGG GCCTG GATAC CTCAG TGGCT TCCTC CTGGT 
            GGGCC CGGGT CTCCC AAACC CGGAC CTATG GAGTC ACCGA AGGAG GACCA 
 
                   4510        4520        4530        4540        4550 
            TCTCC ACAGT CAGAC GGATG GGGAG CCCAC CTGCC CCGCG GGCAT GCCCA 
            AGAGG TGTCA GTCTG CCTAC CCCTC GGGTG GACGG GGCGC CCGTA CGGGT 
 
                   4560        4570        4580        4590        4600 
            GGCCC TGGAC GGGCT ACAGT CTGTT ATACC TGGAA GGACA GGAGA AGGCC 
            CCGGG ACCTG CCCGA TGTCA GACAA TATGG ACCTT CCTGT CCTCT TCCGG 
 
                   4610        4620        4630        4640        4650 
            CACAA TCAGG ACCTT GGTCT GGCAG GGTCT TGCCT TCCCA TGTTC AGCAC 
            GTGTT AGTCC TGGAA CCAGA CCGTC CCAGA ACGGA AGGGT ACAAG TCGTG 
 
                   4660        4670        4680        4690        4700 
            CCTGC CCTTT GCCTA CTGCA ACATC CACCA AGTGT GCCAC TACGC CCGGA 
            GGACG GGAAA CGGAT GACGT TGTAG GTGGT TCACA CGGTG ATGCG GGCCT 
 
                   4710        4720        4730        4740        4750 
            GAAAC GACCG GTCCT ACTGG CTGGC CAGTG CTGCG CCCCT GCCCA TGATG 
            CTTTG CTGGC CAGGA TGACC GACCG GTCAC GACGC GGGGA CGGGT ACTAC 
 
                   4760        4770        4780        4790        4800 
            CCGCT CTCAG AGGAG GAGAT CCGCC CCTAC ATCAG CCGCT GTGCC GTGTG 
            GGCGA GAGTC TCCTC CTCTA GGCGG GGATG TAGTC GGCGA CACGG CACAC 
 
                   4810        4820        4830        4840        4850 
            CGAGG CCCCA GCCCC CGTGG TGGCG CTGCA CAGCC AGGAC CGGTC CATCC 




                   4860        4870        4880        4890        4900 
            CGCCG TGTCC ACGGA GCTGG AGGAG CCTCT GGATC GGGTA CTCGT TCCTG 
            GCGGC ACAGG TGCCT CGACC TCCTC GGAGA CCTAG CCCAT GAGCA AGGAC 
 
                   4910        4920        4930        4940        4950 
            ATGCA CACAG GGGCT GGAGA CCAAG GAGGA GGGCA GGCCC TCATG TCCCC 
            TACGT GTGTC CCCGA CCTCT GGTTC CTCCT CCCGT CCGGG AGTAC AGGGG 
 
                   4960        4970        4980        4990        5000 
            CGGCA GCTGT CTGGA AGATT TCCGA GCCGC ACCGT TCCTC GAATG CCAAG 
            GCCGT CGACA GACCT TCTAA AGGCT CGGCG TGGCA AGGAG CTTAC GGTTC 
 
                   5010        5020        5030        5040        5050 
            GCCGA CAGGG AACTT GCCAC TTTTT TGCAA ATGAG TATAG CTTCT GGCTG 
            CGGCT GTCCC TTGAA CGGTG AAAAA ACGTT TACTC ATATC GAAGA CCGAC 
 
                   5060        5070        5080        5090        5100 
            ACGAC GGTGA GGCCT GACTT GCAGT TTTCC TCGGC ACCAT CACCA GACAC 
            TGCTG CCACT CCGGA CTGAA CGTCA AAAGG AGCCG TGGTA GTGGT CTGTG 
 
                   5110        5120        5130        5140        5150 
            CTTGA AAGAA AGCCA GGCCC AGCGC CAGAA AATCA GCAGG TGCCA GGTAT 
            GAACT TTCTT TCGGT CCGGG TCGCG GTCTT TTAGT CGTCC ACGGT CCATA 
 
                   5160     
            GCATA TGACT AGT 













Canine COL4A4 nucleotide alignment 
 
 
Consensus key (see documentation for details) 
* - single, fully conserved residue 
  - no consensus 
 
 
CLUSTAL W (1.81) multiple sequence alignment 
 
 
Canine_A4_Normal_5-21      CTAGAGGATCTACTAGTCATATGGATGTGAGAGTCTTCTGGAAGAGAAGA 
Human_COL4A4               -------------------------------------------------- 
Mouse_COL4A4               -------------------------------------------------- 
 
 
Canine_A4_Normal_5-21      GAAACCTGACAATCTTTTTTAAGTCCCAAGACTTGACTGTGAGGTAATCC 
Human_COL4A4               -----------------------------------------ATGTGGTCT 
Mouse_COL4A4               -------------------------------------------------- 
 
 
Canine_A4_Normal_5-21      ATGCACATGGCATCAGTAAAGTGTTCATTCAGGTGGATCAAGCCCTTGGC 
Human_COL4A4               CTGCACATAGTACTAATGAGGTGCTCCTTCAGATTGACCAAGTCCTTGGC 
Mouse_COL4A4               ---------------ATGAGGTGCTTTTTCAGATGGACCAAGTCCTTTGT 
                                           * * *** *  ***** * ** **** **** *  
 
Canine_A4_Normal_5-21      CAGAGATCCCTGGTCACTTATATTTATCCTCTTTTCTGTACAACATGCAT 
Human_COL4A4               CACAGGTCCCTGGTCACTTATACTCATTCTCTTTTCTGTACAATATGTAT 
Mouse_COL4A4               CACAGCCCCCTGGTCACTAATATTTATCCTCTTTACTATACAATATGAAT 
                           ** **  *********** *** * ** ****** ** ***** *** ** 
 
Canine_A4_Normal_5-21      ATGGGAGTGGAAAGAAGTTTGTCGGCCCCTGTGGAGGAAGAGATTGCTCG 
Human_COL4A4               ATGGGAGTGGAAAGAAATACATTGGTCCTTGTGGAGGAAGAGATTGCTCT 
Mouse_COL4A4               ATGGGAGTGGCAAGAAGTATGGCGGCCCCTGCGGAGGAAGAAACTGCTCT 
                           ********** ***** *     ** ** ** ********* * *****  
 
Canine_A4_Normal_5-21      GTGTGCCATTGCTTTCCTGAAAAAGGGTCTCGGGGTCAACCAGGACCGCC 
Human_COL4A4               GTTTGCCACTGTGTTCCTGAAAAGGGGTCTCGGGGTCCACCAGGACCACC 
Mouse_COL4A4               GTCTGCCAGTGTTTTCCTGAGAAGGGATCTCGGGGTCACCCAGGACCACT 
                           ** ***** **  ******* ** ** **********  ******** *  
 
Canine_A4_Normal_5-21      GGGGCCACAGGGTCCCATTGGACCCCTGGGACTGCCAGGACCCACAGGAA 
Human_COL4A4               AGGGCCACAGGGTCCAATTGGACCCCTGGGAGCCCCAGGACCCATTGGGC 
Mouse_COL4A4               GGGACCACAGGGACCAATAGGGCCCTTGGGACCCCTGGGACCTATTGGGA 
                            ** ******** ** ** ** *** *****   *  ***** *  **   
 
Canine_A4_Normal_5-21      TTCCAGGAGAGAAAGGGATGAGAGGTGACAGTGGCCCTCCTGGAGCAGCA 
Human_COL4A4               TTTCAGGAGAGAAAGGAATGAGAGGGGACCGCGGCCCTCCTGGAGCAGCA 
Mouse_COL4A4               TTCCAGGAGAAAAAGGAGAGAGAGGAGACAGTGGCTCACCTGGACCACCA 
                           ** ******* *****   ****** *** * *** * ****** ** ** 
 
Canine_A4_Normal_5-21      GGTGACAAAGGTGACAAGGGTCCAACTGGTGTTCCTGGATTTCCAGGGTT 
Human_COL4A4               GGGGACAAAGGAGATAAGGGTCCAACTGGTGTTCCTGGATTTCCAGGTTT 
Mouse_COL4A4               GGAGAGAAAGGAGACAAGGGTCCAACTGGTGTCCCTGGATTTCCAGGTGT 
                           ** ** ***** ** ***************** **************  * 
 
Canine_A4_Normal_5-21      GGATGGCATACCTGGCCACCCGGGGCCTCCTGGATCCAGAGGCAAGCCTG 
Human_COL4A4               AGATGGCATACCTGGGCACCCAGGGCCTCCTGGACCCAGAGGCAAACCTG 
Mouse_COL4A4               GGATGGTGTACCTGGTCACCCAGGGCCTCCTGGACCCAGAGGCAAACCTG 
                            *****  ******* ***** ************ ********** **** 
 
Canine_A4_Normal_5-21      GCATGCATGGCTACAATGGTTCACGAGGTGATCCAGGGTTTCCAGGAAAA 
Human_COL4A4               GTATGAGTGGCCACAATGGCTCAAGAGGTGACCCAGGGTTTCCAGGAGGA 
Mouse_COL4A4               GTGTGGACGGCTACAATGGCTCACGTGGTGATCCGGGCTATCCAGGAGAA 
                           *  **   *** ******* *** * ***** ** ** * *******  * 
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Canine_A4_Normal_5-21      AGAGGAGTTCCTGGCCCAGGAGGCCCCCCAGGCCTTCCTGGGGAAAGGGG 
Human_COL4A4               AGAGGAGCTCTTGGCCCAGGAGGCCCCCTAGGCCATCCTGGGGAAAAGGG 
Mouse_COL4A4               AGAGGAGCTCCAGGCCCAGGCGGCCCCCCTGGTCAGCCTGGGGAAAATGG 
                           ******* **  ******** *******  ** *  **********  ** 
 
Canine_A4_Normal_5-21      AGAAAAAGGAAATTCAGTGTTCATTTTAGGTGCCATTAAAGGTATTCAGG 
Human_COL4A4               AGAAAAAGGAAATTCAGTGTTCATTTTAGGTGCCGTTAAAGGTATTCAGG 
Mouse_COL4A4               AGAAAAAGGAAGATCTGTGTACATTACTGGTGGCGTTAAAGGTATTCAGG 
                           ***********  ** **** ****   **** * *************** 
 
Canine_A4_Normal_5-21      GAGACAGGGGGGACCCAGACCTGCCTGGCTTGCCGGGACCGAAGGGGGCA 
Human_COL4A4               GAGACAGAGGGGACCCAGGACTGCCTGGCTTACCAGGATCTTGGGGTGCA 
Mouse_COL4A4               GAGACCGTGGGGACCCAGGACCACCCGGCTTACCAGGATCTAGGGGTGCA 
                           ***** * **********  *  ** ***** ** *** *   *** *** 
 
Canine_A4_Normal_5-21      GGAGGACCGGCAGGTCCCAAGGGACAGCCAGGAGAGCCTGGGTTAACAGG 
Human_COL4A4               GGAGGACCGGCAGGTCCCACAGGATATCCTGGAGAGCCAGGGTTAGTGGG 
Mouse_COL4A4               CAAGGGTCACCAGGGCCCATGGGGCATGCAGGCGCACCAGGGCTAGCAGG 
                             ***  *  **** ****  **  *  * ** *  ** *** **   ** 
 
Canine_A4_Normal_5-21      TGCTCCGGGCCATCCTGGGAGACCAGGCTTGAAGGGTAATCCTGGTGTGG 
Human_COL4A4               ACCTCCGGGCCAACCAGGGCGTCCAGGTTTGAAGGGAAATCCCGGTGTGG 
Mouse_COL4A4               ACCTATAGGTCATCCTGGAAGCCCTGGGTTGAAGGGAAATCCTGCCACTG 
                             **   ** ** ** **  * ** ** ******** ***** *     * 
 
Canine_A4_Normal_5-21      GAGTAAAGGGGCAAATGGGAGACCCGGGTGAGGTTGGCCAGCAGGGTTCT 
Human_COL4A4               GAGTAAAGGGGCAAATGGGAGACCCGGGTGAGGTTGGTCAGCAAGGTTCT 
Mouse_COL4A4               GACTGAAGGGACAAAGGGGAGAGCCGGGTGAAGTTGGCCAGCGTGGTCCT 
                           ** * ***** **** ****** ******** ***** ****  *** ** 
 
Canine_A4_Normal_5-21      CCTGGACCCACCTTATTGGTACAGCCACCTGATTCCTGTCTGTATAAAGG 
Human_COL4A4               CCTGGACCCACCCTGTTGGTAGAGCCACCTGACTTTTGTCTCTATAAAGG 
Mouse_COL4A4               CCTGGGCCCACGCTGTTGGTACAGCCGCCTGATTTGAGTATCTATAAAGG 
                           ***** *****  * ****** **** ***** *   ** * ******** 
 
Canine_A4_Normal_5-21      AGAAAAGGGCATAAAAGGAATGCCTGGTATGATTGGACCTCCAGGACTAC 
Human_COL4A4               AGAAAAGGGTATAAAAGGAATTCCTGGAATGGTTGGACTGCCAGGACCAC 
Mouse_COL4A4               AGAAAAGGGTGTAAAAGGAATGCCTGGAATGATTGGTCCCCCAGGACCTC 
                           *********  ********** ***** *** **** *  *******  * 
 
Canine_A4_Normal_5-21      CGGGACCCAAGGGAGAACCTGGAATTGGACCAAAAGGAGAGAAGGGTATT 
Human_COL4A4               CAGGACGCAAGGGAGAATCTGGTATTGGGGCAAAAGGAGAAAAAGGTATT 
Mouse_COL4A4               CAGGTCGCAAGGGAGCGCCTGGTGTCGGGATCAAAGGAGAGAAAGGTATC 
                           * ** * ********   ****  * **    ******** ** *****  
 
Canine_A4_Normal_5-21      CCTGGGTTCTCAGGACCTCGGGGTGATCCGGGTTCCTATGGCTCTCCAGG 
Human_COL4A4               CCTGGATTTCCAGGGCCTCGGGGGGATCCTGGTTCCTATGGATCTCCAGG 
Mouse_COL4A4               CCTGGGTTCCCAGGACCCCGGGGTGAGCCTGGTTCGCATGGGCCTCCAGG 
                           ***** **  **** ** ***** ** ** *****  ****  ******* 
 
Canine_A4_Normal_5-21      TTTTCCAGGATTAAAGGGGAAACCAGGACTGTTTGGAGATCCTGGATCAT 
Human_COL4A4               TTTTCCAGGATTAAAGGGAGAACTAGGACTGGTTGGAGATCCTGGGCTAT 
Mouse_COL4A4               TTTTCCAGGATTCAAGGGGATACAAGGAGCAGCTGGAGAGCCTGGGCTGT 
                           ************ *****   ** ****     ****** *****    * 
 
Canine_A4_Normal_5-21      TTGGATTTGTTGGCCCAAAGGGGGATCCTGGAGACCGTGGGTACCCAGGA 
Human_COL4A4               TTGGATTAATTGGCCCAAAGGGGGATCCTGGAAATCGAGGGCACCCAGGA 
Mouse_COL4A4               TCGGATTTCTTGGTCCAAAGGGGGATCTGGGAGATCGCGGGTACCCGGGA 
                           * *****  **** *************  *** * ** *** **** *** 
 
Canine_A4_Normal_5-21      CCACCGGGTGTTCTGGTAACTCCATCTGTTCCACTCAAAGGCCCTCCAGG 
Human_COL4A4               CCACCAGGTGTTTTGGTGACTCCACCTCTTCCACTTAAAGGCCCACCAGG 
Mouse_COL4A4               CCACCAGGCATTTTGTTGACTCCAGCTCCACCACTCAAAGGTGTTCCAGG 




Canine_A4_Normal_5-21      GGATCCGGGGCGCCCTGGCCACTATGGAGAAATGGGGTCCGTTGGACCAC 
Human_COL4A4               GGACCCAGGGTTCCCTGGCCGCTATGGAGAAACAGGGGATGTTGGACCAC 
Mouse_COL4A4               GGACCCAGGACCCCCTGGCTACTATGGGGAGATTGGAGATGTTGGATTAC 
                           *** ** **   *******  ****** ** *  **    ******  ** 
 
Canine_A4_Normal_5-21      CTGGTCCCCCTGGTCCCCCAGGTCCACCAGGGGAAGACTGTGCAGGCATG 
Human_COL4A4               CTGGTCCCCCAGGTCTCTTGGGCAGACCAGGGGAAGCCTGTGCAGGCATG 
Mouse_COL4A4               CAGGTCCTCCAGGGCCCCCAGGCAGACCAGGGGAAACTTGTCCAGGCATG 
                           * ***** ** ** * *   **   **********   *** ******** 
 
Canine_A4_Normal_5-21      ATGGGACCCCCTGGACCAAGAGGATTTCCTGGTCATCCAGGATTTCCAGG 
Human_COL4A4               ATAGGACCCCCTGGGCCACAAGGATTTCCTGGTCTTCCTGGGCTTCCAGG 
Mouse_COL4A4               ATGGGACCTCCTGGACCACCAGGGGTTCCTGGTCCTCCAGGATTTCCAGG 
                           ** ***** ***** ***  ***  ********* *** **  ******* 
 
Canine_A4_Normal_5-21      GGCAGCTGGTATCCCAGGGAGAGCGGATTTAAGTCCAGGAAAACCAGGGA 
Human_COL4A4               AGAAGCTGGTATTCCTGGGAGACCTGATTCTGCTCCAGGAAAACCAGGGA 
Mouse_COL4A4               AGAAGCTGGGGTTCCTGGAAGACTCGACTGTGCCCCAGGAAAACCTGGGA 
                            * ******  * ** ** ***   ** *     *********** **** 
 
Canine_A4_Normal_5-21      AACCGGGACCTCCTGGGTTGCCCGGAGCACCAGGGCTGCAAGGACCCCCA 
Human_COL4A4               AGCCAGGATCACCTGGCTTGCCTGGAGCACCAGGCCTGCAGGGCCTCCCA 
Mouse_COL4A4               AGCCAGGGCTACCCGGCCTGCCTGGCGCACCAGGACCAGAGGGGCCCCCT 
                           * ** **    ** **  **** ** ******** *   * ** * ***  
 
Canine_A4_Normal_5-21      GGATCAGATGTTATCTATTGTAGTGTTGGGCATCCTGGACCACAAGGGAT 
Human_COL4A4               GGATCAAGTGTGATATACTGTAGTGTTGGGAACCCCGGACCACAAGGAAT 
Mouse_COL4A4               GGATCAGATGTGATATACTGTCGCCCTGGGTGCCCTGGGCCAATGGGTGA 
                           ******  *** ** ** *** *   ****   ** ** ***   **    
 
Canine_A4_Normal_5-21      AAAAGGCAAAATGGGTCCTCCAGGAAGAAGAGGCTCGAAAGGAGAAAAAG 
Human_COL4A4               AAAAGGCAAAGTTGGTCCCCCAGGAGGAAGAGGCCCAAAAGGAGAAAAAG 
Mouse_COL4A4               AAAGGGAAAAGTGGGTCCTCCAGGAAGAAGAGGAGCCAAAGGAGCAAAAG 
                           *** ** *** * ***** ****** *******  * ******* ***** 
 
Canine_A4_Normal_5-21      GAAATGCGGGGCTCTGTGCCTGTGAGCCTGGTCCCATGGGCCCACCAGGC 
Human_COL4A4               GAAATGAAGGACTCTGTGCCTGTGAGCCTGGACCCATGGGCCCCCCTGGC 
Mouse_COL4A4               GAAACAAGGGACTCTGTACCTGTCCACCTGGTCCCATGGGACCCCCTGGT 
                           ****    ** ****** *****   ***** ******** ** ** **  
 
Canine_A4_Normal_5-21      CCTCCAGGACTTCCTGGAAGGCAGGGTAGTAAGGGAGACTTGGGGCTCCC 
Human_COL4A4               CCTCCAGGACTTCCTGGGAGGCAGGGGAGTAAGGGAGACTTGGGGCTCCC 
Mouse_COL4A4               CCCCCAGGACCTCCTGGAAGACAAGGAAGTAAAGGAGACTTAGGGCTCCC 
                           ** ******* ****** ** ** ** ***** ******** ******** 
 
Canine_A4_Normal_5-21      TGGGTGGATTGGAGAGAAAGGTCACCCAGGCCCTCCTGGTGCTGAAGGAT 
Human_COL4A4               TGGCTGGCTTGGAACAAAAGGTGACCCAGGACCTCCTGGTGCTGAAGGAC 
Mouse_COL4A4               TGGTTGGCATGGAGAAAAGGGCGATCCAGGTCAGCCTGGTGCTGAAGGAC 
                           *** ***  ****   ** **  * ***** *  ***************  
 
Canine_A4_Normal_5-21      CTCCAGGATCACCAGGAAAACATGGCGCCTCAGGACCACCTGGCAGCAAA 
Human_COL4A4               CTCCAGGGCTACCAGGAAAGCATGGTGCCTCTGGACCACCTGGCAACAAA 
Mouse_COL4A4               CGCCAGGGCCACCAGGAAGACCTGGTGCCATGGGGCCCCCTGGTCACAAA 
                           * *****   ********  * *** ***   ** ** *****   **** 
 
Canine_A4_Normal_5-21      GGAGAAAAGGGCGACAGGGTTGTATCAAGAGTGAAAGGGAAAAAAGGAGA 
Human_COL4A4               GGGGCGAAGGGTGACATGGTTGTATCAAGAGTTAAAGGGCACAAAGGAGA 
Mouse_COL4A4               GGGGAAAAGGGTGACATGGTCATATCAAGAGTGAAAGGGCAAAAAGGAGA 
                           ** *  ***** **** ***  ********** ****** * ******** 
 
Canine_A4_Normal_5-21      AAGAGGTCCTGATGGGCTCCCAGGATTTCCAGGACAACAGGGACAAAATG 
Human_COL4A4               AAGAGGTCCTGATGGGCCCCCAGGATTTCCAGGGCAGCCAGGATCACATG 
Mouse_COL4A4               AAGAGGACTGGATGGGCCACCAGGATTTCCGGGGCCACATGGACAAGATG 
                           ****** *  *******  *********** ** *  *  ***  * *** 
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Canine_A4_Normal_5-21      GTCGGGATGGACTTCCTGGAAAAAAGGGGGATCCAGGCCCCCCGGGGGGT 
Human_COL4A4               GTCGGGATGGACATGCTGGAGAAAAAGGGGATCCAGGACCTCCAGGGGAT 
Mouse_COL4A4               GTGGGGATGGACGTCCTGGAGAAAGAGGGGATCCTGGGCCACGAGGGGAC 
                           ** ********* * ***** ***  ******** ** ** *  ****   
 
Canine_A4_Normal_5-21      CATGAGGATGCAGCCCCAGGTGCTAAAGGGTCTCCTGGACCACCGGGGCC 
Human_COL4A4               CATGAAGATGCGACCCCAGGTGGTAAAGGATTTCCTGGACCTCTGGGCCC 
Mouse_COL4A4               CATAAGGATGCAGCCCCGGGTGAGAGAGGGCTTCCCGGACTGCCAGGCCC 
                           *** * *****  **** ****  * ***   *** ****  *  ** ** 
 
Canine_A4_Normal_5-21      CCCAGGCAGAACAGGACCCAGGGGACAACCAGGTCTGGGATTTCCTGGTC 
Human_COL4A4               CCCAGGCAAAGCAGGACCTGTTGGGCCCCCAGGACTGGGATTTCCTGGTC 
Mouse_COL4A4               TCCAGGAAGAACAGGACCTGAGGGGCCTCCAGGCCTGGGATTTCCAGGCC 
                            ***** * * *******    ** *  ***** *********** ** * 
 
Canine_A4_Normal_5-21      CACCAGGAGAGAGAGGACAACCAGGAGCTCCAGGCCGCCCTGGCGAGAGG 
Human_COL4A4               CACCAGGAGAGCGAGGCCACCCAGGAGTTCCAGGCCACCCAGGTGTGAGG 
Mouse_COL4A4               CACCAGGACAGCGAGGCCTACCCGGAGAGCCCGGGCGTCCGGGCACCAGA 
                           ******** ** **** *  ** ****  ** ** *  ** **    **  
 
Canine_A4_Normal_5-21      GGCTTCGGGGGCTTGAAGGGCCAGAAAGGTGATACAATTTCTTGTAATGT 
Human_COL4A4               GGCCCTGATGGCTTAAAGGGTCAGAAAGGTGACACAATTTCTTGCAACGT 
Mouse_COL4A4               GGCTTTGATGGCACGAAGGGGCAGAAAGGTGACTCCATTCTGTGTAATGT 
                           ***   *  ***   ***** ***********  * ***   ** ** ** 
 
Canine_A4_Normal_5-21      CACCTACCCTGGGAGGCCAGGACCCCCAGGTTTTGATGGACCTCCAGGAC 
Human_COL4A4               AACCTACCCTGGGAGGCATGGCCCTCCAGGTTTTGATGGACCTCCAGGTC 
Mouse_COL4A4               AAGCTACCCGGGAAAACCAGGTCTGCCAGGTCTTGATGGACCTCCAGGTC 
                            * ****** ** *  *  ** *  ****** **************** * 
 
Canine_A4_Normal_5-21      CAAAGGGATTTCCAGGTCCTCAAGGCGCTCCAGGGTTGAGGTGCTTGGAT 
Human_COL4A4               CGAAGGGATTTCCAGGTCCCCAAGGTGCCCCTGGGCTGAGTGGTTCAGAT 
Mouse_COL4A4               TGAAGGGGTTTCCAGGCCCCCCAGGGGCTCCTGGTATGAGATGTCCAGAT 
                             ***** ******** ** * *** ** ** **  ****  *    *** 
 
Canine_A4_Normal_5-21      GGGCCAAAAGGTCAGCGTGGCAAACCAGGAATGTCAGAGATACCCGGTCC 
Human_COL4A4               GGGCATAAAGGCAGACCTGGCACACCAGGAACAGCGGAAATACCAGGTCC 
Mouse_COL4A4               GGGCAGAAAGGCCAGCGGGGCAAACCGGGAATGTCTGGGATTCCAGGTCC 
                           ****  *****    *  **** *** ****   * *  ** ** ***** 
 
Canine_A4_Normal_5-21      ACCTGGTTTTCGTGGTGACATGGGAGATCCGGGTTTTGAAGGTGAAAAGG 
Human_COL4A4               ACCTGGTTTTCGTGGTGACATGGGAGATCCGGGTTTTGGAGGTGAAAAGG 
Mouse_COL4A4               ACCTGGTTTTCGTGGTGACATGGGAGATCCAGGCATCAAAGGTGAAAAGG 
                           ****************************** **  *   *********** 
 
Canine_A4_Normal_5-21      GGTCCTCCCTTCTTGGGCCGCCAGGCTTTCCTGGTTCTCGTGGAGCAAAT 
Human_COL4A4               GGTCCTCCCCTGTTGGGCCCCCAGGCCCTCCCGGCTCACCAGGAGTGAAT 
Mouse_COL4A4               GGACCTCCCCTATTGGACCCCCAGGCCCACCTGGGTCTCCTGGAAAGGAT 
                           ** ****** * **** ** ******   ** ** ** *  ***    ** 
 
Canine_A4_Normal_5-21      GGTCAGAAAGGAATGATGGGAGACATTGCCTATGGCCTCCCAGGCCCCCC 
Human_COL4A4               GGTCAGAAAGGAATCCCGGGAGACCCTGCATTTGGTCACCTGGGACCCCC 
Mouse_COL4A4               GGCCAGAAAGGAATCCCAGGAGACCCTGCATTTGGTGACCCAGGACCCCC 
                           ** ***********    ******  *** * ***   **  ** ***** 
 
Canine_A4_Normal_5-21      AGGAAAGAGAGGTCCTTCCGGAGTGCCAGGGTCCAAAGGACACAGAGGTG 
Human_COL4A4               GGGAAAGAGGGGTCTTTCAGGAGTGCCAGGGATAAAAGGACCCAGAGGTG 
Mouse_COL4A4               TGGAGAGAGGGGTCTTCCAGGAGCACCAGGCATGAAAGGACAGAAAGGTC 
                            *** **** **** * * ****  *****    *******  * ****  
 
Canine_A4_Normal_5-21      ATTCAGGACGTCCAGGGTTTGCAGGGCCAGCCGGCAAGCCTGGATCCCCA 
Human_COL4A4               ATCCGGGATGTCCAGGGGCTGAAGGGCCAGCTGGCATTCCTGGATTCCTA 
Mouse_COL4A4               ACCCAGGGTGCCCAGGGGCTGGAGGCCCTCCTGGCATCCCTGGATCTCCA 




Canine_A4_Normal_5-21      GGTCTCAAAGGTCCCAGAGGCAGAGAGGGAAGTGCTGGGTTTCAAGGTAT 
Human_COL4A4               GGTCTCAAAGGTCCCAAAGGCAGAGAGGGACATGCTGGGTTTCCAGGTGT 
Mouse_COL4A4               GGTCTCAAAGGTCCCAAAGGTAGAGAGGGAAGTCGTGGCTTTCCAGGGAT 
                           **************** *** *********  *  *** **** ***  * 
 
Canine_A4_Normal_5-21      CCCGGGTCCACCTGGCCATTCCTGCAAAAGAGGCGCTCCAGGGATACCAG 
Human_COL4A4               CCCAGGTCCACCTGGCCATTCCTGTGAAAGAGGTGCTCCAGGGATACCAG 
Mouse_COL4A4               CCCAGGATCCCCTGGCCATTCCTGTGAAAGAGGTGCTCCCGGGATCCCAG 
                           *** **  * **************  ******* ***** ***** **** 
 
Canine_A4_Normal_5-21      GGCAACCGGGGCTCCCTGGGGCCCCGGGGAGTCCAGGTGCCCCAGGTTGG 
Human_COL4A4               GGCAACCGGGACTCCCTGGGTATCCAGGTAGCCCAGGTGCTCCAGGTGGG 
Mouse_COL4A4               GACAACCGGGACTTCCTGGAACTCCAGGTGATCCAGGGGCCCCAGGTTGG 
                           * ******** ** *****    ** **    ***** ** ****** ** 
 
Canine_A4_Normal_5-21      AAAGGACAGCGAGGGGATGTGGGGCCTCCGGGTCCAGCTGGAATGAAAGG 
Human_COL4A4               AAAGGACAGCCGGGAGATGTGGGGCCTCCCGGGCCAGCTGGAATGAAAGG 
Mouse_COL4A4               AAAGGCCAGCCAGGAGACATGGGTCCCTCTGGACCAGCTGGGATGAAGGG 
                           ***** ****  ** **  **** **  * ** ******** ***** ** 
 
Canine_A4_Normal_5-21      CCTCCCTGGAGTCCCTGGACGGCCAGGGGCAGAGGGACCCCTAGGATTCC 
Human_COL4A4               CCTCCCCGGACTCCCAGGACGGCCTGGGGCACATGGTCCCCCAGGCCTCC 
Mouse_COL4A4               CCTCCCTGGTCTCCCAGGCCTACCAGGAGCTGATGGTCTCCGAGGGCCTC 
                           ****** **  **** ** *  ** ** **  * ** * ** ***    * 
 
Canine_A4_Normal_5-21      CAGGAGTCCCAGGCCCCTTAGGGGATGATGGGCTGCCTGGTCTTCCAGGC 
Human_COL4A4               CAGGAATCCCAGGTCCCTTTGGAGATGATGGGCTACCTGGTCCTCCAGGT 
Mouse_COL4A4               CTGGGATTCCAGGCCCCAATGGGGAAGATGGTCTACCTGGTCTTCCAGGC 
                           * **  * ***** ***   ** ** ***** ** ******* ******  
 
Canine_A4_Normal_5-21      CCGAAGGGACCCCAGGGGCTGCCTGGCTTCCCCGGTTTTCCAGGGGAGAG 
Human_COL4A4               CCAAAGGGACCCCGGGGGCTGCCTGGTTTCCCAGGTTTTCCCGGAGAAAG 
Mouse_COL4A4               CTGAAGGGACTCCCAGGGCTGCCTGGCTTCCCTGGTTTTCCAGGAGAGAG 
                           *  ******* **  *********** ***** ******** ** ** ** 
 
Canine_A4_Normal_5-21      AGGAAAGCCTGGCCCAGAGGGACGCCCTGGCAGCAAGGGGGAACCAGGAG 
Human_COL4A4               AGGAAAGCCTGGTGCAGAGGGATGTCCTGGCGCAAAGGGAGAACCTGGAG 
Mouse_COL4A4               AGGAAAGCCAGGGCCAGATGGAGAACCTGGAAGAAAGGGAGAGGTTGGAG 
                           ********* **  **** ***   *****    ***** **    **** 
 
Canine_A4_Normal_5-21      AGGATGGTCGGCCTGGCTTCTTCGGAGACCAAGGGGTGAAAGGTGCCAAA 
Human_COL4A4               AGAAGGGCATGTCTGGCCTTCCTGGAGACCGGGGACTGAGAGGGGCCAAA 
Mouse_COL4A4               AGAAAGGCTGGCCTGGCTTGAAGGGAGACCTGGGAGAGCGAGGCGCCAAA 
                           ** * **   * ***** *    *******  **   *  *** ****** 
 
Canine_A4_Normal_5-21      GGAGCGAGAGGACCCCCAGGAGATGAAGGAGAGATGGCGGTCTTTTCCCA 
Human_COL4A4               GGAGCCATAGGACCTCCCGGAGATGAAGGAGAAATGGCTATCATTTCACA 
Mouse_COL4A4               GGAGACAGAGGACTTCCTGGTGATGCAGGAGAA---GCAGTCACTTCCAG 
                           ****  * *****  ** ** **** ******    **  **  ***    
 
Canine_A4_Normal_5-21      AAAAGGGAAAACCGGGGAACCTGGACCTCCAGGAGATGATGGATTCCCAG 
Human_COL4A4               AAAGGGAACACCTGGGGAACCTGGACCTCCTGGAGATGATGGATTCCCAG 
Mouse_COL4A4               AAAGGGTGAACCTGGGGATGCTGGGCCTCCAGGAGATGGTGGGTTCTCAG 
                           *** **   * * *****  **** ***** ******* *** *** *** 
 
Canine_A4_Normal_5-21      GAGAAGAAGGTGATAAAGGCAATCCAGGGATGCCGGGGAGGAGAGGAGAG 
Human_COL4A4               GAGAAAGAGGTGATAAAGGAACTCCCGGGATGCAAGGGAGAAGAGGAGAG 
Mouse_COL4A4               GAGAGAGAGGTGATAAAGGAAGCTCAGGGATGCGAGGGGGAAGAGGGGAT 
                           ****   ************ *   * *******  *** * ***** **  
 
Canine_A4_Normal_5-21      CCTGGAAGATTCGGAGCACCTGGATTTCACAGAGGGGAGCCCGGGAGAAC 
Human_COL4A4               CTGGGAAGATACGGACCACCTGGATTTCACAGAGGGGAACCTGGTGAGAA 
Mouse_COL4A4               CCCGGAAGAGATGGACTACCGGGACTCCACAGAGGGCAGCCTGGGATAGA 
                           *  ******   ***  *** *** * ********* * ** **       
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Canine_A4_Normal_5-21      CGGGCAGCCAGGGCTTCCTGGCCCCCCAGGCCCCCCAGGCTCACCTGGGC 
Human_COL4A4               AGGTCAGCCAGGGCCTCCTGGACCCCCAGGCCCTCCAGGCTCAACTGGTC 
Mouse_COL4A4               TGGGCCTCCTGGGCCTCCTGGGCCCCCTGGCCCTCCAGGATCACCTGGAC 
                            ** *  ** **** ****** ***** ***** ***** *** **** * 
 
Canine_A4_Normal_5-21      TGAGAGGGATTATTGGTTTTCCGGGATTTCCAGGTGACCAGGGTGAGCCA 
Human_COL4A4               TAAGAGGGTTCATTGGTTTTCCAGGACTTCCAGGTGACCAGGGTGAGCCA 
Mouse_COL4A4               TGAGAGGAGTCATTGGTTTCCCAGGATTTCCAGGTGACCAGGGTGATCCA 
                           * *****  * ******** ** *** ******************* *** 
 
Canine_A4_Normal_5-21      GGTTCTCCAGGGTCTCCTGGACTTTCAGGAATTGATGGAATGAGAGGACC 
Human_COL4A4               GGTTCTCCAGGTCCCCCTGGATTTTCAGGAATTGATGGAGCAAGAGGACC 
Mouse_COL4A4               GGTTCTCCAGGACCCCCTGGATTCCCAGGAGATGATGGAGCAAGAGGACC 
                           ***********  * ****** *  *****  *******   ******** 
 
Canine_A4_Normal_5-21      TAAAGGAAGCAAAGGTGACCCTGCAAGTCAGTTCGGCCCACCTGGTCCAA 
Human_COL4A4               TAAAGGAAACAAAGGTGACCCTGCCAGTCACTTTGGTCCACCTGGTCCAA 
Mouse_COL4A4               TAAAGGATACAAAGGTGACCCTGCCAGTCAGTGTGGTCCACCTGGTCCAA 
                           *******  *************** ***** *  ** ************* 
 
Canine_A4_Normal_5-21      AGGGTGAACCAGGTAGCCCTGGATGTCCAGGACAAGTTGGAGCACCTGGA 
Human_COL4A4               AGGGTGAGCCAGGTAGCCCTGGATGTCCAGGGCATTTTGGAGCATCCGGA 
Mouse_COL4A4               AGGGTGAGCCAGGTAGTCCTGGATACCAAGGACGTACTGGAGTCCCCGGA 
                           ******* ******** *******  * *** *    *****   * *** 
 
Canine_A4_Normal_5-21      GAGCAGGGCTTGCCTGGTGTTCAAGGGCTCAGAGGACCACCTGGAAGGCC 
Human_COL4A4               GAGCAGGGCTTGCCTGGTATTCAAGGGCCCAGAGGATCACCTGGAAGGCC 
Mouse_COL4A4               GAGAAAGGCTTTCCTGGAGATGAAGGACCCCGAGGACCACCAGGCAGACC 
                           *** * ***** *****   * **** * * ***** **** ** ** ** 
 
Canine_A4_Normal_5-21      AGGATTACCTGGCTCCTCCGGACCACCAGGGTGTCCAGGTAATCAAGGGG 
Human_COL4A4               AGGGCCACCTGGCTCCTCTGGACCACCAGGGTGCCCAGGTGATCACGGGA 
Mouse_COL4A4               TGGACAGCCTGGATCTTTTGGACCACCAGGGTGTCCAGGTGACCCAGGGA 
                            **    ***** ** *  ************** ****** * *  ***  
 
Canine_A4_Normal_5-21      TGCCTGGGCTGACAGGGCCTCCAGGAGAAACAGGGGATCCTGGGCCAAGA 
Human_COL4A4               TGCCTGGGCTGAGGGGACAGCCAGGAGAAATGGGAGACCCTGGGCCAAGA 
Mouse_COL4A4               TGCCCGGACTCAAGGGACATCCAGGAGAAGTGGGAGACCCTGGGCCAAGA 
                           **** ** ** *  ** *  *********   ** ** ************ 
 
Canine_A4_Normal_5-21      GGCATGATGGGAGATCCAGGGCCACCAGGTCTTCCAGGAATAAAAGGTCC 
Human_COL4A4               GGCCTCCAGGGGGATCCAGGGATACCAGGTCCTCCGGGAATAAAAGGTCC 
Mouse_COL4A4               GGTGATGCGGGAGATTTCGGGAGGCCAGGTCCTGCTGGAGTGAAAGGGCC 
                           **      *** ***   ***   ******* * * *** * ***** ** 
 
Canine_A4_Normal_5-21      CTCCGGGTCGCCGGGTCTGAATGGCTTGCATGGTTTAAAGGGTCAGAAAG 
Human_COL4A4               CTCCGGATCACCTGGCCTGAACGGCTTGCATGGATTGAAAGGTCAGAAAG 
Mouse_COL4A4               TCTCGGGTCTCCTGGTCTGAATGGCTTACATGGTCTGAAGGGTGAGAAAG 
                              *** ** ** ** ***** ***** *****  * ** *** ****** 
 
Canine_A4_Normal_5-21      GAGCCAAAGGTGCTTCAGGTTTGCACGAAGTGGGCCCACCCGGTCCAGTG 
Human_COL4A4               GAACTAAAGGTGCTTCAGGTTTGCATGATGTGGGGCCACCTGGTCCAGTG 
Mouse_COL4A4               GAACAAAAGGCGCCTCAGGTTTGCTCGAAATGGGTCCACCTGGGCCAATG 
                           ** * ***** ** **********  **  **** ***** ** *** ** 
 
Canine_A4_Normal_5-21      GGCGTACCTGGGCTGAAAGGGGAGCCGGGAGACCCTGGGAGCCCAGGAAT 
Human_COL4A4               GGAATACCTGGGCTAAAAGGGGAGAGAGGAGACCCTGGGAGCCCAGGAAT 
Mouse_COL4A4               GGGATGCCTGGGCAAAAAGGAGAGAAAGGAGACCCTGGGAGTCCAGGGAT 
                           **  * *******  ***** ***   ************** ***** ** 
 
Canine_A4_Normal_5-21      TTCTCCCCCAGGCCTTTCTGGAGAAAGAGGCCCCCCCGGCCCCCCAGGGA 
Human_COL4A4               CTCTCCTCCAGGTCCTCGTGGAAAGAAAGGTCCCCCAGGACCCCCAGGGA 
Mouse_COL4A4               TTCTCCTCCAGGTCTTCCTGGAGAAAAGGGCTTCCCAGGACCCCCAGGGA 




Canine_A4_Normal_5-21      GACCTGGAGCCCCTGGTCCTGCAGGTGCCACAGGAAGAGCTGCTGAAGGT 
Human_COL4A4               GTTCAGGACCACCTGGTCCTGCAGGTGCCACAGGAAGAGCTCCTAAGG-- 
Mouse_COL4A4               GACCAGGACCACCTGGTCCCGCAGGTGCCCCAGGAAGAGCTGCTAAAGGT 
                           *  * *** * ******** ********* *********** ** * *   
 
Canine_A4_Normal_5-21      CACGTTCCTGACCCAGGTCCACCCGGAGATGTGGGTCCTCCTGGCCCCGA 
Human_COL4A4               -ACATTCCTGACCCGGGTCCACCTGGAGATCAGGGACCTCCTGGTCCTGA 
Mouse_COL4A4               GACATTCCTGATCCAGGTCCACCTGGAGACCGGGGACCTCCTGGCCCCGA 
                            ** ******* ** ******** *****   *** ******** ** ** 
 
Canine_A4_Normal_5-21      TGGTCCGAGAGGAGCGCCCGGGCCCCCAGGCCCCCCTGGGAGCGTTGACC 
Human_COL4A4               TGGCCCAAGAGGAGCACCTGGGCCTCCAGGCCTCCCTGGGAGTGTTGACC 
Mouse_COL4A4               TGGCCCAAGAGGAGTACCTGGGCCTCCGGGTTCCCCTGGGAATGTTGACC 
                           *** ** *******  ** ***** ** **   ********  ******* 
 
Canine_A4_Normal_5-21      TTCTGAGAGGGGAACCAGGAGACTGTGGGCCGCCGGGGCCTCCAGGTCCC 
Human_COL4A4               TTCTGAGAGGGGAGCCAGGTGACTGTGGTCTACCAGGGCCACCAGGTCCC 
Mouse_COL4A4               TTCTGAAAGGGGACCCAGGTGACTGTGGTTTGCCAGGACCACCTGGCTCC 
                           ****** ****** ***** ********    ** ** ** ** **  ** 
 
Canine_A4_Normal_5-21      CCGGGCCCACCCGGCCCTCCAGGACACCAAGGCTTCCCAGGATGCGATGG 
Human_COL4A4               CCTGGCCCACCAGGCCCTCCAGGATACAAAGGCTTTCCAGGATGTGATGG 
Mouse_COL4A4               CGAGGCCCACCAGGCCCTCCAGGGTGTCAGGGTCCCCCAGGATGTGATGG 
                           *  ******** ***********     * **    ******** ***** 
 
Canine_A4_Normal_5-21      AAAAGACGGCCAGAAAGGACCAATAGGATTCCCGGGGCTGCAGGGGCCTC 
Human_COL4A4               AAAAGATGGCCAGAAAGGACCAATGGGATTCCCGGGACCGCAGGGACCAC 
Mouse_COL4A4               CAAAGATGGCCAGAAAGGACCAATGGGACTTCCAGGGTTGCCAGGGCCAC 
                            ***** ***************** *** * ** **   **  ** ** * 
 
Canine_A4_Normal_5-21      AGGGACTTCCTGGGCTCCCTGGGGAGAAGGGTCTGCTGGGCATTCCAGGC 
Human_COL4A4               ATGGATTTCCTGGGCCACCTGGAGAGAAGGGTTTACCTGGACCTCCAGGG 
Mouse_COL4A4               CTGGTCTTCCTGGGGCACCTGGCGAGAAGGGATTACCTGGCCCTCCAGGC 
                             **  ********   ***** ********  * *  **   ******  
 
Canine_A4_Normal_5-21      CGGCGAGGGCACCCCGGTCCTCCAGGTTCCAGAGGTGAACCAGGGCCTCC 
Human_COL4A4               AGAAAAGGGCCCACTGGTCTTCCAGGTCCCAGAGGTGAACCGGGGCCACC 
Mouse_COL4A4               AGAAAAGGGCCAGTAGGTCCTCCAGGCTGCAGAGGTGAACCTGGGCCTCC 
                            *   *****     **** ******   ************ ***** ** 
 
Canine_A4_Normal_5-21      TGCAGATGTGGATTCGTGCCCCCGCATCCCCGGGCTTCCTGGGGTACCAG 
Human_COL4A4               TGCAGATGTGGATGACTGTCCCCGAATCCCAGGCCTTCCTGGGGCGCCAG 
Mouse_COL4A4               TGCAGACGTGGATTCCTGTCCTCGAATCCCAGGACTTCCTGGAGTGCCAG 
                           ****** ******   ** ** ** ***** ** ******** *  **** 
 
Canine_A4_Normal_5-21      GCCCAAGAGGACCAGAAGGAGCCATGGGGGTCCCTGGAAGGAGAGGGCCC 
Human_COL4A4               GCATGAGAGGACCAGAAGGAGCCATGGGGCTCCCTGGAATGAGAGGCCCC 
Mouse_COL4A4               GTCCCAGAGGACCAGAAGGAGCTATGGGGGAACCTGGACGGAGAGGCCTG 
                           *    ***************** ******   ******  ****** *   
 
Canine_A4_Normal_5-21      CCAGGACCAGGGTGCAAAGGAGAGCCGGGACTGGAGGGCAGGAGGGGCGA 
Human_COL4A4               CCAGGACCAGGGTGCAAAGGAGAGCCTGGGCTGGATGGCAGGAGGGGTGT 
Mouse_COL4A4               CCTGGACCAGGGTGCAAAGGAGAGCCTGGACCGGATGGCAGACGGGGCCA 
                           ** *********************** ** * *** *****  ****    
 
Canine_A4_Normal_5-21      GGCCGGCCTCCCAGGACCTCCGGGGCCTCCCGGAAGCACAGGGGACGCAG 
Human_COL4A4               GGATGGCGTCCCTGGGTCTCCTGGGCCTCCCGGACGTAAAGGTGACACAG 
Mouse_COL4A4               GGATGGCATCCCTGGATCTCCCGGGCCTCCTGGACGCAAAGGTGACACTG 
                           **  *** **** **  **** ******** *** * * *** *** * * 
 
Canine_A4_Normal_5-21      GAGAAGCCGGTTGCCCCGGAGCACCAGGGCCCCCCGGGCCCATTGGGGAC 
Human_COL4A4               GAGAAGACGGCTACCCTGGAGGACCAGGGCCTCCTGGTCCCATTGGGGAT 
Mouse_COL4A4               GAGAGGCAGGGTGTCCTGGAGCACCAGGCCCTCCTGGTCCAACTGGTGAT 
                           **** *  ** *  ** **** ****** ** ** ** ** * *** **  
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Canine_A4_Normal_5-21      CCCGGGCCCAGAGGGTTTGGGCCTGGATACCTCAGTGGCTTCCTCCTGGT 
Human_COL4A4               CCTGGGCCCAAAGGGTTTGGCCCTGGATACCTCGGTGGCTTCCTCCTGGT 
Mouse_COL4A4               CCTGGGCCCAAGGGGTTTGGCCCTGGATCGCTCAGTGGCTTCCTCCTGGT 
                           ** *******  ******** *******  *** **************** 
 
Canine_A4_Normal_5-21      TCTCCACAGTCAGACGGATGGGGAGCCCACCTGCCCCGCGGGCATGCCCA 
Human_COL4A4               TCTCCACAGTCAGACGGACCAGGAGCCCACCTGCCCCCTGGGCATGCCCA 
Mouse_COL4A4               TCTCCACAGTCAGACTGACCAGGAACCGGCCTGCCCCGTGGGCATGCCTC 
                           *************** **   *** **  ********  *********   
 
Canine_A4_Normal_5-21      GGCCCTGGACGGGCTACAGTCTGTTATACCTGGAAGGACAGGAGAAGGCC 
Human_COL4A4               GGCTCTGGACTGGGTATAGTCTGTTATACCTGGAAGGGCAAGAGAAAGCT 
Mouse_COL4A4               GGCTTTGGACAGGGTACAGCTTGTTGTACATGGAAGGACAGGAGAAGGCG 
                           ***  ***** ** ** **  **** *** ******* ** ***** **  
 
Canine_A4_Normal_5-21      CACAATCAGGACCTTGGTCTGGCAGGGTCTTGCCTTCCCATGTTCAGCAC 
Human_COL4A4               CACAATCAAGACCTTGGTCTGGCAGGGTCTTGCCTTCCCGTATTTAGCAC 
Mouse_COL4A4               CACAATCAAGATCTTGGTTTGGCAGGCTCTTGTCTTCCTGTGTTTAGCAC 
                           ******** ** ****** ******* ***** *****  * ** ***** 
 
Canine_A4_Normal_5-21      CCTGCCCTTTGCCTACTGCAACATCCACCAAGTGTGCCACTACGCCCGGA 
Human_COL4A4               GCTGCCCTTTGCCTACTGCAACATCCACCAGGTGTGCCACTATGCCCAGA 
Mouse_COL4A4               TCTGCCCTTTGCCTACTGCAACATCCACCAAGTGTGCCACTACGCCCAGA 
                            ***************************** *********** **** ** 
 
Canine_A4_Normal_5-21      GAAACGACCGGTCCTACTGGCTGGCCAGTGCTGCGCCCCTGCCCATGATG 
Human_COL4A4               GAAACGACAGATCCTACTGGCTGGCCAGCGCTGCGCCCCTCCCCATGATG 
Mouse_COL4A4               GAAATGACAGGTCCTACTGGCTGTCCAGTGCGGCTCCTCTTCCTATGATG 
                           **** *** * ************ **** ** ** ** ** ** ****** 
 
Canine_A4_Normal_5-21      CCGCTCTCAGAGGAGGAGATCCGCCCCTACATCAGCCGCTGTGCCGTGTG 
Human_COL4A4               CCACTCTCTGAAGAGGCGATCCGCCCCTATGTCAGCCGCTGTGCGGTATG 
Mouse_COL4A4               CCACTCTCAGAGGAAGAGATCCGCTCTTACATCAGCCGCTGTGCGGTGTG 
                           ** ***** ** ** * ******* * **  ************* ** ** 
 
Canine_A4_Normal_5-21      CGAGGCCCCAGCCCCCGTGGTGGCGCTGCACAGCCAGGACCGGTCCATCC 
Human_COL4A4               CGAGGCCCCGGCCCAGGCGGTGGCGGTGCACAGCCAGGACCAGTCCATCC 
Mouse_COL4A4               TGAGGCCCCAGCACAGGCCGTGGCGGTCCACAGTCAGGACCAATCCATCC 
                            ******** ** *  *  ****** * ***** *******  ******* 
 
Canine_A4_Normal_5-21      CGCCGTGTCCACGGAGCTGGAGGAGCCTCTGGATCGGGTACTCGTTCCTG 
Human_COL4A4               CCCCATGTCCGCAGACCTGGAGGAGCCTCTGGATCGGGTATTCATTCCTG 
Mouse_COL4A4               CACCGTGTCCACGGACATGGAGGAGTCTCTGGATTGGGTACTCATTTCTG 
                           * ** ***** * **  ******** ******** ***** ** ** *** 
 
Canine_A4_Normal_5-21      ATGCACACAGGGGCTGGAGACCAAGGAGGAGGGCAGGCCCTCATGTCCCC 
Human_COL4A4               ATGCACACAGGAGCTGGGGACCAAGGAGGAGGGCAGGCCCTTATGTCACC 
Mouse_COL4A4               ATGCACACTGGAGCTGGGGACCAAGGAGGTGGGCAGGCACTGATGTCACC 
                           ******** ** ***** *********** ******** ** ***** ** 
 
Canine_A4_Normal_5-21      CGGCAGCTGTCTGGAAGATTTCCGAGCCGCACCGTTCCTCGAATGCCAAG 
Human_COL4A4               TGGCAGCTGCCTGGAAGATTTCAGAGCAGCACCATTCCTTGAATGCCAGG 
Mouse_COL4A4               TGGCAGCTGCCTAGAGGACTTCAGAGCTGCACCGTTCGTTGAATGCCAGG 
                            ******** ** ** ** *** **** ***** *** * ******** * 
 
Canine_A4_Normal_5-21      GCCGACAGGGAACTTGCCACTTTTTTGCAAATGAGTATAGCTTCTGGCTG 
Human_COL4A4               GCCGGCAGGGAACTTGCCACTTTTTCGCAAATAAGTATAGCTTCTGGCTC 
Mouse_COL4A4               GCCGACAGGGAACCTGTCACTTTTTTGCAAACGAGTACAGCTTCTGGCTG 
                           **** ******** ** ******** *****  **** ***********  
 
Canine_A4_Normal_5-21      ACGACGGTGAGGCCTGACTTGCAGTTTTCCTCGGCACCATCACCAGACAC 
Human_COL4A4               ACAACGGTGAAAGCAGACTTGCAGTTTTCCTCTGCTCCAGCACCAGACAC 
Mouse_COL4A4               ACCACCGTGAACCCAGACCTGCAGTTTGCCTCTGGCCCGTCACCAGACAC 




Canine_A4_Normal_5-21      CTTGAAAGAAAGCCAGGCCCAGCGCCAGAAAATCAGCAGGTGCCAGGTAT 
Human_COL4A4               CTTAAAAGAAAGCCAGGCCCAACGCCAGAAAATCAGCCGGTGCCAGGTCT 
Mouse_COL4A4               CTTGAAAGAAGTTCAGGCCCAGCGCCGGAAAATCAGCAGGTGCCAGGTTT 
                           *** ******   ******** **** ********** ********** * 
 
Canine_A4_Normal_5-21      GCAT-----ATGACTAGT 
Human_COL4A4               GCGTGAAGTATAGCTAG- 
Mouse_COL4A4               GCATGAAGCACAGCTAA- 









Canine COL4A4 amino acid sequence alignments 
 
Consensus key (see documentation for details) 
* - single, fully conserved residue 
: - conservation of strong groups 
. - conservation of weak groups 
  - no consensus 
 
 
CLUSTAL W (1.81) multiple sequence alignment 
 
 
Canine_A4_Normal_5-21_Transl      RIYSYGCESLLEEKRNLTIFFKSQDLTVRSMHMASVKCSFRWIKPLARDP 
Human_COL4A4_Translated_-_Fr      ---------------------------MWSLHIVLMRCSFRLTKSLATGP 
Mouse_COL4A4_Translated_-_Fr      -----------------------------------MRCFFRWTKSFVTAP 
                                                                     ::* **  *.:.  * 
 
Canine_A4_Normal_5-21_Transl      WSLIFILFSVQHAYGSGKKFVGPCGGRDCSVCHCFPEKGSRGQPGPPGPQ 
Human_COL4A4_Translated_-_Fr      WSLILILFSVQYVYGSGKKYIGPCGGRDCSVCHCVPEKGSRGPPGPPGPQ 
Mouse_COL4A4_Translated_-_Fr      WSLIFILFTIQYEYGSGKKYGGPCGGRNCSVCQCFPEKGSRGHPGPLGPQ 
                                  ****:***::*: ******: ******:****:*.******* *** *** 
 
Canine_A4_Normal_5-21_Transl      GPIGPLGLPGPTGIPGEKGMRGDSGPPGAAGDKGDKGPTGVPGFPGLDGI 
Human_COL4A4_Translated_-_Fr      GPIGPLGAPGPIGLSGEKGMRGDRGPPGAAGDKGDKGPTGVPGFPGLDGI 
Mouse_COL4A4_Translated_-_Fr      GPIGPLGPLGPIGIPGEKGERGDSGSPGPPGEKGDKGPTGVPGFPGVDGV 
                                  *******  ** *:.**** *** *.**..*:**************:**: 
 
Canine_A4_Normal_5-21_Transl      PGHPGPPGSRGKPGMHGYNGSRGDPGFPGKRGVPGPGGPPGLPGERGEKG 
Human_COL4A4_Translated_-_Fr      PGHPGPPGPRGKPGMSGHNGSRGDPGFPGGRGALGPGGPLGHPGEKGEKG 
Mouse_COL4A4_Translated_-_Fr      PGHPGPPGPRGKPGVDGYNGSRGDPGYPGERGAPGPGGPPGQPGENGEKG 
                                  ********.*****: *:********:** **. ***** * ***.**** 
 
Canine_A4_Normal_5-21_Transl      NSVFILGAIKGIQGDRGDPDLPGLPGPKGAGGPAGPKGQPGEPGLTGAPG 
Human_COL4A4_Translated_-_Fr      NSVFILGAVKGIQGDRGDPGLPGLPGSWGAGGPAGPTGYPGEPGLVGPPG 
Mouse_COL4A4_Translated_-_Fr      RSVYITGGVKGIQGDRGDPGPPGLPGSRGAQGSPGPMGHAGAPGLAGPIG 
                                  .**:* *.:**********. *****. ** *..** * .* ***.*. * 
 
Canine_A4_Normal_5-21_Transl      HPGRPGLKGNPGVGVKGQMGDPGEVGQQGSPGPTLLVQPPDSCLYKGEKG 
Human_COL4A4_Translated_-_Fr      QPGRPGLKGNPGVGVKGQMGDPGEVGQQGSPGPTLLVEPPDFCLYKGEKG 
Mouse_COL4A4_Translated_-_Fr      HPGSPGLKGNPATGLKGQRGEPGEVGQRGPPGPTLLVQPPDLSIYKGEKG 
                                  :** *******..*:*** *:******:*.*******:*** .:****** 
 
Canine_A4_Normal_5-21_Transl      IKGMPGMIGPPGLPGPKGEPGIGPKGEKGIPGFSGPRGDPGSYGSPGFPG 
Human_COL4A4_Translated_-_Fr      IKGIPGMVGLPGPPGRKGESGIGAKGEKGIPGFPGPRGDPGSYGSPGFPG 
Mouse_COL4A4_Translated_-_Fr      VKGMPGMIGPPGPPGRKGAPGVGIKGEKGIPGFPGPRGEPGSHGPPGFPG 
                                  :**:***:* ** ** ** .*:* *********.****:***:*.***** 
 
Canine_A4_Normal_5-21_Transl      LKGKPGLFGDPGSFGFVGPKGDPGDRGYPGPPGVLVTPSVPLKGPPGDPG 
Human_COL4A4_Translated_-_Fr      LKGELGLVGDPGLFGLIGPKGDPGNRGHPGPPGVLVTPPLPLKGPPGDPG 
Mouse_COL4A4_Translated_-_Fr      FKGIQGAAGEPGLFGFLGPKGDLGDRGYPGPPGILLTPAPPLKGVPGDPG 
                                  :**  *  *:** **::***** *:**:*****:*:**. **** ***** 
 
Canine_A4_Normal_5-21_Transl      RPGHYGEMGSVGPPGPPGPPGPPGEDCAGMMGPPGPRGFPGHPGFPGAAG 
Human_COL4A4_Translated_-_Fr      FPGRYGETGDVGPPGPPGLLGRPGEACAGMIGPPGPQGFPGLPGLPGEAG 
Mouse_COL4A4_Translated_-_Fr      PPGYYGEIGDVGLPGPPGPPGRPGETCPGMMGPPGPPGVPGPPGFPGEAG 
                                   ** *** *.** *****  * *** *.**:***** *.** **:** ** 
 
Canine_A4_Normal_5-21_Transl      IPGRADLSPGKPGKPGPPGLPGAPGLQGPPGSDVIYCSVGHPGPQGIKGK 
Human_COL4A4_Translated_-_Fr      IPGRPDSAPGKPGKPGSPGLPGAPGLQGLPGSSVIYCSVGNPGPQGIKGK 
Mouse_COL4A4_Translated_-_Fr      VPGRLDCAPGKPGKPGLPGLPGAPGPEGPPGSDVIYCRPGCPGPMGEKGK 




Canine_A4_Normal_5-21_Transl      MGPPGRRGSKGEKGNAGLCACEPGPMGPPGPPGLPGRQGSKGDLGLPGWI 
Human_COL4A4_Translated_-_Fr      VGPPGGRGPKGEKGNEGLCACEPGPMGPPGPPGLPGRQGSKGDLGLPGWL 
Mouse_COL4A4_Translated_-_Fr      VGPPGRRGAKGAKGNKGLCTCPPGPMGPPGPPGPPGRQGSKGDLGLPGWH 
                                  :**** **.** *** ***:* *********** ***************  
 
Canine_A4_Normal_5-21_Transl      GEKGHPGPPGAEGSPGSPGKHGASGPPGSKGEKGDRVVSRVKGKKGERGP 
Human_COL4A4_Translated_-_Fr      GTKGDPGPPGAEGPPGLPGKHGASGPPGNKGAKGDMVVSRVKGHKGERGP 
Mouse_COL4A4_Translated_-_Fr      GEKGDPGQPGAEGPPGPPGRPGAMGPPGHKGEKGDMVISRVKGQKGERGL 
                                  * **.** *****.** **: ** **** ** *** *:*****:*****  
 
Canine_A4_Normal_5-21_Transl      DGLPGFPGQQGQNGRDGLPGKKGDPGPPGGHEDAAPGAKGSPGPPGPPGR 
Human_COL4A4_Translated_-_Fr      DGPPGFPGQPGSHGRDGHAGEKGDPGPPGDHEDATPGGKGFPGPLGPPGK 
Mouse_COL4A4_Translated_-_Fr      DGPPGFPGPHGQDGGDGRPGERGDPGPRGDHKDAPGERGLPGLPGPPGR 
                                  ** *****  *..* ** .*::***** *.*:**:** :* **  ****: 
 
Canine_A4_Normal_5-21_Transl      TGPRGQPGLGFPGPPGERGQPGAPGRPGERGFGGLKGQKGDTISCNVTYP 
Human_COL4A4_Translated_-_Fr      AGPVGPPGLGFPGPPGERGHPGVPGHPGVRGPDGLKGQKGDTISCNVTYP 
Mouse_COL4A4_Translated_-_Fr      TGPEGPPGLGFPGPPGQRGLPGEPGRPGTRGFDGTKGQKGDSILCNVSYP 
                                  :** * **********:** ** **:** ** .* ******:* ***:** 
 
Canine_A4_Normal_5-21_Transl      GRPGPPGFDGPPGPKGFPGPQGAPGLRCLDGPKGQRGKPGMSEIPGPPGF 
Human_COL4A4_Translated_-_Fr      GRHGPPGFDGPPGPKGFPGPQGAPGLSGSDGHKGRPGTPGTAEIPGPPGF 
Mouse_COL4A4_Translated_-_Fr      GKPGLPGLDGPPGLKGFPGPPGAPGMRCPDGQKGQRGKPGMSGIPGPPGF 
                                  *: * **:***** ****** ****:   ** **: *.** : ******* 
 
Canine_A4_Normal_5-21_Transl      RGDMGDPGFEGEKGSSLLGPPGFPGSRGANGQKGMMGDIAYGLPGPPGKR 
Human_COL4A4_Translated_-_Fr      RGDMGDPGFGGEKGSSPVGPPGPPGSPGVNGQKGIPGDPAFGHLGPPGKR 
Mouse_COL4A4_Translated_-_Fr      RGDMGDPGIKGEKGTSPIGPPGPPGSPGKDGQKGIPGDPAFGDPGPPGER 
                                  ********: ****:* :**** *** * :****: ** *:*  ****:* 
 
Canine_A4_Normal_5-21_Transl      GPSGVPGSKGHRGDSGRPGFAGPAGKPGSPGLKGPRGREGSAGFQGIPGP 
Human_COL4A4_Translated_-_Fr      GLSGVPGIKGPRGDPGCPGAEGPAGIPGFLGLKGPKGREGHAGFPGVPGP 
Mouse_COL4A4_Translated_-_Fr      GLPGAPGMKGQKGHPGCPGAGGPPGIPGSPGLKGPKGREGSRGFPGIPGS 
                                  * .*.** ** :*..* **  **.* **  *****:****  ** *:**. 
 
Canine_A4_Normal_5-21_Transl      PGHSCKRGAPGIPGQPGLPGAPGSPGAPGWKGQRGDVGPPGPAGMKGLPG 
Human_COL4A4_Translated_-_Fr      PGHSCERGAPGIPGQPGLPGYPGSPGAPGGKGQPGDVGPPGPAGMKGLPG 
Mouse_COL4A4_Translated_-_Fr      PGHSCERGAPGIPGQPGLPGTPGDPGAPGWKGQPGDMGPSGPAGMKGLPG 
                                  *****:************** **.***** *** **:**.********** 
 
Canine_A4_Normal_5-21_Transl      VPGRPGAEGPLGFPGVPGPLGDDGLPGLPGPKGPQGLPGFPGFPGERGKP 
Human_COL4A4_Translated_-_Fr      LPGRPGAHGPPGLPGIPGPFGDDGLPGPPGPKGPRGLPGFPGFPGERGKP 
Mouse_COL4A4_Translated_-_Fr      LPGLPGADGLRGPPGIPGPNGEDGLPGLPGLKGLPGLPGFPGFPGERGKP 
                                  :** ***.*  * **:*** *:***** ** **  *************** 
 
Canine_A4_Normal_5-21_Transl      GPEGRPGSKGEPGEDGRPGFFGDQGVKGAKGARGPPGDEGEMAVFSQKGK 
Human_COL4A4_Translated_-_Fr      GAEGCPGAKGEPGEKGMSGLPGDRGLRGAKGAIGPPGDEGEMAIISQKGT 
Mouse_COL4A4_Translated_-_Fr      GPDGEPGRKGEVGEKGWPGLKGDLGERGAKGDRGLPGDAG-EAVTSRKGE 
                                  *.:* ** *** **.* .*: ** * :****  * *** *  *: *:**  
 
Canine_A4_Normal_5-21_Transl      TGEPGPPGDDGFPGEEGDKGNPGMPGRRGEPGRFGAPGFHRGEPGRTGQP 
Human_COL4A4_Translated_-_Fr      PGEPGPPGDDGFPGERGDKGTPGMQGRRGELGRYGPPGFHRGEPGEKGQP 
Mouse_COL4A4_Translated_-_Fr      PGDAGPPGDGGFSGERGDKGSSGMRGGRGDPGRDGLPGLHRGQPGIDGPP 
                                  .*:.*****.**.**.****..** * **: ** * **:***:**  * * 
 
Canine_A4_Normal_5-21_Transl      GLPGPPGPPGSPGLRGIIGFPGFPGDQGEPGSPGSPGLSGIDGMRGPKGS 
Human_COL4A4_Translated_-_Fr      GPPGPPGPPGSTGLRGFIGFPGLPGDQGEPGSPGPPGFSGIDGARGPKGN 
Mouse_COL4A4_Translated_-_Fr      GPPGPPGPPGSPGLRGVIGFPGFPGDQGDPGSPGPPGFPGDDGARGPKGY 
                                  * *********.****.*****:*****:*****.**:.* ** *****  
 
Canine_A4_Normal_5-21_Transl      KGDPASQFGPPGPKGEPGSPGCPGQVGAPGEQGLPGVQGLRGPPGRPGLP 
Human_COL4A4_Translated_-_Fr      KGDPASHFGPPGPKGEPGSPGCPGHFGASGEQGLPGIQGPRGSPGRPGPP 
Mouse_COL4A4_Translated_-_Fr      KGDPASQCGPPGPKGEPGSPGYQGRTGVPGEKGFPGDEGPRGPPGRPGQP 
                                  ******: *************  *: *..**:*:** :* **.***** * 
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Canine_A4_Normal_5-21_Transl      GSSGPPGCPGNQGVPGLTGPPGETGDPGPRGMMGDPGPPGLPGIKGPSGS 
Human_COL4A4_Translated_-_Fr      GSSGPPGCPGDHGMPGLRGQPGEMGDPGPRGLQGDPGIPGPPGIKGPSGS 
Mouse_COL4A4_Translated_-_Fr      GSFGPPGCPGDPGMPGLKGHPGEVGDPGPRGDAGDFGRPGPAGVKGPLGS 
                                  ** *******: *:*** * *** *******  ** * ** .*:*** ** 
 
Canine_A4_Normal_5-21_Transl      PGLNGLHGLKGQKGAKGASGLHEVGPPGPVGVPGLKGEPGDPGSPGISPP 
Human_COL4A4_Translated_-_Fr      PGLNGLHGLKGQKGTKGASGLHDVGPPGPVGIPGLKGERGDPGSPGISPP 
Mouse_COL4A4_Translated_-_Fr      PGLNGLHGLKGEKGTKGASGLLEMGPPGPMGMPGQKGEKGDPGSPGISPP 
                                  ***********:**:****** ::*****:*:** *** *********** 
 
Canine_A4_Normal_5-21_Transl      GLSGERGPPGPPGRPGAPGPAGATGRAAEGHVPDPGPPGDVGPPGPDGPR 
Human_COL4A4_Translated_-_Fr      GPRGKKGPPGPPGSSGPPGPAGATGRAPK-DIPDPGPPGDQGPPGPDGPR 
Mouse_COL4A4_Translated_-_Fr      GLPGEKGFPGPPGRPGPPGPAGAPGRAAKGDIPDPGPPGDRGPPGPDGPR 
                                  *  *::* ***** .*.******.***.: .:******** ********* 
 
Canine_A4_Normal_5-21_Transl      GAPGPPGPPGSVDLLRGEPGDCGPPGPPGPPGPPGPPGHQGFPGCDGKDG 
Human_COL4A4_Translated_-_Fr      GAPGPPGLPGSVDLLRGEPGDCGLPGPPGPPGPPGPPGYKGFPGCDGKDG 
Mouse_COL4A4_Translated_-_Fr      GVPGPPGSPGNVDLLKGDPGDCGLPGPPGSRGPPGPPGCQGPPGCDGKDG 
                                  *.***** **.****:*:***** *****. ******* :* ******** 
 
Canine_A4_Normal_5-21_Transl      QKGPIGFPGLQGPQGLPGLPGEKGLLGIPGRRGHPGPPGSRGEPGPPADV 
Human_COL4A4_Translated_-_Fr      QKGPMGFPGPQGPHGFPGPPGEKGLPGPPGRKGPTGLPGPRGEPGPPADV 
Mouse_COL4A4_Translated_-_Fr      QKGPMGLPGLPGPPGLPGAPGEKGLPGPPGRKGPVGPPGCRGEPGPPADV 
                                  ****:*:**  ** *:** ****** * ***:*  * ** ********** 
 
Canine_A4_Normal_5-21_Transl      DSCPRIPGLPGVPGPRGPEGAMGVPGRRGPPGPGCKGEPGLEGRRGEAGL 
Human_COL4A4_Translated_-_Fr      DDCPRIPGLPGAPGMRGPEGAMGLPGMRGPPGPGCKGEPGLDGRRGVDGV 
Mouse_COL4A4_Translated_-_Fr      DSCPRIPGLPGVPGPRGPEGAMGEPGRRGLPGPGCKGEPGPDGRRGQDGI 
                                  *.*********.** ******** ** ** ********** :****  *: 
 
Canine_A4_Normal_5-21_Transl      PGPPGPPGSTGDAGEAGCPGAPGPPGPIGDPGPRGFGPGYLSGFLLVLHS 
Human_COL4A4_Translated_-_Fr      PGSPGPPGRKGDTGEDGYPGGPGPPGPIGDPGPKGFGPGYLGGFLLVLHS 
Mouse_COL4A4_Translated_-_Fr      PGSPGPPGRKGDTGEAGCPGAPGPPGPTGDPGPKGFGPGSLSGFLLVLHS 
                                  **.***** .**:** * **.****** *****:***** *.******** 
 
Canine_A4_Normal_5-21_Transl      QTDGEPTCPAGMPRPWTGYSLLYLEGQEKAHNQDLGLAGSCLPMFSTLPF 
Human_COL4A4_Translated_-_Fr      QTDQEPTCPLGMPRLWTGYSLLYLEGQEKAHNQDLGLAGSCLPVFSTLPF 
Mouse_COL4A4_Translated_-_Fr      QTDQEPACPVGMPRLWTGYSLLYMEGQEKAHNQDLGLAGSCLPVFSTLPF 
                                  *** **:** **** ********:*******************:****** 
 
Canine_A4_Normal_5-21_Transl      AYCNIHQVCHYARRNDRSYWLASAAPLPMMPLSEEEIRPYISRCAVCEAP 
Human_COL4A4_Translated_-_Fr      AYCNIHQVCHYAQRNDRSYWLASAAPLPMMPLSEEAIRPYVSRCAVCEAP 
Mouse_COL4A4_Translated_-_Fr      AYCNIHQVCHYAQRNDRSYWLSSAAPLPMMPLSEEEIRSYISRCAVCEAP 
                                  ************:********:************* **.*:********* 
 
Canine_A4_Normal_5-21_Transl      APVVALHSQDRSIPPCPRSWRSLWIGYSFLMHTGAGDQGGGQALMSPGSC 
Human_COL4A4_Translated_-_Fr      AQAVAVHSQDQSIPPCPQTWRSLWIGYSFLMHTGAGDQGGGQALMSPGSC 
Mouse_COL4A4_Translated_-_Fr      AQAVAVHSQDQSIPPCPRTWRSLWIGYSFLMHTGAGDQGGGQALMSPGSC 
                                  * .**:****:******::******************************* 
 
Canine_A4_Normal_5-21_Transl      LEDFRAAPFLECQGRQGTCHFFANEYSFWLTTVRPDLQFSSAPSPDTLKE 
Human_COL4A4_Translated_-_Fr      LEDFRAAPFLECQGRQGTCHFFANKYSFWLTTVKADLQFSSAPAPDTLKE 
Mouse_COL4A4_Translated_-_Fr      LEDFRAAPFVECQGRQGTCHFFANEYSFWLTTVNPDLQFASGPSPDTLKE 
                                  *********:**************:********..****:*.*:****** 
 
Canine_A4_Normal_5-21_Transl      SQAQRQKISRCQVCIL-- 
Human_COL4A4_Translated_-_Fr      SQAQRQKISRCQVCVKYS 
Mouse_COL4A4_Translated_-_Fr      VQAQRRKISRCQVCMKHS 








Comparison of ECS-HN and normal COL4A3 
 
 
 30        40        50        60        70        80         
ECS_A3 CGATGGTGTACCAGGATGCAATGGTTCTAAGGGTGAGCAAGGGTTTCCAGGCCTTCCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CGATGGTGTACCAGGATGCAATGGTTCTAAGGGTGAGCAAGGGTTTCCAGGCCTTCCAGG 
         30        40        50        60        70        80       
 
       90       100       110       120       130       140         
ECS_A3 GACACCAGGCTACCCAGGGATCCCGGGTGCTGTTGGCCTGAAAGGAGAAAAAGGTGCTCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL GACACCAGGCTACCCAGGGATCCCGGGTGCTGTTGGCCTGAAAGGAGAAAAAGGTGCTCC 
         90       100       110       120       130       140       
 
      150       160       170       180       190       200         
ECS_A3 TGCCACAGAAGGTATAGAACTTGATGGAAGAGGTGACCCTGGGTTGCCAGGAGCTCCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TGCCACAGAAGGTATAGAACTTGATGGAAGAGGTGACCCTGGGTTGCCAGGAGCTCCAGG 
        150       160       170       180       190       200       
 
      210       220       230       240       250       260         
ECS_A3 ATTCCAGGGTTTACCRGGCCTTCCAGGCTTTCCGGGACCTGCTGGTCCACCTGGCCCTCC 
       :::::::::::::::.:::::::::::::::::::::::::::::::::::::::::::: 
NORMAL ATTCCAGGGTTTACCAGGCCTTCCAGGCTTTCCGGGACCTGCTGGTCCACCTGGCCCTCC 
        210       220       230       240       250       260       
 
      270       280       290       300       310       320         
ECS_A3 GGGATTCTTAGGCTTTCCAGGAGCCATGGGACCTCCAGGACCTAAGGGTCAAATGGGCGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL GGGATTCTTAGGCTTTCCAGGAGCCATGGGACCTCCAGGACCTAAGGGTCAAATGGGCGA 
        270       280       290       300       310       320       
 
      330       340       350       360       370       380         
ECS_A3 TAAAGTGATAGGACAAAAAGGAGAGCGGGGTGTGAAAGGATTAACAGGACCTCCCGGACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TAAAGTGATAGGACAAAAAGGAGAGCGGGGTGTGAAAGGATTAACAGGACCTCCCGGACC 
        330       340       350       360       370       380       
 
      390       400       410       420       430       440         
ECS_A3 ACCAGGAACAGTTATTGTGACGCTAACCGGCCCTGATAACAGAACGGACCTYAAGGGGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::.:::::::: 
NORMAL ACCAGGAACAGTTATTGTGACGCTAACCGGCCCTGATAACAGAACGGACCTCAAGGGGGA 
        390       400       410       420       430       440       
 
      450       460       470       480       490       500         
ECS_A3 GAAGGGAGACAAGGGAGCCATGGGGAAGCCTGGACCTCCTGGGCCCTTGGGACCGCCTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL GAAGGGAGACAAGGGAGCCATGGGGAAGCCTGGACCTCCTGGGCCCTTGGGACCGCCTGG 
        450       460       470       480       490       500       
 
      510       520       530       540       550       560         
ECS_A3 AGAATCCTATGGATCTGAAAAAGGTGCTCCTGGAGAACCTGGCCCGCAGGGAAAACCTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGAATCCTATGGATCTGAAAAAGGTGCTCCTGGAGAACCTGGCCCGCAGGGAAAACCTGG 
        510       520       530       540       550       560       
 
      570       580       590       600       610       620         
ECS_A3 CAAAGATGGTGCCCCTGGTTTCCCTGGCACTGAGGGGCCCAAAGGCAACAGAGGCTTCCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CAAAGATGGTGCCCCTGGTTTCCCTGGCACTGAGGGGCCCAAAGGCAACAGAGGCTTCCC 




      630       640       650       660       670       680         
ECS_A3 TGGGTTACGGGGTGAAGACGGCATTAAGGGGTGGAAAGGGGACATTGGCCCGCCAGGATT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TGGGTTACGGGGTGAAGACGGCATTAAGGGGTGGAAAGGGGACATTGGCCCGCCAGGATT 
        630       640       650       660       670       680       
 
      690       700       710       720       730       740         
ECS_A3 TCGTGGTCCAACAGAATATTATGATGCATACCAGGAAAAGGGTGATGAAGGAATTCCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TCGTGGTCCAACAGAATATTATGATGCATACCAGGAAAAGGGTGATGAAGGAATTCCAGG 
        690       700       710       720       730       740       
 
      750       760       770       780       790       800         
ECS_A3 CCCACCAGGCCCCAAAGGAGCTCGTGGCCCCCAGGGTCCCAGCGGTCCCCCTGGAGTTCT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CCCACCAGGCCCCAAAGGAGCTCGTGGCCCCCAGGGTCCCAGCGGTCCCCCTGGAGTTCT 
        750       760       770       780       790       800       
 
      810       820       830       840       850       860         
ECS_A3 TGGAAGTGCTGGGTCATCAAAGCCTGGCCTCAGAGGAGCTCCTGGATCTCCAGGCATGAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TGGAAGTGCTGGGTCATCAAAGCCTGGCCTCAGAGGAGCTCCTGGATCTCCAGGCATGAA 
        810       820       830       840       850       860       
 
      870       880       890       900       910       920         
ECS_A3 AGGACGTAAAGGGGAACAAGGGCCCCCGGGAAAGAATGCAGTGGGGCCTCCTGGGTCCCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGGACGTAAAGGGGAACAAGGGCCCCCGGGAAAGAATGCAGTGGGGCCTCCTGGGTCCCC 
        870       880       890       900       910       920       
 
      930       940       950       960       970       980         
ECS_A3 AGGTTGTCCTGGTTCACCAGGCCCCATAGGGCTGCCGGGATATCCAGGACCACCAGGTGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGGTTGTCCTGGTTCACCAGGCCCCATAGGGCTGCCGGGATATCCAGGACCACCAGGTGA 
        930       940       950       960       970       980       
 
      990      1000      1010      1020      1030      1040         
ECS_A3 CATCGTGTTTCGCAAAGGTCCACCTGGGGTTGGTGGACTCCCCGGCCATGTTGGGTTTCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CATCGTGTTTCGCAAAGGTCCACCTGGGGTTGGTGGACTCCCCGGCCATGTTGGGTTTCC 
        990      1000      1010      1020      1030      1040       
 
     1050      1060      1070      1080      1090      1100         
ECS_A3 AGGCATCCCAGGAGTCGAGGGGCCCAAAGGGGAACCAGGCCTCTTGTGCGTACAGTGTGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGGCATCCCAGGAGTCGAGGGGCCCAAAGGGGAACCAGGCCTCTTGTGCGTACAGTGTGC 
       1050      1060      1070      1080      1090      1100       
 
     1110      1120      1130      1140      1150      1160         
ECS_A3 TTATATCCCAGGGCGTCCAGGTCTCCCAGGACTGCCAGGGTTGGATGGCATAAAAGGAAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TTATATCCCAGGGCGTCCAGGTCTCCCAGGACTGCCAGGGTTGGATGGCATAAAAGGAAT 
       1110      1120      1130      1140      1150      1160       
 
     1170      1180      1190      1200      1210      1220         
ECS_A3 CCCAGGAGGACAAGGGGCAGCTGGCATTAAAGGAAGCCCAGGGTCCCCAGGAAGTGCGGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CCCAGGAGGACAAGGGGCAGCTGGCATTAAAGGAAGCCCAGGGTCCCCAGGAAGTGCGGG 
       1170      1180      1190      1200      1210      1220       
 
     1230      1240      1250      1260      1270      1280         
ECS_A3 TCTTCCAGGATTTCCAGGATTCCCGGGTGCTCCGGGTGCTCCAGGACTTAAAGGAGAAAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TCTTCCAGGATTTCCAGGATTCCCGGGTGCTCCGGGTGCTCCAGGACTTAAAGGAGAAAA 
       1230      1240      1250      1260      1270      1280       
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     1290      1300      1310      1320      1330      1340         
ECS_A3 AGGAGAAACATCTGAGCCTGAGGGACAGGTGGGTGCTCCAGGGGACCCCGGGCTCAGAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGGAGAAACATCTGAGCCTGAGGGACAGGTGGGTGCTCCAGGGGACCCCGGGCTCAGAGG 
       1290      1300      1310      1320      1330      1340       
 
     1350      1360      1370      1380      1390      1400         
ECS_A3 CCATCCTGGAAGAAAGGGCTTGGATGGAATTCCTGGAACTCCTGGAATTAAAGGACCACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CCATCCTGGAAGAAAGGGCTTGGATGGAATTCCTGGAACTCCTGGAATTAAAGGACCACC 
       1350      1360      1370      1380      1390      1400       
 
     1410      1420      1430      1440      1450      1460         
ECS_A3 AGGACCCAAAGGTGAACCGGCCCTGAGTGGTGAGAAGGGGGACCAGGGTCCTCCAGGGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGGACCCAAAGGTGAACCGGCCCTGAGTGGTGAGAAGGGGGACCAGGGTCCTCCAGGGGA 
       1410      1420      1430      1440      1450      1460       
 
     1470      1480      1490      1500      1510      1520         
ECS_A3 TCCTGGGATCCCAGGGTCCCCAGGACCTGCAGGACCACCTGGACCACCAAACTATGGACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TCCTGGGATCCCAGGGTCCCCAGGACCTGCAGGACCACCTGGACCACCAAACTATGGACC 
       1470      1480      1490      1500      1510      1520       
 
     1530      1540      1550      1560      1570      1580         
ECS_A3 ACAGGGAGAGCCTGGTCCAAAGGGCACCCAAGGAGTTCCTGGAGCCCCTGGACCACCTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL ACAGGGAGAGCCTGGTCCAAAGGGCACCCAAGGAGTTCCTGGAGCCCCTGGACCACCTGG 
       1530      1540      1550      1560      1570      1580       
 
     1590      1600      1610      1620      1630      1640         
ECS_A3 AGAAGCCGGTCCTAAGGGAGAATTCGGTATTTCGACACCAGTCCCAGGGCCCCCAGGACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGAAGCCGGTCCTAAGGGAGAATTCGGTATTTCGACACCAGTCCCAGGGCCCCCAGGACC 
       1590      1600      1610      1620      1630      1640       
 
     1650      1660      1670      1680      1690      1700         
ECS_A3 TCCAGGGCCCCCTGGTTATGCTGGCCCCCGAGGTCCACCTGGTATCCCTGGATCCATAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TCCAGGGCCCCCTGGTTATGCTGGCCCCCGAGGTCCACCTGGTATCCCTGGATCCATAGG 
       1650      1660      1670      1680      1690      1700       
 
     1710      1720      1730      1740      1750      1760         
ECS_A3 AAAATGTGGTGATCCGGGTCTTCCTGGGCCTGATGGTGAACCAGGAATTCCAGGAATTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AAAATGTGGTGATCCGGGTCTTCCTGGGCCTGATGGTGAACCAGGAATTCCAGGAATTGG 
       1710      1720      1730      1740      1750      1760       
 
     1770      1780      1790      1800      1810      1820         
ECS_A3 CTTCCCTGGGCCCCCTGGACCTAAGGGAGACCAAGGTTTTCCAGGAGCAAAAGGAGCACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CTTCCCTGGGCCCCCTGGACCTAAGGGAGACCAAGGTTTTCCAGGAGCAAAAGGAGCACC 
       1770      1780      1790      1800      1810      1820       
 
     1830      1840      1850      1860      1870      1880         
ECS_A3 GGGTTGTCCAGGAGAAATGGGGAAGCCCGGGTCACCTGGAGAACCAGGTCTCCCAGGAGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL GGGTTGTCCAGGAGAAATGGGGAAGCCCGGGTCACCTGGAGAACCAGGTCTCCCAGGAGC 
       1830      1840      1850      1860      1870      1880       
 
     1890      1900      1910      1920      1930      1940         
ECS_A3 CAAGGGAGAACCAGGACTAGCCATACCTGGAGAACCAGGAATACCAGGTTTTCCAGGAGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL CAAGGGAGAACCAGGACTAGCCATACCTGGAGAACCAGGAATACCAGGTTTTCCAGGAGA 
       1890      1900      1910      1920      1930      1940       
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     1950      1960      1970      1980      1990      2000         
ECS_A3 AAGAGGCAATTCTGGGGAAAATGGAGAAATTGGACTCCCTGGACTTCCAGGTCTCCCTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AAGAGGCAATTCTGGGGAAAATGGAGAAATTGGACTCCCTGGACTTCCAGGTCTCCCTGG 
       1950      1960      1970      1980      1990      2000       
 
     2010      2020      2030      2040      2050      2060         
ECS_A3 AATTCCAGGAACTGGAGGGCTTGATGGACCACCAGGGGATCCAGGGAAGCCTGGACCACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AATTCCAGGAACTGGAGGGCTTGATGGACCACCAGGGGATCCAGGGAAGCCTGGACCACC 
       2010      2020      2030      2040      2050      2060       
 
     2070      2080      2090      2100      2110      2120         
ECS_A3 TGGAGAAAAAGGACCCCCAGGAAGTTGCACAGAGGGTCCCAGAGGAGCCCACGGACTTCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL TGGAGAAAAAGGACCCCCAGGAAGTTGCACAGAGGGTCCCAGAGGAGCCCACGGACTTCC 
       2070      2080      2090      2100      2110      2120       
 
     2130      2140      2150      2160      2170      2180         
ECS_A3 AGGATTAAATGGATTGGAAGGGCAACCAGGCAGAAGAGGTGAAACAGGGCCAAAAGGAGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
NORMAL AGGATTAAATGGATTGGAAGGGCAACCAGGCAGAAGAGGTGAAACAGGGCCAAAAGGAGA 
       2130      2140      2150      2160      2170      2180       
 
     2190      2200      2210      2220      2230      2240         
ECS_A3 CCCAGGTATTCCAGGCTTGGATAGATCAGGCTTTCCTGGAGAACCTGGACCACCAGGAAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal CCCAGGTATTCCAGGCTTGGATAGATCAGGCTTTCCTGGAGAACCTGGACCACCAGGAAT 
       2190      2200      2210      2220      2230      2240       
 
     2250      2260      2270      2280      2290      2300         
ECS_A3 GCCAGGTCATCGAGGTGAGATAGGACCACCTGGCCAAAAAGGATATCCAGGAAATCCGGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GCCAGGTCATCGAGGTGAGATAGGACCACCTGGCCAAAAAGGATATCCAGGAAATCCGGG 
       2250      2260      2270      2280      2290      2300       
 
     2310      2320      2330      2340      2350      2360         
ECS_A3 ATTTTTAGGACTACCAGGTGAAGATGGARTGATTGGGATGATGGGCTATCCAGGAAACAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal ATTTTTAGGACTACCAGGTGAAGATGGAGTGATTGGGATGATGGGCTATCCAGGAAACAC 
       2310      2320      2330      2340      2350      2360       
 
     2370      2380      2390      2400      2410      2420         
ECS_A3 TGGCCCTCCTGGGCCTCCCGGGATCCCAGGCACCCCAGGACAGAGGGGTAGCTTTGGAAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TGGCCCTCCTGGGCCTCCCGGGATCCCAGGCACCCCAGGACAGAGGGGTAGCTTTGGAAT 
       2370      2380      2390      2400      2410      2420       
 
     2430      2440      2450      2460      2470      2480         
ECS_A3 TCCAGGTGCAAAGGGTGAGAAAGGGCCCCCAGGAGCCAAGGGGGAAGAAGGAGAGAAAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TCCAGGTGCAAAGGGTGAGAAAGGGCCCCCAGGAGCCAAGGGGGAAGAAGGAGAGAAAGG 
       2430      2440      2450      2460      2470      2480       
 
     2490      2500      2510      2520      2530      2540         
ECS_A3 ACCTATGGGGCCTTGTCGAATAACCAGCTCAGTGGGGGACAAAGGAGAACCAGGCCTCAA 
       ::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::: 
Normal ACCTATGGGGCCTTGTCAAATAACCAGCTCAGTGGGGGACAAAGGAGAACCAGGCCTCAA 
       2490      2500      2510      2520      2530      2540       
 
     2550      2560      2570      2580      2590      2600         
ECS_A3 AGGGTTTGCAGGAAAGCCGGGTGAGAAAGGAAACAGAGGCATTCCAGGGTTACCAGGTTT 
       :::::::::::::::::::::::: ::::::::::::::::::::::::::::::::::: 
Normal AGGGTTTGCAGGAAAGCCGGGTGAAAAAGGAAACAGAGGCATTCCAGGGTTACCAGGTTT 




     2610      2620      2630      2640      2650      2660         
ECS_A3 GAAAGGATTCGAAGGGCCACCTGGACCACCAGGCCCACCAGGCCCCCGAGGAGATCCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GAAAGGATTCGAAGGGCCACCTGGACCACCAGGCCCACCAGGCCCCCGAGGAGATCCAGG 
       2610      2620      2630      2640      2650      2660       
 
     2670      2680      2690      2700      2710      2720         
ECS_A3 CAGCATTGGGAATCCTGGAGAAGCAGGACCACGTGGAAGTCCAGGAAACATGGGGAACAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal CAGCATTGGGAATCCTGGAGAAGCAGGACCACGTGGAAGTCCAGGAAACATGGGGAACAT 
       2670      2680      2690      2700      2710      2720       
 
     2730      2740      2750      2760      2770      2780         
ECS_A3 GGGGATGCCAGGTCTTAAAGGACACAGGGGACCTTTGGGACTACCAGGTGTCACTGGAAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GGGGATGCCAGGTCTTAAAGGACACAGGGGACCTTTGGGACTACCAGGTGTCACTGGAAG 
       2730      2740      2750      2760      2770      2780       
 
     2790      2800      2810      2820      2830      2840         
ECS_A3 ACCAGGCCTCCCAGGTGTTCACGGTCTCCAAGGAGACAAGGGAGAGCCAGGTTATTCAGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal ACCAGGCCTCCCAGGTGTTCACGGTCTCCAAGGAGACAAGGGAGAGCCAGGTTATTCAGC 
       2790      2800      2810      2820      2830      2840       
 
     2850      2860      2870      2880      2890      2900         
ECS_A3 AGGTACAAGGCCAGGACCACCGGGACTAAAGGGAGATCCAGGATTACCAGGTGCCATGGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AGGTACAAGGCCAGGACCACCGGGACTAAAGGGAGATCCAGGATTACCAGGTGCCATGGG 
       2850      2860      2870      2880      2890      2900       
 
     2910      2920      2930      2940      2950      2960         
ECS_A3 AAGGAAAGGAGAAAGAGGGCTACCTGGCACCCCTGGCCATTCGGGGCCTGCTGGAACTGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AAGGAAAGGAGAAAGAGGGCTACCTGGCACCCCTGGCCATTCGGGGCCTGCTGGAACTGA 
       2910      2920      2930      2940      2950      2960       
 
     2970      2980      2990      3000      3010      3020         
ECS_A3 GGGAGCCCCTGGACATCCCGGAAGTCCTGGCCACCCAGGAAAGCCAGGCCCTGATGGAGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GGGAGCCCCTGGACATCCCGGAAGTCCTGGCCACCCAGGAAAGCCAGGCCCTGATGGAGA 
       2970      2980      2990      3000      3010      3020       
 
     3030      3040      3050      3060      3070      3080         
ECS_A3 TTTGGGGTTAAAAGGCATCAAAGGCTTCCCTGGGTCCCCAGGAGTCAAAGGACCTCCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TTTGGGGTTAAAAGGCATCAAAGGCTTCCCTGGGTCCCCAGGAGTCAAAGGACCTCCAGG 
       3030      3040      3050      3060      3070      3080       
 
     3090      3100      3110      3120      3130      3140         
ECS_A3 ACCTCCAGGAATCCTAGGATCTCCTGGACCTATGGGCATGAGAGGCAACCAGGGCCGTGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal ACCTCCAGGAATCCTAGGATCTCCTGGACCTATGGGCATGAGAGGCAACCAGGGCCGTGA 
       3090      3100      3110      3120      3130      3140       
 
     3150      3160      3170      3180      3190      3200         
ECS_A3 TGGAATCCCTGGTCCCCCAGGAGAAAAGGGAGAAACAGGTTTGCTGGGGGCACATCCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TGGAATCCCTGGTCCCCCAGGAGAAAAGGGAGAAACAGGTTTGCTGGGGGCACATCCAGG 
       3150      3160      3170      3180      3190      3200       
 
     3210      3220      3230      3240      3250      3260         
ECS_A3 CCCAGGAGGGATCCCTGGTCCTCCAGGAGCCAAAGGAGACAAGGGAGCCCCAGGCCTACC 
       ::::::::::: ::::::::::::::::::::::::::::: ::: :::::::::::::: 
Normal CCCAGGAGGGAGCCCTGGTCCTCCAGGAGCCAAAGGAGACAGGGGCGCCCCAGGCCTACC 
       3210      3220      3230      3240      3250      3260       
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     3270      3280      3290      3300      3310      3320         
ECS_A3 AGGCCCCCCAGGCAGGAAAGGGGCAGTGGGAGATGCCGGGCCACGGGGACCCACTGGCAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AGGCCCCCCAGGCAGGAAAGGGGCAGTGGGAGATGCCGGGCCACGGGGACCCACTGGCAT 
       3270      3280      3290      3300      3310      3320       
 
     3330      3340      3350      3360      3370      3380         
ECS_A3 GACGGGACTCCCAGGGCCACCAGGTTTTCCTGGTGCAGTCATCCCTGGCCAGAAAGGAAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GACGGGACTCCCAGGGCCACCAGGTTTTCCTGGTGCAGTCATCCCTGGCCAGAAAGGAAA 
       3330      3340      3350      3360      3370      3380       
 
     3390      3400      3410      3420      3430      3440         
ECS_A3 TCAAGGTCCACCAGGCTTCAGAGGAAACCCAGGTGAGCCTGGTCCTCCAGGCCCTCCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TCAAGGTCCACCAGGCTTCAGAGGAAACCCAGGTGAGCCTGGTCCTCCAGGCCCTCCAGG 
       3390      3400      3410      3420      3430      3440       
 
     3450      3460      3470      3480      3490      3500         
ECS_A3 GAGCCACGTGAAAGGCATAAAAGGAGACAAGGGACTCATGGGTGAGCCTGGCCCCAGAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GAGCCACGTGAAAGGCATAAAAGGAGACAAGGGACTCATGGGTGAGCCTGGCCCCAGAGG 
       3450      3460      3470      3480      3490      3500       
 
     3510      3520      3530      3540      3550      3560         
ECS_A3 TCTACCTGGAACTGTGGGAGACAAGGGGCCACCGGGTCAACCGGGAGCACCAGGGAGCCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TCTACCTGGAACTGTGGGAGACAAGGGGCCACCGGGTCAACCGGGAGCACCAGGGAGCCC 
       3510      3520      3530      3540      3550      3560       
 
     3570      3580      3590      3600      3610      3620         
ECS_A3 AGGTCTGCCAGGGCTCAGGGGCGATCCTGGATTCTATGGATTTCCAGGTGTTAAAGGAGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AGGTCTGCCAGGGCTCAGGGGCGATCCTGGATTCTATGGATTTCCAGGTGTTAAAGGAGA 
       3570      3580      3590      3600      3610      3620       
 
     3630      3640      3650      3660      3670      3680         
ECS_A3 GAAGGGTAACCCAGGATTTCCGGGACCAGCTGGACCTCCAGGGCAAATTGGGCCAAAAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GAAGGGTAACCCAGGATTTCCGGGACCAGCTGGACCTCCAGGGCAAATTGGGCCAAAAGG 
       3630      3640      3650      3660      3670      3680       
 
     3690      3700      3710      3720      3730      3740         
ECS_A3 ACCACCTGGTGTCCGTGGAGACCCTGGCACAGTTAAGATCATCTCCCTTCCAGGAAGCCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal ACCACCTGGTGTCCGTGGAGACCCTGGCACAGTTAAGATCATCTCCCTTCCAGGAAGCCC 
       3690      3700      3710      3720      3730      3740       
 
     3750      3760      3770      3780      3790      3800         
ECS_A3 AGGGCCACCTGGCCGTGCTGGAGGACCGGGGATGCCAGGAGAACCAGGGCCACCAGGGCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AGGGCCACCTGGCCGTGCTGGAGGACCGGGGATGCCAGGAGAACCAGGGCCACCAGGGCC 
       3750      3760      3770      3780      3790      3800       
 
     3810      3820      3830      3840      3850      3860         
ECS_A3 ACCAGGAATCCTAGGACCCTGTGGACCAAGAGGTAAACCAGGCATGGATGGAATACCAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal ACCAGGAATCCTAGGACCCTGTGGACCAAGAGGTAAACCAGGCATGGATGGAATACCAGG 
       3810      3820      3830      3840      3850      3860       
 
     3870      3880      3890      3900      3910      3920         
ECS_A3 AACTCCTGGGCCAATTGGAGAAAAAGGCAACAAAGGTTGTAAAGGCGAGCAAGGACCACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AACTCCTGGGCCAATTGGAGAAAAAGGCAACAAAGGTTGTAAAGGCGAGCAAGGACCACC 
       3870      3880      3890      3900      3910      3920       
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     3930      3940      3950      3960      3970      3980         
ECS_A3 TGGATTAGATGGACTGCCAGGCTTGAAGGGGAGACCTGGAGACCCTGGACCACCTGCAAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TGGATTAGATGGACTGCCAGGCTTGAAGGGGAGACCTGGAGACCCTGGACCACCTGCAAC 
       3930      3940      3950      3960      3970      3980       
 
     3990      4000      4010      4020      4030      4040         
ECS_A3 TGGGACCATGAAGAGGGGCTTTATCTTCACCAGGCATAGTCAGACCACAGTGATTCCTTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TGGGACCATGAAGAGGGGCTTTATCTTCACCAGGCATAGTCAGACCACAGTGATTCCTTC 
       3990      4000      4010      4020      4030      4040       
 
     4050      4060      4070      4080      4090      4100         
ECS_A3 CTGTCCAGAAGGGACAGCGCCACTCTATAGTGGCTTTTCTCTTCTTTTCATACAAGGAAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal CTGTCCAGAAGGGACAGCGCCACTCTATAGTGGCTTTTCTCTTCTTTTCATACAAGGAAA 
       4050      4060      4070      4080      4090      4100       
 
     4110      4120      4130      4140      4150      4160         
ECS_A3 TGAACAAGCCCATGGACAAGACTTGGGAACTCTCGGCAGCTGCCTGCAGCGATTTACCAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal TGAACAAGCCCATGGACAAGACTTGGGAACTCTCGGCAGCTGCCTGCAGCGATTTACCAC 
       4110      4120      4130      4140      4150      4160       
 
     4170      4180      4190      4200      4210      4220         
ECS_A3 AATGCCATTCTTGTTCTGTAACATCAACAATGTCTGTAATTTTGCATCTCGAAATGACTA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AATGCCATTCTTGTTCTGTAACATCAACAATGTCTGTAATTTTGCATCTCGAAATGACTA 
       4170      4180      4190      4200      4210      4220       
 
     4230      4240      4250      4260      4270      4280         
ECS_A3 CTCATACTGGCTGTCAACACCAGCTCTGATGCCAATGGACATGGCTCCAATTACTGGCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal CTCATACTGGCTGTCAACACCAGCTCTGATGCCAATGGACATGGCTCCAATTACTGGCAG 
       4230      4240      4250      4260      4270      4280       
 
     4290      4300      4310      4320      4330      4340         
ECS_A3 GGCCCTGGAGCCTTATATTAGCAGATGCACTGTCTGTGAAGGTCCTACGATTGCCATAGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal GGCCCTGGAGCCTTATATTAGCAGATGCACTGTCTGTGAAGGTCCTACGATTGCCATAGC 
       4290      4300      4310      4320      4330      4340       
 
     4350      4360      4370      4380      4390      4400         
ECS_A3 CATTCACAGCCAAACCACTGACATTCCCTCATGTCCCAATGGCTGGATTTCTCTCTGGAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal CATTCACAGCCAAACCACTGACATTCCCTCATGTCCCAATGGCTGGATTTCTCTCTGGAA 
       4350      4360      4370      4380      4390      4400       
 
     4410      4420      4430      4440      4450      4460         
ECS_A3 AGGATTTTCGTTTATCATGTTCACAAGTGCAGGTTCTGAGGGTGCTGGGCAAGCACTGGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AGGATTTTCGTTTATCATGTTCACAAGTGCAGGTTCTGAGGGTGCTGGGCAAGCACTGGC 
       4410      4420      4430      4440      4450      4460       
 
     4470      4480      4490      4500      4510      4520         
ECS_A3 CTCCCCCGGCTCCTGCCTGGAAGAGTTCCGAGCCAGTCCGTTTATASAATGTCACGGAAG 
       ::::::::::::::::::::::::::::::::::::::::::::::.::::::::::::: 
Normal CTCCCCCGGCTCCTGCCTGGAAGAGTTCCGAGCCAGTCCGTTTATAGAATGTCACGGAAG 
       4470      4480      4490      4500      4510      4520       
 
     4530      4540      4550      4560      4570      4580         
ECS_A3 AGGAACGTGCAACTACTATTCAAATTCCTACAGTTTCTGGTTGGCTTCGTTAAACCCCCA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AGGAACGTGCAACTACTATTCAAATTCCTACAGTTTCTGGTTGGCTTCGTTAAACCCCCA 




     4590      4600      4610      4620       4630      4640     
ECS_A3 AAGAATGTTCAGAAAACCTATTCCATCAACTGTGAAAGCTGAATCCATATGACTAGT 
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Normal AAGAATGTTCAGAAAACCTATTCCATCAACTGTGAAAGCTGAATCCATATGACTAGT 








Comparison of ECS-HN and normal COL4A4 
 
 
 30        40        50        60        70        80   
Normal GGATGTGAGAGTCTTCTGGAAGAGAAGAGAAACCTGACAATCTTTTTTAAGTCCCAAGAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGATGTGAGAGTCTTCTGGAAGAGAAGAGAAACCTGACAATCTTTTTTAAGTCCCAAGAC 
               10        20        30        40        50        60 
 
             90       100       110       120       130       140   
Normal TTGACTGTGAGGTAATCCATGCACATGGCATCAGTAAAGTGTTCATTCAGGTGGATCAAG 
       ::::::::::::::::::::::::::::::::::::: :::::::::::::::::::::: 
ESC A4 TTGACTGTGAGGTAATCCATGCACATGGCATCAGTAAGGTGTTCATTCAGGTGGATCAAG 
               70        80        90       100       110       120 
 
            150       160       170       180       190       200   
Normal CCCTTGGCCAGAGATCCCTGGTCACTTATATTTATCCTCTTTTCTGTACAACATGCATAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CCCTTGGCCAGAGATCCCTGGTCACTTATATTTATCCTCTTTTCTGTACAACATGCATAT 
              130       140       150       160       170       180 
 
            210       220       230       240       250       260   
Normal GGGAGTGGAAAGAAGTTTGTCGGCCCCTGTGGAGGAAGAGATTGCTCGGTGTGCCATTGC 
       :::::::::::: ::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGGAGTGGAAAGNAGTTTGTCGGCCCCTGTGGAGGAAGAGATTGCTCGGTGTGCCATTGC 
              190       200       210       220       230       240 
 
            270       280       290       300       310       320   
Normal TTTCCTGAAAAAGGGTCTCGGGGTCAACCAGGACCGCCGGGGCCACAGGGTCCCATTGGA 
        ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CTTCCTGAAAAAGGGTCTCGGGGTCAACCAGGACCGCCGGGGCCACAGGGTCCCATTGGA 
              250       260       270       280       290       300 
 
            330       340       350       360       370       380   
Normal CCCCTGGGACTGCCAGGACCCACAGGAATTCCAGGAGAGAAAGGGATGAGAGGTGACAAG 
       ::::::::::::::::::::::::::::::::::::::::::::::::::: :::::::: 
ESC A4 CCCCTGGGACTGCCAGGACCCACAGGAATTCCAGGAGAGAAAGGGATGAGAAGTGACAAG 
              310       320       330       340       350       360 
 
             390       400       410       420       430       440  
Normal TGGCCCTCCTGGAGCAGCAGGTGACAAAGGTGACAAGGGTCCAACTGGTGTTCCTGGATT 
       ::::::::::::: :::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGGCCCTCCTGGAACAGCAGGTGACAAAGGTGACAAGGGTCCAACTGGTGTTCCTGGATT 
               370       380       390       400       410          
 
             450       460       470       480       490       500  
Normal TCCAGGGTTGGATGGCATACCTGGCCCCCCGGGGCCTCCTGGATCCAGAGGCAAGCCTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::: 
ESC A4 TCCAGGGTTGGATGGCATACCTGGCCCCCCGGGGCCTCCTGGATCCAGAGGCAACCCTGG 
     420       430       440       450       460       470          
 
             510       520        530       540       550       560 
Normal CATGCATGGCTACAATGGTTCACGAAGGTGATCCAGGGTTTCCAGGAAAAAGAGGAGTTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CATGCATGGCTACAATGGTTCACGAAGGTGATCCAGGGTTTCCAGGAAAAAGAGGAGTTC 
     480       490       500       510       520       530          
 
              570       580       590       600       610       620 
Normal CTGGCCCAGGAGGCCCCCCAGGCCTTCCTGGGGAAAGGGGAGAAAAAGGAAATTCAGTGT 
       :::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::: 
ESC A4 CTGGCCCAGGAGGCCCCCCAGGCCTTCCTGGGNAAAGGGGAGAAAAAGGAAATTCAGTGT 
     540       550       560       570        580        590        
 160
              630       640       650       660       670       680 
Normal TCATTTTAGGTGCCATTAAAGGTATTCAGGGAGACAGGGGGGACCCAGACCTGCCTGGCT 
       ::::::::::::::::::::::::::::::: :::::::::::::::::::: ::::::: 
ESC A4 TCATTTTAGGTGCCATTAAAGGTATTCAGGGNGACAGGGGGGACCCAGACCTNCCTGGCT 
       600       610       620       630       640        650       
 
              690       700       710       720       730       740 
Normal TGCCGGGACCGAAGGGGGCAGGAGGACCGGCAGGTCCCAAGGGACAGCCAGGAGAGCCTG 
       :::::::::::::::::::: ::::::::::::: ::::::::::::::::::::::::: 
ESC A4 TGCCGGGACCGAAGGGGGCACGAGGACCGGCAGGNCCCAAGGGGACAGCCAGGAGAGCCT 
        660       670       680       690       700       710       
 
              750       760       770       780       790       800 
Normal GGTTAACAGGTGCTCCGGGCCATCCTGGGAGACCAGGCTTGAAGGGTAATCCTGGTGTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGTTAACAGGTGCTCCGGGCCATCCTGGGAGACCAGGCTTGAAGGGTAATCCTGGTGTGG 
        720       730       740       750       760       770       
 
              810       820       830       840       850       860 
Normal GAGTAAAGGGGCAAATGGGAGACCCGGGTGAGGTTGGCCAGCAGGGTTCTCCTGGACCCA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GAGTAAAGGGGCAAATGGGAGACCCGGGTGAGGTTGGCCAGCAGGGTTCTCCTGGACCCA 
        780       790       800       810       820       830       
 
              870       880       890       900       910       920 
Normal CCTTATTGGTACAGCCACCTGATTCCTGTCTGTATAAAGGAGAAAAGGGCATAAAAGGAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CCTTATTGGTACAGCCACCTGATTCCTGTCTGTATAAAGGAGAAAAGGGCATAAAAGGAA 
        840       850       860       870       880       890       
 
              930       940       950       960       970       980 
Normal TGCCTGGTATGATTGGACCTCCAGGACTACCGGGACCCAAGGGAGAACCTGGAATTGGAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGCCTGGTATGATTGGACCTCCAGGACTACCGGGACCCAAGGGAGAACCTGGAATTGGAC 
        900       910       920       930       940       950       
 
              990      1000      1010      1020      1030      1040 
Normal CAAAAGGAGAGAAGGGTATTCCTGGGTTCTCAGGACCTCGGGGTGATCCGGGTTCCTATG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CAAAAGGAGAGAAGGGTATTCCTGGGTTCTCAGGACCTCGGGGTGATCCGGGTTCCTATG 
        960       970       980       990      1000      1010       
 
             1050      1060      1070      1080      1090      1100 
Normal GCTCTCCAGGTTTTCCAGGATTAAAGGGGAAACCAGGACTGTTTGGAGATCCTGGATCAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GCTCTCCAGGTTTTCCAGGATTAAAGGGGAAACCAGGACTGTTTGGAGATCCTGGATCAT 
       1020      1030      1040      1050      1060      1070       
 
             1110      1120      1130      1140      1150      1160 
Normal TTGGATTTGTTGGCCCAAAGGGGGATCCTGGAGACCGTGGGTACCCAGGACCACCGGGTG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TTGGATTTGTTGGCCCAAAGGGGGATCCTGGAGACCGTGGGTACCCAGGACCACCGGGTG 
       1080      1090      1100      1110      1120      1130       
 
             1170      1180      1190      1200      1210      1220 
Normal TTCTGGTAACTCCATCTGTTCCACTCAAAGGCCCTCCAGGGGATCCGGGGCGCCCTGGCC 
       :::::::::::::: ::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TTCTGGTAACTCCACCTGTTCCACTCAAAGGCCCTCCAGGGGATCCGGGGCGCCCTGGCC 
       1140      1150      1160      1170      1180      1190       
 
             1230      1240      1250      1260      1270      1280 
Normal ACTATGGAGAAATGGGGTCCGTTGGACCACCTGGTCCCCCTGGTCCCCCAGGTCCACCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 ACTATGGAGAAATGGGGTCCGTTGGACCACCTGGTCCCCCTGGTCCCCCAGGTCCACCAG 




             1290      1300      1310      1320      1330      1340 
Normal GGGAAGACTGTGCAGGCATGATGGGACCCCCTGGACCAAGAGGATTTCCTGGTCATCCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGGAAGACTGTGCAGGCATGATGGGACCCCCTGGACCAAGAGGATTTCCTGGTCATCCAG 
       1260      1270      1280      1290      1300      1310       
 
             1350      1360      1370      1380      1390      1400 
Normal GATTTCCAGGGGCAGCTGGTATCCCAGGGAGAGCGGATTTAAGTCCAGGAAAACCAGGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GATTTCCAGGGGCAGCTGGTATCCCAGGGAGAGCGGATTTAAGTCCAGGAAAACCAGGGA 
       1320      1330      1340      1350      1360      1370       
 
             1410      1420      1430      1440      1450      1460 
Normal AACCGGGACCTCCTGGGTTGCCCGGAGCACCAGGGCTGCAAGGACCCCCAGGATCAGATG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 AACCGGGACCTCCTGGGTTGCCCGGAGCACCAGGGCTGCAAGGACCCCCAGGATCAGATG 
       1380      1390      1400      1410      1420      1430       
 
             1470      1480      1490      1500      1510      1520 
Normal TTATCTATTGTAGTGTTGGGCATCCTGGACCACAAGGGATAAAAGGCAAAATGGGTCCTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TTATCTATTGTAGTGTTGGGCATCCTGGACCACAAGGGATAAAAGGCAAAATGGGTCCTC 
       1440      1450      1460      1470      1480      1490       
 
             1530      1540      1550      1560      1570      1580 
Normal CAGGAAGAAGAGGCTCGAAAGGAGAAAAAGGAAATGCGGGGCTCTGTGCCTGTGAGCCTG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CAGGAAGAAGAGGCTCGAAAGGAGAAAAAGGAAATGCGGGGCTCTGTGCCTGTGAGCCTG 
       1500      1510      1520      1530      1540      1550       
 
             1590      1600      1610      1620      1630      1640 
Normal GTCCCATGGGCCCACCAGGCCCTCCAGGACTTCCTGGAAGGCAGGGTAGTAAGGGAGACT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GTCCCATGGGCCCACCAGGCCCTCCAGGACTTCCTGGAAGGCAGGGTAGTAAGGGAGACT 
       1560      1570      1580      1590      1600      1610       
 
             1650      1660      1670      1680      1690      1700 
Normal TGGGGCTCCCTGGGTGGATTGGAGAGAAAGGTCACCCAGGCCCTCCTGGTGCTGAAGGAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGGGGCTCCCTGGGTGGATTGGAGAGAAAGGTCACCCAGGCCCTCCTGGTGCTGAAGGAT 
       1620      1630      1640      1650      1660      1670       
 
             1710      1720      1730      1740      1750      1760 
Normal CTCCAGGATCACCAGGAAAACATGGCGCCTCAGGACCACCTGGCAGCAAAGGAGAAAAGG 
       ::::::::::::::::::::::::: :::::::::::::::::::::::::::::::::: 
ESC A4 CTCCAGGATCACCAGGAAAACATGGTGCCTCAGGACCACCTGGCAGCAAAGGAGAAAAGG 
       1680      1690      1700      1710      1720      1730       
 
             1770      1780      1790      1800      1810      1820 
Normal GCGACAGGGTTGTATCAAGAGTGAAAGGGAAAAAAGGAGAAAGAGGTCCTGATGGGCTCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GCGACAGGGTTGTATCAAGAGTGAAAGGGAAAAAAGGAGAAAGAGGTCCTGATGGGCTCC 
       1740      1750      1760      1770      1780      1790       
 
             1830      1840      1850      1860      1870      1880 
Normal CAGGATTTCCAGGACAACAGGGACAAAATGGTCGGGATGGACTTCCTGGAAAAAAGGGGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CAGGATTTCCAGGACAACAGGGACAAAATGGTCGGGATGGACTTCCTGGAAAAAAGGGGG 
       1800      1810      1820      1830      1840      1850       
 
             1890      1900      1910      1920      1930      1940 
Normal ATCCAGGCCCCCCGGGGGGTCATGAGGATGCAGCCCCAGGTGCTAAAGGGTCTCCTGGAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 ATCCAGGCCCCCCGGGGGGTCATGAGGATGCAGCCCCAGGTGCTAAAGGGTCTCCTGGAC 
       1860      1870      1880      1890      1900      1910       
 162
 
             1950      1960      1970      1980      1990      2000 
Normal CACCGGGGCCCCCAGGCAGAACAGGACCCAGGGGACAACCAGGTCTGGGATTTCCTGGTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CACCGGGGCCCCCAGGCAGAACAGGACCCAGGGGACAACCAGGTCTGGGATTTCCTGGTC 
       1920      1930      1940      1950      1960      1970       
 
           2010      2020      2030      2040      2050      2060 
Normal CACCAGGAGAGAGAGGACAACCAGGAGCTCCAGGCCGCCCTGGCGAGAGGGGCTTCGGGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CACCAGGAGAGAGAGGACAACCAGGAGCTCCAGGCCGCCCTGGCGAGAGGGGCTTCGGGG 
       1980      1990      2000      2010      2020      2030       
 
             2070      2080      2090      2100      2110      2120 
Normal GCTTGAAGGGCCAGAAAGGTGATACAATTTCTTGTAATGTCACCTACCCTGGGAGGCCAG 
       ::::::::::::::::::::::::::::::::::::: :::::::::::::::::::: : 
ESC A4 GCTTGAAGGGCCAGAAAGGTGATACAATTTCTTGTAACGTCACCTACCCTGGGAGGCCGG 
       2040      2050      2060      2070      2080      2090       
 
             2130      2140      2150      2160      2170      2180 
Normal GACCCCCAGGTTTTGATGGACCTCCAGGACCAAAGGGATTTCCAGGTCCTCAAGGCGCTC 
       : :::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGCCCCCAGGTTTTGATGGACCTCCAGGACCAAAGGGATTTCCAGGTCCTCAAGGCGCTC 
       2100      2110      2120      2130      2140      2150       
 
             2190      2200      2210      2220      2230      2240 
Normal CAGGGTTGAGGTGCTTGGATGGGCCAAAAGGTCAGCGTGGCAAACCAGGAATGTCAGAGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CAGGGTTGAGGTGCTTGGATGGGCCAAAAGGTCAGCGTGGCAAACCAGGAATGTCAGAGA 
       2160      2170      2180      2190      2200      2210       
 
             2250      2260      2270      2280      2290      2300 
Normal TACCCGGTCCACCTGGTTTTCGTGGTGACATGGGAGATCCGGGTTTTGAAGGTGAAAAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TACCCGGTCCACCTGGTTTTCGTGGTGACATGGGAGATCCGGGTTTTGAAGGTGAAAAGG 
       2220      2230      2240      2250      2260      2270       
 
             2310      2320      2330      2340      2350      2360 
Normal GGTCCTCCCTTCTTGGGCCGCCAGGCTTTCCTGGTTCTCGTGGAGCAAATGGTCAGAAAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGTCCTCCCTTCTTGGGCCGCCAGGCTTTCCTGGTTCTCGTGGAGCAAATGGTCAGAAAG 
       2280      2290      2300      2310      2320      2330       
 
             2370      2380      2390      2400      2410      2420 
Normal GAATGATGGGAGACATTGCCTATGGCCTCCCAGGCCCCCCAGGAAAGAGAGGTCCTTCCG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GAATGATGGGAGACATTGCCTATGGCCTCCCAGGCCCCCCAGGAAAGAGAGGTCCTTCCG 
       2340      2350      2360      2370      2380      2390       
 
             2430      2440      2450      2460      2470      2480 
Normal GAGTGCCAGGGTCCAAAGGACACAGAGGTGATTCAGGACGTCCAGGGTTTGCAGGGCCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GAGTGCCAGGGTCCAAAGGACACAGAGGTGATTCAGGACGTCCAGGGTTTGCAGGGCCAG 
       2400      2410      2420      2430      2440      2450       
 
             2490      2500      2510      2520      2530      2540 
Normal CCGGCAAGCCTGGATCCCCAGGTCTCAAAGGTCCCAGAGGCAGAGAGGGAAGTGCTGGGT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CCGGCAAGCCTGGATCCCCAGGTCTCAAAGGTCCCAGAGGCAGAGAGGGAAGTGCTGGGT 
       2460      2470      2480      2490      2500      2510       
 
             2550      2560      2570      2580      2590      2600 
Normal TTCAAGGTATCCCGGGTCCACCTGGCCATTCCTGCAAAAGAGGCGCTCCAGGGATACCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TTCAAGGTATCCCGGGTCCACCTGGCCATTCCTGCAAAAGAGGCGCTCCAGGGATACCAG 
       2520      2530      2540      2550      2560      2570       
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             2610      2620      2630      2640      2650      2660 
Normal GGCAACCGGGGCTCCCTGGGGCCCCGGGGAGTCCAGGTGCCCCAGGTTGGAAAGGACAGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGCAACCGGGGCTCCCTGGGGCCCCGGGGAGTCCAGGTGCCCCAGGTTGGAAAGGACAGC 
       2580      2590      2600      2610      2620      2630       
 
             2670      2680      2690      2700      2710      2720 
Normal GAGGGGATGTGGGGCCTCCGGGTCCAGCTGGAATGAAAGGCCTCCCTGGAGTCCCTGGAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GAGGGGATGTGGGGCCTCCGGGTCCAGCTGGAATGAAAGGCCTCCCTGGAGTCCCTGGAC 
       2640      2650      2660      2670      2680      2690       
 
             2730      2740      2750      2760      2770      2780 
Normal GGCCAGGGGCAGAGGGACCCCTAGGATTCCCAGGAGTCCCAGGCCCCTTAGGGGATGATG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGCCAGGGGCAGAGGGACCCCTAGGATTCCCAGGAGTCCCAGGCCCCTTAGGGGATGATG 
       2700      2710      2720      2730      2740      2750       
 
             2790      2800      2810      2820      2830      2840 
Normal GGCTGCCTGGTCTTCCAGGCCCGAAGGGACCCCAGGGGCTGCCTGGCTTCCCCGGTTTTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGCTGCCTGGTCTTCCAGGCCCGAAGGGACCCCAGGGGCTGCCTGGCTTCCCCGGTTTTC 
       2760      2770      2780      2790      2800      2810       
 
             2850      2860      2870      2880      2890      2900 
Normal CAGGGGAGAGAGGAAAGCCTGGCCCAGAGGGACGCCCTGGCAGCAAGGGGGAACCAGGAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CAGGGGAGAGAGGAAAGCCTGGCCCAGAGGGACGCCCTGGCAGCAAGGGGGAACCAGGAG 
       2820      2830      2840      2850      2860      2870       
 
             2910      2920      2930      2940      2950      2960 
Normal AGGATGGTCGGCCTGGCTTCTTCGGAGACCAAGGGGTGAAAGGTGCCAAAGGAGCGAGAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 AGGATGGTCGGCCTGGCTTCTTCGGAGACCAAGGGGTGAAAGGTGCCAAAGGAGCGAGAG 
       2880      2890      2900      2910      2920      2930       
 
             2970      2980      2990      3000      3010      3020 
Normal GACCCCCAGGAGATGAAGGAGAGATGGCGGTCTTTTCCCAAAAAGGGAAAACCGGGGAAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GACCCCCAGGAGATGAAGGAGAGATGGCGGTCTTTTCCCAAAAAGGGAAAACCGGGGAAC 
       2940      2950      2960      2970      2980      2990       
 
             3030      3040      3050      3060      3070      3080 
Normal CTGGACCTCCAGGAGATGATGGATTCCCAGGAGAAGAAGGTGATAAAGGCAATCCAGGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CTGGACCTCCAGGAGATGATGGATTCCCAGGAGAAGAAGGTGATAAAGGCAATCCAGGGA 
       3000      3010      3020      3030      3040      3050       
 
             3090      3100      3110      3120      3130      3140 
Normal TGCCGGGGAGGAGAGGAGAGCCTGGAAGATTCGGAGCACCTGGATTTCACAGAGGGGAGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGCCGGGGAGGAGAGGAGAGCCTGGAAGATTCGGAGCACCTGGATTTCACAGAGGGGAGC 
       3060      3070      3080      3090      3100      3110       
 
             3150      3160      3170      3180      3190      3200 
Normal CCGGGAGAACCGGGCAGCCAGGGCTTCCTGGCCCCCCAGGCCCCCCAGGCTCACCTGGGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CCGGGAGAACCGGGCAGCCAGGGCTTCCTGGCCCCCCAGGCCCCCCAGGCTCACCTGGGC 
       3120      3130      3140      3150      3160      3170       
 
             3210      3220      3230      3240      3250      3260 
Normal TGAGAGGGATTATTGGTTTTCCGGGATTTCCAGGTGACCAGGGTGAGCCAGGTTCTCCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGAGAGGGATTATTGGTTTTCCGGGATTTCCAGGTGACCAGGGTGAGCCAGGTTCTCCAG 




             3270      3280      3290      3300      3310      3320 
Normal GGTCTCCTGGACTTTCAGGAATTGATGGAATGAGAGGACCTAAAGGAAGCAAAGGTGACC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGTCTCCTGGACTTTCAGGAATTGATGGAATGAGAGGACCTAAAGGAAGCAAAGGTGACC 
       3240      3250      3260      3270      3280      3290       
 
             3330      3340      3350      3360      3370      3380 
Normal CTGCAAGTCAGTTCGGCCCACCTGGTCCAAAGGGTGAACCAGGTAGCCCTGGATGTCCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CTGCAAGTCAGTTCGGCCCACCTGGTCCAAAGGGTGAACCAGGTAGCCCTGGATGTCCAG 
       3300      3310      3320      3330      3340      3350       
 
        3390      3400      3410      3420      3430      3440 
Normal GACAAGTTGGAGCACCTGGAGAGCAGGGCTTGCCTGGTGTTCAAGGGCTCAGAGGACCAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GACAAGTTGGAGCACCTGGAGAGCAGGGCTTGCCTGGTGTTCAAGGGCTCAGAGGACCAC 
       3360      3370      3380      3390      3400      3410       
 
             3450      3460      3470      3480      3490      3500 
Normal CTGGAAGGCCAGGATTACCTGGCTCCTCCGGACCACCAGGGTGTCCAGGTAATCAAGGGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CTGGAAGGCCAGGATTACCTGGCTCCTCCGGACCACCAGGGTGTCCAGGTAATCAAGGGG 
       3420      3430      3440      3450      3460      3470       
 
             3510      3520      3530      3540      3550      3560 
Normal TGCCTGGGCTGACAGGGCCTCCAGGAGAAACAGGGGATCCTGGGCCAAGAGGCATGATGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGCCTGGGCTGACAGGGCCTCCAGGAGAAACAGGGGATCCTGGGCCAAGAGGCATGATGG 
       3480      3490      3500      3510      3520      3530       
 
             3570      3580      3590      3600      3610      3620 
Normal GAGATCCAGGGCCACCAGGTCTTCCAGGAATAAAAGGTCCCTCCGGGTCGCCGGGTCTGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GAGATCCAGGGCCACCAGGTCTTCCAGGAATAAAAGGTCCCTCCGGGTCGCCGGGTCTGA 
       3540      3550      3560      3570      3580      3590       
 
             3630      3640      3650      3660      3670      3680 
Normal ATGGCTTGCATGGTTTAAAGGGTCAGAAAGGAGCCAAAGGTGCTTCAGGTTTGCACGAAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 ATGGCTTGCATGGTTTAAAGGGTCAGAAAGGAGCCAAAGGTGCTTCAGGTTTGCACGAAG 
       3600      3610      3620      3630      3640      3650       
 
             3690      3700      3710      3720      3730      3740 
Normal TGGGCCCACCCGGTCCAGTGGGCGTACCTGGGCTGAAAGGGGAGCCGGGAGACCCTGGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGGGCCCACCCGGTCCAGTGGGCGTACCTGGGCTGAAAGGGGAGCCGGGAGACCCTGGGA 
       3660      3670      3680      3690      3700      3710       
 
             3750      3760      3770      3780      3790      3800 
Normal GCCCAGGAATTTCTCCCCCAGGCCTTTCTGGAGAAAGAGGCCCCCCCGGCCCCCCAGGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GCCCAGGAATTTCTCCCCCAGGCCTTTCTGGAGAAAGAGGCCCCCCCGGCCCCCCAGGGA 
       3720      3730      3740      3750      3760      3770       
 
             3810      3820      3830      3840      3850      3860 
Normal GACCTGGAGCCCCTGGTCCTGCAGGTGCCACAGGAAGAGCTGCTGAAGGTCACGTTCCTG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GACCTGGAGCCCCTGGTCCTGCAGGTGCCACAGGAAGAGCTGCTGAAGGTCACGTTCCTG 
       3780      3790      3800      3810      3820      3830       
 
             3870      3880      3890      3900      3910      3920 
Normal ACCCAGGTCCACCCGGAGATGTGGGTCCTCCTGGCCCCGATGGTCCGAGAGGAGCGCCCG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 ACCCAGGTCCACCCGGAGATGTGGGTCCTCCTGGCCCCGATGGTCCGAGAGGAGCGCCCG 
       3840      3850      3860      3870      3880      3890       
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             3930      3940      3950      3960      3970      3980 
Normal GGCCCCCAGGCCCCCCTGGGAGCGTTGACCTTCTGAGAGGGGAACCAGGAGACTGTGGGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGCCCCCAGGCCCCCCTGGGAGCGTTGACCTTCTGAGAGGGGAACCAGGAGACTGTGGGC 
       3900      3910      3920      3930      3940      3950       
 
             3990      4000      4010      4020      4030      4040 
Normal CGCCGGGGCCTCCAGGTCCCCCGGGCCCACCCGGCCCTCCAGGACACCAAGGCTTCCCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CGCCGGGGCCTCCAGGTCCCCCGGGCCCACCCGGCCCTCCAGGACACCAAGGCTTCCCAG 
       3960      3970      3980      3990      4000      4010       
 
             4050      4060      4070      4080      4090      4100 
Normal GATGCGATGGAAAAGACGGCCAGAAAGGACCAATAGGATTCCCGGGGCTGCAGGGGCCTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GATGCGATGGAAAAGACGGCCAGAAAGGACCAATAGGATTCCCGGGGCTGCAGGGGCCTC 
       4020      4030      4040      4050      4060      4070       
 
             4110      4120      4130      4140      4150      4160 
Normal AGGGACTTCCTGGGCTCCCTGGGGAGAAGGGTCTGCTGGGCATTCCAGGCCGGCGAGGGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 AGGGACTTCCTGGGCTCCCTGGGGAGAAGGGTCTGCTGGGCATTCCAGGCCGGCGAGGGC 
       4080      4090      4100      4110      4120      4130       
 
             4170      4180      4190      4200      4210      4220 
Normal ACCCCGGTCCTCCAGGTTCCAGAGGTGAACCAGGGCCTCCTGCAGATGTGGATTCGTGCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 ACCCCGGTCCTCCAGGTTCCAGAGGTGAACCAGGGCCTCCTGCAGATGTGGATTCGTGCC 
       4140      4150      4160      4170      4180      4190       
 
             4230      4240      4250      4260      4270      4280 
Normal CCCGCATCCCCGGGCTTCCTGGGGTACCAGGCCCAAGAGGACCAGAAGGAGCCATGGGGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 CCCGCATCCCCGGGCTTCCTGGGGTACCAGGCCCAAGAGGACCAGAAGGAGCCATGGGGG 
       4200      4210      4220      4230      4240      4250       
 
             4290      4300      4310      4320      4330      4340 
Normal TCCCTGGAAGGAGAGGGCCCCCAGGACCAGGGTGCAAAGGAGAGCCGGGACTGGAGGGCA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TCCCTGGAAGGAGAGGGCCCCCAGGACCAGGGTGCAAAGGAGAGCCGGGACTGGAGGGCA 
       4260      4270      4280      4290      4300      4310       
 
             4350      4360      4370      4380      4390      4400 
Normal GGAGGGGCGAGGCCGGCCTCCCAGGACCTCCGGGGCCTCCCGGAAGCACAGGGGACGCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGAGGGGCGAGGCCGGCCTCCCAGGACCTCCGGGGCCTCCCGGAAGCACAGGGGACGCAG 
       4320      4330      4340      4350      4360      4370       
 
             4410      4420      4430      4440      4450      4460 
Normal GAGAAGCCGGTTGCCCCGGAGCACCAGGGCCCCCCGGGCCCATTGGGGACCCCGGGCCCA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GAGAAGCCGGTTGCCCCGGAGCACCAGGGCCCCCCGGGCCCATTGGGGACCCCGGGCCCA 
       4380      4390      4400      4410      4420      4430       
 
             4470      4480      4490      4500      4510      4520 
Normal GAGGGTTTGGGCCTGGATACCTCAGTGGCTTCCTCCTGGTTCTCCACAGTCAGACGGATG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GAGGGTTTGGGCCTGGATACCTCAGTGGCTTCCTCCTGGTTCTCCACAGTCAGACGGATG 
       4440      4450      4460      4470      4480      4490       
 
             4530      4540      4550      4560      4570      4580 
Normal GGGAGCCCACCTGCCCCGCGGGCATGCCCAGGCCCTGGACGGGCTACAGTCTGTTATACC 
       ::::::::::::::::::::::::::::::::: :::::::::::::::::::::::::: 
ESC A4 GGGAGCCCACCTGCCCCGCGGGCATGCCCAGGCTCTGGACGGGCTACAGTCTGTTATACC 
       4500      4510       4520      4530      4540      4550      
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             4590      4600      4610      4620      4630      4640 
Normal TGGAAGGACAGGAGAAGGCCCACAATCAGGACCTTGGTCTGGCAGGGTCTTGCCTTCCCA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGGAAGGACAGGAGAAGGCCCACAATCAGGACCTTGGTCTGGCAGGGTCTTGCCTTCCCA 
        4560      4570      4580      4590      4600      4610      
 
             4650      4660      4670      4680      4690      4700 
Normal TGTTCAGCACCCTGCCCTTTGCCTACTGCAACATCCACCAAGTGTGCCACTACGCCCGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGTTCAGCACCCTGCCCTTTGCCTACTGCAACATCCACCAAGTGTGCCACTACGCCCGGA 
        4620      4630      4640      4650      4660      4670      
 
             4710      4720      4730      4740      4750      4760 
Normal GAAACGACCGGTCCTACTGGCTGGCCAGTGCTGCGCCCCTGCCCATGATGCCGCTCTCAG 
       :::::::::::::::::::::::::::::.:::::::::::::::::::::::::::::: 
ESC A4 GAAACGACCGGTCCTACTGGCTGGCCAGTSCTGCGCCCCTGCCCATGATGCCGCTCTCAG 
        4680      4690      4700      4710      4720      4730      
 
 
         4770      4780      4790      4800      4810      4820 
Normal AGGAGGAGATCCGCCCCTACATCAGCCGCTGTGCCGTGTGCGAGGCCCCAGCCCCCGTGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 AGGAGGAGATCCGCCCCTACATCAGCCGCTGTGCCGTGTGCGAGGCCCCAGCCCCCGTGG 
        4740      4750      4760      4770        4780      4790    
 
             4830      4840      4850      4860      4870      4880 
Normal TGGCGCTGCACAGCCAGGACCGGTCCATCCCGCCGTGTCCACGGAGCTGGAGGAGCCTCT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 TGGCGCTGCACAGCCAGGACCGGTCCATCCCGCCGTGTCCACGGAGCTGGAGGAGCCTCT 
          4800      4810      4820      4830      4840      4850    
 
             4890      4900      4910      4920      4930      4940 
Normal GGATCGGGTACTCGTTCCTGATGCACACAGGGGCTGGAGACCAAGGAGGAGGGCAGGCCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GGATCGGGTACTCGTTCCTGATGCACACAGGGGCTGGAGACCAAGGAGGAGGGCAGGCCC 
          4860      4870      4880      4890      4900      4910    
 
             4950      4960      4970      4980      4990      5000 
Normal TCATGTCCCCCGGCAGCTGTCTGGAAGATTTCCGAGCCGCACCGTTCCTCGAATGCCAAG 
       ::::::::::::::::::::::::::::::::::::::::::::::::::::: :::::: 
ESC A4 TCATGTCCCCCGGCAGCTGTCTGGAAGATTTCCGAGCCGCACCGTTCCTCGAACGCCAAG 
          4920      4930      4940      4950      4960      4970    
 
             5010      5020      5030        5040  5050 
Normal GCCGACAGGGAACTTGCCACTTTTTTGCAAATGAGTATAGCTTCTGGCTTCTGGCTGACGAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ESC A4 GCCGACAGGGAACTTGCCACTTTTTTGCAAATGAGTATAGCTTCTGGCTTCTGGCTGACGAC 














Position  Change  Effect 
 
ECS 225  R   All bases conserve proline (CCN) 
 
ECS 440  Y   All bases conserve leucine (CTN) 
 
ECS 2340  R   All bases conserve valine (GTN) 
 
ECS 2507  A-G   Conserves codon for glutamic acid 
 
ECS 2575  G-A   Conserves codon for glutamic acid 
 
ECS 3250  A-G   Conserves codon for glutamine 
 
ECS 3338  Y   All bases conserve threonine (ACN) 
 
ECS 3220  G-T   serine-isoleucine 
 
ECS 3250  G-A   arginine-lysine 
 












Position  Change  Effect 
 
ECS 99  G-A   Conserves AAA codon for lysine 
 
ECS 195  N   Unknown 
 
ECS 351  G-A   Conserves GAA codon for glutamine 
 
ECS 371  G-A   Conserves GAA codon for glutamine 
 
ECS 475  G-C   Asparagine-Lysine 
 
ECS 573  N   Unknown 
 
ECS 630  N   Unknown 
 
ECS 650  N   All bases conserve leucine (CTN) 
 
ECS 691  N   All bases conserve glycine (GGN) 
 
ECS 1179  C-T   Conserves codon for leucine 
 
ECS 1707  C-T   Conserves codon for glycine 
 
ECS 2078  C-T   Conserves codon for asparagine 
 
ECS 2099  C-T   Conserves codon for proline 
 
ECS 2100  A-G   Conserves codon for glycine 
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